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Abstract
Periodontitis has been associated with elevated inflammatory markers in otherwise 
healthy populations. However the nature o f this association has not been determined. 
The aim of this work was to establish whether or not periodontitis causes systemic 
inflammation.
A first pilot intervention trial indicated that standard periodontal therapy, in a cohort of 
94 individuals suffering from severe generalized periodontitis, produced a 0,5 mg/L 
decrease in serum CRP concentration 6 months after therapy. This decrease was 
affected by the degree of clinical periodontal response and carriage of specific 
polymorphisms in inflammatory genes (IL-1 A, IL-6).
Periodontal treatment, on the other hand, produced a moderate acute phase response of 
one week duration [10-fold increase in CRP (P<0.001)]. Carriage o f rare alleles in the 
CRP gene was associated with a greater acute CRP response to periodontal therapy after 
correcting for conventional cardiovascular and inflammatory factors.
Standard (SPT) and an intensive periodontal therapy (IPT, including local delivery of 
antimicrobials) resulted in a significant reduction in serum CRP compared to an 
untreated control 2 months after treatment (0.5±0.2 mg/L, P=0.030 and 0.8±0.2 mg/L, 
P=0.001 respectively) in a randomized controlled trial involving 65 healthy subjects 
with severe generalized periodontitis. The IPT group showed also a decrease in total 
cholesterol and LDL-cholesterol.
These data were confirmed by the results o f a second randomized trial where a cluster 
o f inflammatory and metabolic parameters were evaluated at baseline, 1, 2 and 6 
months after either a SPT or IPT regimen. IPT patients showed significant reductions in 
inflammatory markers at one (p=0.0406) and two (p=0.0060) months together with an 
improved metabolic state (2-6 months reduction in lipid markers p=0.0320 and 
p=0.0432 respectively).
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Periodontitis causes an increased reversible systemic inflammatory burden and an 
intensive therapy regimen is more effective in re-establishing a more favourable 
systemic homeostasis.
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1.1 S y s t e m i c  I n f l a m m a t io n  (A c u t e  P h a s e  R e s p o n s e )
1.1 .1  D e f in it io n
Inflammation represents a highly conserved and complex reaction of the organism to a 
series o f pathological insults such as infection, tissue injuries, tissue infarction, surgery 
or malignancies (Baumann & Gauldie 1994). Inflammation can be clinically defined as 
the presence o f rubor (redness), tumor (swelling), calor (heat), dolor (pain) eventually 
leading to functio laesa (loss of function). Systemic inflammation encompasses a series 
of physiologic changes (plasma proteins levels, behavioural, biochemical and nutritional 
changes) produced by a pathological insult that are usually distant from the site of 
application of the inflammatory stimulus (Table 1) (Baumann & Gauldie 1994).
Table 1 Acute Phase Reaction
ACUTE PHASE PHENOMENA
Neuro-endocrine
Changes
Fever, somnolence and anorexia 
t  ACTH and cortisol 
t  Vasopressin
T Circulating catecholamines
Hemapoietic Changes
Leucocytosis
Thrombocytosis
Anemia
M etabolic Changes
4 gluconeogenesis 
t  hepatic lipogenesis 
T lipolysis in adipose tissue 
Osteoporosis
t  lipoprotein lipase activity (muscle and 
adipose tissue)
Cachexia
Hepatic Changes
T production of plasma proteins (CRP, 
Fibrinogen, Serum Amyloid A, 
Ceruloplasmin, Haptoglobin....) 
t  inducible NO synthase, heme oxygenase, 
manganese superoxide dismutase, tissue 
inhibitor o f metalloproteinase-1
Biochemical Changes
4 Zinc 
4 Fe 
4 Cu
T plasma retinol and glutathione
These mechanisms have been classically referred to as the acute phase response (APR) 
even though they are present in both acute and chronic inflammatory conditions
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(Baumann & Gauldie 1994; Gabay & Kushner 1999).The organism undertakes such 
changes to remove or contain the injury; this is accomplished by isolating and 
destroying the infective organisms, removing any harmful molecules, and/or activating 
the repair process. APR is a non specific rapid response to a variety of stimuli and it is 
part o f the innate immunity. Complex organisms produce it in response to injury via 
cellular and humoral mechanisms. Over the ages, the evolution o f this response has 
allowed complex organisms to protect themselves from infections and a series of 
external noxious agents thanks to the rapidity by which the APR manifests. The 
induction o f such defensive mechanisms seems to depend upon recognition of very 
broad molecular patterns in pathogens by highly preserved pattern recognition receptors 
(PRR) present on defensive cells like macrophages and polymorphonuclear leucocytes. 
All multicellular organisms are believed to have some form of innate host defences. 
Plants resistance to diseases and defence against pathogens includes the action of highly 
conserved protein modules found also in vertebrates. In mammals similar transcription 
factors and recognition protein are also involved in the control of innate immune 
responses (NFkB family, Toll domain) (Medzhitov & Janeway, Jr. 1996; Medzhitov & 
Janeway, Jr. 1998; Medzhitov & Janeway, Jr. 2000).
Highly preserved mechanisms as those based on pattern recognition molecules (i.e. 
against bacterial LPS) are examples of the protective effects o f the APR within the 
human response to endotoxemia (Baumann & Gauldie 1994; Medzhitov et al. 1998). 
APR further improves survival after an injury such as a trauma, bum or an ischemic 
necrosis (myocardial infarction) (Ebersole & Cappelli 2000; Pepys & Hirschfleld 2001; 
Liuzzo et al. 1999). APR is not the only defensive reaction that the organism can mount 
as part o f the homeostatic response to injury: innate cellular responses also play a 
significant role.
20
30,100
~  30,000-
700-
C-reactive protein600-
500-
L— Serum amyloid A
O 400-
300-
Haptoglobin
200
100 - '  C3
O
Transferrin
Albumin
Time after Inflammatory Stimulus (days)
Figure 1 Acute-Phase Proteins Kinetics 
Adapted from (Gabay & Kushner 1999)
1 .1 .2  A c u t e -P h a s e  M e d ia t o r s
The APR has been primarily associated with the systemic response of the organism to 
an insult. This reaction, however, is initiated at the site of injury where activated cellular 
components produce a co-ordinated cascade of signalling peptides (cytokines). Some of 
these eventually gain access to the circulation and are thus able to produce distant 
effects (amplification and modulation of the APR).
At the cellular level, macrophages and monocytes are the major sources of 
inflammatory cytokines involved in the APR (Koj 1996). Cytokines have multiple 
targets; their regulatory activities are exerted via specific receptors that activate 
intracellular signalling pathways which promote nuclear gene transcription, changes in 
the expression signature and eventually change in the cellular phenotype (Lin et al. 
2000).
At the vascular level the action of many cytokines leads to increased permeability and 
vascular leakage to facilitate the host response towards the injury. This results in
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oedema, redness and sometimes compromised function of the tissue involved according 
to the nature of the insult (Baumann & Gauldie 1994). The liver is the main target of the 
inflammatory mediators generated at the site of injury; it responds by producing a series 
o f plasma proteins capable of helping to contain or to clear the local insult. An acute- 
phase protein (APP) has been defined as one whose plasma concentration increases 
(positive APPs) or decreases (negative APPs) by at least 25 percent during inflammation 
(Kushner & Rzewnicki 1994; Morley & Kushner 1982). The magnitude in rise of each 
plasma protein varies from 2 to 10 or in some cases up to 1000 fold within 24-48 hours 
from the injury as for C-Reactive protein (CRP). The kinetics o f changes in serum 
concentrations o f each protein following an inflammatory stimulus are presumably 
associated with its function and have been widely studied and used reliably for 
monitoring the induction or resolution of the APR itself (Figure 1). Although plasma 
proteins seem to increase according to an exponential curve, not all individuals show 
uniformity in such increase. These differences might be due to different pattern of 
production o f specific cytokines (Kushner 1991; Kushner 1993; Kushner et al. 1995). 
The synthesis o f the APPs is regulated not only by molecular mediators (cytokines) but 
also by hormones (i.e glucocorticoids) and growth factors. Arbitrarily we can consider 
i) Interleukin-1 (IL-1) type cytokines [IL-1, Tumor Necrosis Factor-a (TNF-a)] 
considered local rapid mediators and inducers of the systemic response, ii) Interleukin-6 
type cytokines (IL-6, interleukin-11 etc) responsible for the systemic acute-phase 
changes described above and iii) glucocorticoids and growth factors (including insulin) 
mainly involved in modulating the APR. Cytokines in particular stimulate the plasma 
proteins gene-expression, while glucocorticoids and growth factors modulate cytokine 
activity. When these two opposing mechanisms are balanced then the organism 
successfully resolves the APR by clearing the insult and/or by repairing any damage.
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The effect o f each cytokine depends ultimately upon the context in which it is working 
(Spom 1997). IL-6 is widely known as the primary inducer of the APR, acting directly 
at the hepatocyte level by stimulating or inhibiting the synthesis rate o f each protein at 
the transcriptional level (Baumann & Gauldie 1994; Ganapathi et al. 1988a; Ganapathi 
et al. 1988b; Kishimoto et al. 1992; Mackiewicz et al. 1991). Its activity, however, 
seems to be dependent upon the nature of the stimulus. Experimental models to study 
the initiation of the APR in which animals where rendered incapable o f producing IL-6 
(knock-out), indicated that only after tissue injury (turpentine injection, sterile 
inflammatory stimulus) and not infection (LPS injection) a normal systemic APR 
developed (Fattori et al. 1994). This observation indicates that during an infectious 
process besides IL-6 other peptides (IL-1 and TNF-a) act independently as potent 
systemic acute phase inducers; some cytokines initiate and amplify the response, others 
sustain or attenuate it, and some of them cause it to resolve. The inter-relationship 
between IL-6 and other inducing cytokines (IL-1, TNF-a) together with the 
hypothalamic-adrenocortical axis stimulation completes the complex web of 
interactions involved in the APR. It is rare that in vivo cells are stimulated only by one 
cytokine while presumably we should expect more an interchange o f additive or 
inhibitory activities exerted by all mediators involved.
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1 .1 .3  I n t e r l e u k in -6
IL-6 is a pleiotropic peptide of 26 kDa that shows a variety of actions on the immune 
system, haemostasis control and neuroendocrine system (Barton 1997). It was originally 
known as hepatocyte-stimulating factor (HSF) but now IL-6 is considered to be 
primarily responsible for the regulation of production o f acute phase proteins (Barton 
1997; Ritchie & Fuller 1983). Unlike the other cytokines that act primarily as 
auto/paracrine factors and their circulating levels are un-related with their patho­
physiological role, IL-6 acts at distant sites as hormones do.
During inflammation it is generally believed that different cytokines are produced 
following a specific sequence (TNF-a —> IL-lp —> IL-6) (van Deventer et al. 1990). 
Interleukin-6 shows an inhibitory activity on the secretion o f both TNF-a and IL-ip 
(Schindler et al. 1990); IL-6 also activates the hepatic synthesis o f APPs (Heinrich et al. 
1990), and stimulates the hypothalamic-pituitary-adrenal axis (HPA) (Lyson & 
McCann 1991) to help control the inflammation. This is why IL-6 can be considered 
both as a pro-inflammatory and an anti-inflammatory molecule. The latter activity 
seems to be essential in survival and response to acute infection (Xing et al. 1998).
IL-6 is one of the principal mediators also of the clinical manifestations of tissue injury, 
including fever, cachexia, and elevation in resting metabolic rate (Tsigos et al. 1997b; 
Tsigos et al. 1997a). When injected in healthy volunteers, leukocytosis, thrombocytosis, 
decreased plasma levels of albumin, reductions in serum total cholesterol, 
apolipoprotein B and triglyceride levels were observed within 24 hours (Papanicolaou et 
al. 1998). IL-6 type cytokines play also a profound role in skeletal homeostasis since 
they promote osteoblasts/osteoclasts development (Manolagas 1995).
Besides immune accessory cells (such as monocytes, macrophages etc) which are the 
main reservoir, IL-6 is produced by many non-immune cells (such as osteoblasts, 
keratinocytes, etc) (Papanicolaou et al. 1998). Adipocytes o f healthy individuals can
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produce great quantities o f this peptide such as to account for up to 30% of total 
circulating IL-6 (Mohamed-Ali et al. 1997; Mohamed-Ali et al. 1998). IL-6 promotes 
megakaryocyte maturation and B cell differentiation even though it is not essential for B 
cell development (Baatout 1996; Fattori et al. 1994). Plasma concentrations of this 
cytokine increase rapidly after sepsis and the magnitude of its increase correlates well 
with the extent, duration and severity of the stimulus (Barton 1997).
IL-6 actions are mediated through a cellular receptor (130 kDa) which once activated 
induces a cascade signalling pathway (kinases, transcription factors) (Hallek et al. 1997) 
and a soluble circulating receptor (Papanicolaou et al. 1998). Notably IL-6 synthesis has 
been thought for some years to be affected by a diurnal variation (Chrousos 1995) 
however, new evidence is suggesting that the increased concentrations o f IL-6 reported 
in the afternoon perhaps are a consequence of the sampling (IV catheter) procedure 
referring to a possible vascular damage and local site o f inflammation (Haack et al. 
2002) rather than a different synthesis rate.
During acute stimulation IL-6 activates the HPA axis by acting primarily on the 
corticotropin-releasing hormone neuron. (Nishimura et al. 2000) and resulting in 
elevated plasma levels o f adrenocorticotropin hormone (ACTH) and consequently 
cortisol (Tsigos et al. 1997a). Glucocorticoids’ synthesis inhibits production of 
interleukin-6 in vitro and in vivo (Breuninger et al. 1993; Mastorakos et al. 1993) acting 
as a negative feedback control.
Located on the short arm of chromosome 7, the IL-6 gene consists o f 5 exons and 4 
introns and has a fairly complex transcriptional regulation (Sehgal 1992). The 5’ and 3’ 
flanking regions have been reported to be polymorphic (Fishman et al. 1998). A 
biological activity o f a specific base exchange (G/C -174) has been recently reported in 
a population o f individuals suffering from systemic-onset juvenile rheumatoid arthritis. 
G allele carriers (common allele) showed higher spontaneous and induced (IL-1, LPS)
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IL-6 concentrations when compared with individuals homozygous for the rare allele 
(Fishman et al. 1998). Mechanistic explanation of such differences is still lacking and 
controversial since other reports have shown an opposite genotype effect (Matsusaka et 
al. 1993).
1 .1 .4  C -R e a c t iv e  P r o t e in
CRP was first discovered in 1930 and 
named after the capacity to bind the C- 
polysaccharide of Streptococcus 
pneumoniae during the acute phase of 
infection. Since then and thanks to its 
sensitivity to inflammatory stimuli, its fast
response and wide range of observed 
concentrations it has been considered the 
prototype acute phase marker (Hirschfield & Pepys 2003; Pepys & Baltz 1983; Pepys 
1981). CRP is a pentameric protein composed of five identical subunits (figure 2). It 
belongs to a family o f highly evolutionary conserved pattern recognition molecules, the 
pentraxins which are all Ca++ dependent ligand-binding proteins. CRP in particular 
binds with high avidity to phosphocholine and to a series o f other autologous and 
extrinsic ligands (i.e. lipoproteins, damaged cell membranes, apoptotic cells and FcyRI 
and FcyRII) (Hirschfield & Pepys 2003; Szalai et al. 1997; Szalai 2002; Szalai & 
McCrory 2002). When bound to bacteria it is immediately recognized by C lq  and 
subsequently it activates the classical complement pathway miming the opsonization 
activity of antibodies (Hirschfield & Pepys 2003). Many believe that one of its 
biological functions is to bridge together innate and adaptive immunity (Szalai et al. 
1997). Besides complement activation, CRP actions are predominantly defensive
Figure 2 CRP pentameric structure
Protein Data Bank (Human C-Reactive Protein
IGNHXHirschfield & Pepys 2003)
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including enhancement of bacterial opsonization, scavenging o f apoptotic cells and 
modulation o f PMN function (Pepys 1981).
In healthy individuals its serum concentrations are below lmg/1 with a 90th percentile of 
3mg/l (Hirschfield & Pepys 2003). Within 4-5 hours of an intense inflammatory 
stimulus (surgery or tissue infarction) its concentration increases rapidly reaching its 
peak within 24-40 hrs (up to 500 mg/1). It is mainly produced by hepatocytes under 
stimulation o f one potent inducer (IL-6), but other local sites o f production (such as the 
stimulated endothelium) have been recently discovered (Gabay & Kushner 1999).
Due to its relatively short but constant plasma half-life (19 hours) CRP serum values are 
only dependent of the synthesis rate. This important feature enables physicians to use 
CRP concentrations to monitor the entire course of the systemic inflammatory response 
from initiation to resolution. CRP does not present diurnal variation and the individual 
concentration is relatively stable with peaks only during periods o f infection or 
inflammation (Macy et al. 1997). There is no seasonal variation and over 5 years time 
its concentration self-correlation coefficient is similar to that o f cholesterol (0.5). CRP 
concentrations are therefore a sensible and reliable marker o f individual inflammatory 
burden in presence of organic diseases, infections or other inflammatory conditions. IL- 
6 concentrations are highly correlated with this marker both in health and disease (de 
Maat et al. 1996; de Maat & Kluft 2001).
Women tend to have higher concentrations of this marker in physiological conditions 
(de Maat & Kluft 2001), even though the association between hormone replacement 
therapy and higher CRP concentration is well established (de Maat & Kluft 2001). 
Smokers as well as obese individuals show higher CRP serum levels presumably 
because o f local tissue-damage or recurrent infections and increased IL-6 concentrations 
respectively (de Maat & Kluft 2001; Szalai & McCrory 2002). Finally some 
medications (e.g. non-steroidal anti-inflammatory drugs, statins) have clearly shown
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either a positive or negative effect on the serum level of CRP (de Maat & Kluft 2001; 
Szalai & McCrory 2002).
Twin and family studies indicate that CRP concentrations are a heritable trait 
(MacGregor et al. 2004; Pankow et al. 2001). Recent data have indicated that the CRP 
gene is polymorphic. A polymorphism in the exon 2 o f the CRP gene has been 
described but without any biological activity. A novel polymorphism (+1444C>T) in 
the 3’ untranslated region of the gene encoding CRP has been reported to have 
functional activity (Brull et al. 2003). Healthy subjects and coronary artery bypass graft 
(CABG) patients who were homozygous for the T allele were associated with higher 
basal and stimulated CRP concentrations in male subjects (Brull et al. 2003). However, 
it is likely that other important genetic influences, such as the -174G>C polymorphism 
o f the IL-6 gene, (Vickers et al. 2002) may also determine the basal and stimulated 
concentrations o f CRP as a consequence o f different cytokine concentrations. 
Polymorphisms in other pro-inflammatory genes (IL-1 mainly) have also been 
associated with higher CRP concentrations in healthy and diseased population studies. 
Relatively little, however, is known about the exact mechanisms through which the 
inflammatory burden and/or systemic response is increased (Berger et al. 2002).
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1.1.5 APR a n d  H o m e o s t a s is
APR includes a series o f neuroendocrine, haematopoietic, metabolic and hepatic 
changes, which scientists have interpreted to be presumably defensive. Fever appears 
during the early stage of the APR and it is thought to be induced by specific cytokines 
(IL-1 and IL-6) and is accompanied by other neuroendocrine (activation of the HPA- 
axis) (Chrousos 1995) and behavioural changes (anorexia, somnolence).
Neutrophilia, reduced serum iron with consequent anaemia, increased gluconeogenesis 
and coagulation activation are also part of the same reaction (Moshage 1997). The 
acute-phase changes include an increase in the number of circulating leucocytes 
(polymorphonuclear) and platelets, released both from the circulatory pool to the local 
sites and resulting from increased production in the bone marrow (Suffredini et al. 
1999).
Many of these events are potentially harmful to the organism. An uncontrolled 
inflammatory reaction to a variety of stimuli can produce more damage than benefits. In 
the past decade we have witnessed an increased awareness that a long-term exposure to 
stressful (inflammatory) stimuli may produce disease rather than repair. Inflammatory 
diseases such as Rheumatoid Arthritis or Periodontal Chronic Infections are prototypic 
examples. We assume that APR is a defensive mechanism o f the organism since the 
action o f each individual mediator we have studied has been thought to be protective. 
This process however is not a linear cascade of activation of peptides and organs but a 
series o f fine tuned modulating mechanisms which are evoked in order to contain this 
reaction and protect the host.
Over the years the term “homeostasis” has been referred to a status of general health 
and equilibrium that the organism seeks during his lifespan. APR represents perhaps 
one o f the most common, rapid and efficient mechanisms through which every 
organism may accomplish the homeostatic status. According to the entity of the
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inflammatory stimulus or sometimes to an individual variability, an acute phase reaction 
can be different in magnitude even though the pathogenetic mechanisms remain similar. 
Deviation from normal homeostasis may sometimes produce uncontrolled and 
potentially harmful conditions such as sepsis or systemic inflammatory response 
syndrome. The latter encompasses a series o f haemodynamic, vascular permeability 
changes, coagulation defects and multiple organ failure that, when it accompanies 
severe injuries (trauma or infections), may negatively affect survival (Angele & Faist 
2002; Das 2000; Riewald & Ruf 2003).
Over the past decades therefore a series of experimental models to study acute 
inflammation in humans have been developed. To study the regulation of the synthesis 
of pro-inflammatory cytokines, for instance, investigators have predominantly adopted 
in vitro models (stimulation o f blood mononuclear cells with LPS, other stimuli or 
whole blood assay). However it is still not known to what extent the information 
obtained can be referred to an in vivo situation where a more complex web of signalling 
takes place. To prevent this problem experimental human models o f acute inflammation 
have been developed. The prototype model is the parenteral injection of bacterial 
endotoxin (LPS) in healthy individuals which causes a sharp increase in all acute 
inflammatory markers and it is accompanied by classical flu-like symptoms (Suffredini 
et al. 1995; Suffredini et al. 1999). Drug-induced models have also been developed 
(vaccination against S. tiphy or Yellow fever) (Hingorani et al. 2000; van, I et al. 2002). 
The only non drug-induced inflammation model reported to date and accompanied by a 
similar systemic involvement but smaller in magnitude is the strenuous exercise model 
(Fiuza & Suffredini 2001; Martich et al. 1993; Moldoveanu et al. 2001; Parker & 
Watkins 2001; Shek & Shephard 1998; Shephard & Shek 1998; Shephard 2002). This 
line of research aims at the identification if ever possible of individual hypo/hyper­
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responders to mild or strong inflammatory stimuli and at the discovery of specific 
preventive or therapeutic measures for both healthy subjects and patients.
Increased interest in studying the onset and resolution o f low-grade inflammatory 
processes has recently increased especially after the discovery o f a possible important 
pathogenetic role of persistent low-grade inflammation on systemic diseases such as 
atherosclerosis, diabetes, hypertension (Bautista 2003; Libby et al. 2002; Pradhan et al. 
2002).
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1.2 APR a n d  S y s t e m i c  D i s e a s e s
1.2.1 D ia b e t e s
Chronic sub-clinical inflammation, assessed by moderately elevated CRP and IL-6 
levels, plays a significant role in the pathogenesis of type-2 diabetes (Festa et al. 2003; 
Pradhan et al. 2002). Insulin resistance (IR), which represents perhaps the main 
characteristic o f patients in their pre-diabetic state, has been significantly associated 
with levels of acute phase proteins in response to pro-inflammatory cytokines (Festa et 
al. 2003). The term IR refers to a diminished ability o f insulin to metabolize glucose, 
producing glucose intolerance and hyperglycaemia. The relationship between insulin 
resistance and inflammation is bidirectional. Independent of the inflammatory triggering 
factors a deficit in insulin activity leads to a worsening of a chronic inflammatory state 
(Fernandez-Real et al. 2003; Fernandez-Real & Ricart 2003). Among all possible risk 
factors behind the individual inflammatory burden, obesity may play a crucial role. 
Adipose tissue represents a major source of inflammatory cytokines (IL-6, IL-IRa, 
TNF-a) (Fernandez-Real & Ricart 2003). In normal conditions adipose tissue is 
targeted by a variety of still unknown stimuli. IL-lp for example appears to be a greater 
inducer than TNF-a or LPS on the production of IL-6 from adipocytes (Mohamed-Ali 
et al. 1998). This observation suggests a possible role of the adipose tissue in innate 
immunity. Measures of obesity (e.g. body mass index) are positively correlated with IL- 
6. IR is negatively correlated with plasma and adipose content o f IL-6 (Fernandez-Real 
et al. 2003). A second possible source of inflammation might be the muscles corporeal 
mass. Insulin can stimulate IL-6 production after strenuous exercise (Fernandez-Real et 
al. 2003). Insulin is also one of the major modulators of the cytokine-associated APR 
(Campos & Baumann 1992; O’Riordain et al. 1995). Its main activity would be to 
attenuate the IL-6-type cytokines stimulation of liver APR (Campos & Baumann 1992;
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O'Riordain et al. 1995). Type-2 diabetic patients therefore, because of a reduced insulin 
action or concentration, when challenged by various insults mount prolonged acute 
phase reactions due to the absence of such modulating activity (Fernandez-Real & 
Ricart 2003).
Crude markers o f systemic infection/inflammation such as white cell counts (WBC) 
have been associated with several components of the insulin resistance syndrome (IRS) 
(Targher et al. 1996). Plasma insulin was associated with the number of lymphocytes 
and monocytes in healthy individuals or those suffering from an infection (Targher et al. 
1996). Acute infections indeed cause insulin resistance leaving some glucose 
impairment even after clinical symptoms resolve (Yki-Jarvinen et al. 1989).
Given its haematopoietic activity, IL-6 has been suggested to be the mechanistic link 
between IR and increased WBC (Fernandez-Real & Ricart 2003). Serum CRP 
concentration in particular has been significantly associated with measures of IR 
(Fernandez-Real & Ricart 2003). This negative correlation seems to be independent of 
obesity (Campos & Baumann 1992).
1 .2 .2  H y p e r t e n s io n
Mechanisms underlying various forms of hypertension are multi-factorial even though 
Nitric Oxide (NO) seems to play a major role (Manning et al. 2001). This molecule is 
essential for vascular relaxation due to its antagonistic activity against a potent 
vasoconstrictor (Angiotensin-II) (Bataineh & Raij 1998). NO production is reduced 
during hypertension (Leclercq et al. 2002). Systemic chronic inflammation has been 
associated with high blood pressure in several epidemiological studies (Bautista 2003). 
Serum CRP concentrations and hypertension seem to be positively associated (Bautista 
2003). This association is however highly modulated by the effect of other recognized 
risk factors such as age, gender and body mass index. IL-6 and TNF-a have also been 
separately linked to hypertension but the evidence reported in the literature still lacks
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control for classical cardiovascular risk factors such as smoking and diabetes (Volpato 
et al. 2001). The plausible biological mechanism behind this link could be that systemic 
inflammation produces an imbalance of the normal endothelial contracting and 
vasodilator factors and activity (endothelial dysfunction). There is for instance 
considerable evidence of the influential effect of chronic and acute inflammation, 
defined by serum levels of CRP, and endothelial dysfunction (Bhagat & Vallance 1997; 
Hingorani et al. 2000; Vallance et al. 1997). An impaired endothelial-dependent 
dilatation activity has been observed following the action o f a series of inflammatory 
mediators (IL-1, TNF-a, IL-6). In physiologic conditions NO is released by endothelial 
cells whenever vasoconstrictor, mechanical and/or thrombogenic stimuli are present. 
NO induces vasodilatation, inhibits platelet aggregation and WBC adhesion to the 
endothelium (Bautista 2003). A plausible effect of systemic low-grade inflammation, 
even produced by bacterial endotoxin (Hingorani et al. 2000), is that of directly 
affecting the endothelial cells and thus of reducing the local availability of vasodilating 
factors by: i) decrease in intrinsic NO production (Yoshizumi 2004), ii) increase in NO 
degradation through an elevated production of O2- radicals (Gryglewski et al. 1986), iii) 
increased production o f Cox-derived prostanoids which manifest potent contracting 
activity (Taddei et al. 1996). More research however is needed to establish whether 
cytokine elevation in chronic inflammation is the cause rather than the consequence of 
essential hypertension.
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1 .2 .3  A t h e r o s c l e r o s is
Inflammation defined by increased concentrations of serum levels o f pro-inflammatory 
cytokines and acute phase reactants has been closely linked with atherosclerosis. 
Among all the possible associations between APR and systemic diseases perhaps this 
one represents the most interesting one because of the potential preventive and 
therapeutic implications.
The word “atherogenesis” has evolved over the years and assumed several meanings. It 
is not anymore referred just to a mere accumulation of lipids in the intima portion of 
arterial walls even though increased LDL-cholesterol still represents the major risk 
factor. It is now widely accepted to consider atherosclerosis an inflammatory disease 
(Ross 1999). Each stage of the atherosclerotic process from the early fatty streak 
formation (a leucocytes infiltrate of the vascular wall) to the advanced lesion 
development and plaque rupture are being considered an inflammatory process at the 
molecular level (Berliner et al. 1995; Libby et al. 2002)(Figure 3).
In normal conditions the vascular endothelium does not bind any lipoprotein molecules 
and only upon starting an atherogenic diet animal models have shown that leucocytes 
adhere and start infiltrating the intimal space. Why the endothelium integrity is impaired 
remains a matter o f debate. The discussion about atherosclerosis’ aetiology has been a 
major research topic for many decades. Various pathogenetic theories have been 
postulated. The response to injury and shear stress thesis are among them (Libby et al.
2002). The first referred to a potential endothelial harmful activity predominantly of 
circulating lipoproteins which turned into an enhanced expression o f vascular adhesion 
molecules. This particular stage of the atherosclerotic process is known to always 
precede leucocytic infiltration within the arterial wall (Libby et al. 2002). The shear 
stress theory focused instead on the potential damage that changes in the
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haemodinamics of the blood flow could produce at specific sites of the vasculature (e.g. 
bifurcation, aortic sinus).
Advances made in understanding the molecular pathophysiology of the vascular 
endothelium have underlined the importance of the integrity o f the normal vasodilator- 
vasoconstrictor activities in avoiding the onset of atherosclerosis (endothelial function). 
Pro-inflammatory cytokines promote the expression of vascular adhesion molecules and 
the migration of monocytes in the sub-endothelial space. Inflammatory processes
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Figure 3 Development of Atherosclerotic Plaque
Low-density cholesterol (LDL) molecules can infiltrate the endothelium. Once trapped into the 
intimal space, oxidative processes can modify LDL and produce oxidized-LDL. Monocytes can 
adhere to the endothelial cell (EC) surface via a series o f vascular adhesion molecules and once into 
the intima space may differentiate in intravascular macrophage. SMC(smooth muscle 
cel Is). Macrophages can uptake Ox-LDL and become foam cells.
Source (Berliner et al. 1995)
accompany the evolution of the fatty streak lesion and IL-1, TNF-a and IL-6 are all 
implicated in the maturation of the macrophages in the local plaque formation up to the 
foam cell stage. Inflammation furthermore seems to contribute decisively to 
precipitating the acute thromboembolic complications of the atheroma (Libby et al. 
2002).
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A large amount of clinical evidence from a series of prospective population studies has 
clearly confirmed this hypothesis. Elevated levels of inflammatory mediators among 
apparently healthy individuals predict the occurrence of future cardiovascular events on
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Figure 4 CRP as predictor for future CVD events in different population studies.
In a series o f epidemiological studies one single measure o f serum CRP revealed its 
value as predictor of future CVD. Whenever individuals o f the upper quartile were 
compared with those o f the lowest quartile o f CRP concentrations a Relative Risk at 
least double was always reported.
Adapted from (Ridker et al. 2000a)
an atherosclerotic basis (fatal and non-fatal myocardial infarction, stroke, sudden 
cardiac death). In particular some epidemiological studies have found an increased 
cardiovascular risk to be associated with increased basal levels of IL-6 and TNF-a 
(Harris et al. 1999; Ridker et al. 1997). Many classic cardiovascular risk factors 
(obesity, diabetes and hypertension) correlated well with a cluster of inflammatory 
markers (CRP, TNF-a, IL-6).
Similarly CRP has been measured across different populations and it has demonstrated 
to be a better predictor of future cardiovascular events than the classical Framingham 
risk factors. A meta-analysis showed how this acute phase marker constantly manifested 
a strong and significant association with future cardiovascular events after correcting for
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the confounding effect of other risk factors such as smoking, age, cholesterol, diabetes, 
hypertension etc (Danesh et al. 2000)(Figure 4).
Mildly increased basal levels o f CRP (2-3mg/l), which in the past would have not been 
detected due to the limited sensitivity of the assay methods, strongly predict the onset of 
future coronary events in different settings and populations. After a series of post-hoc 
analyses in various prospective studies, the predictive role of CRP has been proven to 
be always higher than that of cholesterol or other well recognized serum risk markers. 
Participants with baseline CRP levels in the highest quartile of the sample distribution 
are 2 to 3 times more likely to have a future vascular event than are those in the lower 
quartile. When serum concentrations of CRP were combined with those of lipid markers 
(Total cholesterol/HDL ratio) an even higher relative risk of future cardiovascular 
events was found (Bassuk et al. 2004)(Figure 5). Data produced from large 
interventional randomized trials (statins) indicated that a reduction of cardiovascular 
mortality and number of events was highly influenced by the presence of a concomitant
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Figure 5. High sensitivity CRP predictive role of future CVD  
events compared with other traditional cardiovascular risk factors. 
From epidemiological evidence CRP predictive role for future CVD 
events was greater than other novel inflammatory biomarkers (IL-6, 
slCAM-1) as well as o f traditional cardiovascular risk factors (LDL- 
cholesterol). Maximum prediction was obtained combining informations 
from CRP and lipid markers.
Adapted from (Bassuk et al. 2004)
reduction in serum CRP concentrations (Ridker et al. 1998; Ridker et al. 1999).
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The exact mechanisms behind the link of inflammation and cardiovascular events, 
however, are still under careful consideration.
It might well be that the APR observed in so many populations considered healthy was 
the consequence and not the cause of a latent atherosclerotic process. Many 
investigations have demonstrated a clear significant local (atheroma) production of 
inflammatory cytokines (Berliner et al. 1995; Libby et al. 2002). Evidence supporting a 
series of possible other triggers however has been accumulating over the past decade:
i) LDL bound to proteoglycans can undergo oxidative modification within the intima 
wall and are capable of inducing expression of cell adhesion molecules as well as 
chemokines and pro-inflammatory cytokines (Berliner et al. 1997).
ii) Increased VLDL serum levels can be oxidized in a similar manner or the hypothesis 
is that they can themselves stimulate a vascular inflammatory reaction (Dichtl et al. 
1999).
iii) Hypertension can influence intima homeostasis and induce lipid oxidation and pro- 
inflammatory cytokines production; a concept supported by the fact that Angiotensin II, 
one of the influential molecules in the control of blood pressure, has shown such 
activities (Griendling & Alexander 1997).
iv) The hyperglycaemic status of diabetic patients results in the generation of advanced 
glycation end products (AGE) which are well capable of insulting the endothelial cells.
v) Obesity can predispose to atherosclerosis by inducing a pre-diabetic state (insulin 
resistance) and further enhancing VLDL production from hepatocytes due to increased 
circulating free fatty acids (Yudkin et al. 1999; Yudkin et al. 2004).
A possible aetiologic activity o f CRP itself has been recently proposed due to the 
protein capacity of enhancing each step of the atherosclerotic process within the intimal 
wall (Libby et al. 2002). Further evidence of its pivotal role in atherogenesis comes 
from the discovery o f the involvement of acute systemic inflammation with acute
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cardiovascular events. As previously mentioned APR is common after tissue ischemia 
events (Pepys & Hirschfield 2001). Serum concentrations o f IL-6 and CRP are elevated 
after an acute coronary event. These inflammatory markers correlate with the rate of 
hospitalization and adverse prognosis (Liuzzo et al. 1999; Biasucci et al. 1999) and may 
represent not just the consequence of tissue necrosis but also the primary inducer of the 
vascular instability. Patients with unstable angina without myocardial necrosis but who 
present later with recurrent episodes of infarction and complications have consistently 
higher inflammatory markers levels (Liuzzo et al. 1999; Biasucci et al. 1999).
Finally, the infectious hypothesis has gathered increasing consensus in the last decade. 
After reviewing the attributable cause of all cardiovascular events, 30-40 % of cases 
cannot be explained by the known cardiovascular risk factors (Fong 2000; Kiechl et al. 
2001; Kol & Santini 2004; Leinonen & Saikku 2002).
A series of studies has associated chronic and acute infections with cardiovascular 
diseases. Starting with childhood acute infections might increase the risk of 
atherosclerosis (Leinonen & Saikku 2002). Furthermore preceding the events of an 
acute myocardial infarction an influenza-like syndrome has been reported in the 
literature many times (Leinonen & Saikku 2002). Acute infections can impair 
endothelial function and therefore pose a threat to general health (Bhagat & Vallance 
1997; Hingorani et al. 2000). Sero-epidemological studies have been reported linking 
CMV, HSV, and C. pneumoniae to atherosclerosis (Leinonen & Saikku 2002; 
Muhlestein & Anderson 2003; Shah 2002). The evidence produced on the infectious 
aetiology o f atherogenesis is based upon the discovery o f such pathogens in 
atherosclerotic plaques (C. pneumoniae in particular) and on animal experimental 
models where the onset and progression of atherosclerosis was enhanced by the 
presence of the specific pathogen as well as in vitro research showing potential 
atherogenic activity of such infectious agents. Possible mechanistic explanations
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include: i) pathogens may induce inflammatory changes within the atheroma, ii) some 
infectious agents (C. pneumoniae) in the presence o f LDL can accelerate macrophage 
transformation into foam cells, iii) an immune response towards the pathogens or their 
product might cross-react with host components [e.g. bacterial Heat Shock Proteins 
(HSP)], iv) chronic infections may produce a low-grade inflammatory systemic status, 
assessed by increased CRP levels and thus contribute to the atherosclerotic process by 
inducing inflammatory responses, v) finally the presence o f not just one but several 
infectious agents (pathogen burden) throughout the individual lifespan might have an 
additive effect on the individual inflammatory burden and therefore predispose or 
influence atherosclerosis (Leinonen & Saikku 2002).
Chronic infections furthermore can interact with other cardiovascular disease risk 
factors such as age, smoking, gender and diet (Leinonen & Saikku 2002). In particular 
several pathogens have shown the ability to produces changes in lipid metabolism. 
Infections can cause a state of hyperlipidaemia due to both a decreased clearance and/or 
increased hepatic lipoprotein production. Pro-inflammatory cytokines (TNF-a, IL-1 and 
IL-6) can mediate changes in lipid metabolism (Yudkin et al. 2000). Bacterial toxins 
(LPS) can also induce changes in cholesterol concentrations (reduced HDL and 
increased LDL) or target glucose metabolism and produce a state o f IR. Among other 
emerging cardiovascular risk factors, fibrinogen concentrations can be influenced by 
chronic infections inducing a systemic pro-coagulant state that ultimately may represent 
a crucial pathogenetic link between infections and the atherosclerotic process (Lowe 
2001; Rader 2000).
1 .2 .4  M e t a b o l ic  S y n d r o m e
Metabolic syndrome is defined as the presence of at least two o f the following factors: 
abdominal obesity, atherosclerosis, IR and hyperinsulinaemia, hyperlipidaemia 
(elevated levels o f triglycerides and reduced HDL-cholesterol), essential hypertension,
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type-2 diabetes and coronary heart disease (Fernandez-Real & Ricart 2003; Yudkin et 
al. 2004). Risk factors for these disorders seem to share a common inflammatory or 
genetic basis although the precise pathogenetic mechanisms are still unknown. A low- 
grade state o f systemic inflammation defined by raised concentrations in serum of 
inflammatory markers (especially IL-6 and CRP) has been demonstrated both before 
and after the onset o f this syndrome and might represent the missing link among them. 
The trigger o f this systemic inflammation however is still unknown. Obesity or 
hyperglycaemia can both induce an increased production of IL-6 from adipocytes 
(Mohamed-Ali et al. 2001; Yudkin et al. 1999; Yudkin et al. 2000; Yudkin et al. 2004) 
or endothelial cells and macrophages respectively (Chae et al. 2000; Morohoshi et al. 
1996). Dyslipidaemia, with increased oxidation of LDL together with a reduced 
availability of NO, may then develop and explain why cardiovascular diseases are so 
common in individuals suffering from metabolic syndrome.
A chronic infection could well be the cause of the association between acute-phase 
markers, insulin resistance and atherosclerosis. In this unifying view a reduced insulin 
action is the consequence o f the host response to an external insult.
The inter-individual variability to mount an acute phase response is also genetically 
determined (Baumann et al. 1984; Castell et al. 1990; Kushner 1988; Moshage et al. 
1988). Polymorphisms in pro-inflammatory genes responsible for hyper-inflammatory 
phenotypes could be the consequence of the selective pressure o f infectious diseases 
(Tabrizi et al. 2001; Waterer & Wunderink 2003). It may be that these genetic variants 
are more beneficial in eradicating the infectious insults but on the other-side the 
continuous exaggerated acute-phase response produced may contribute to insulin 
resistance. Further investigations, however, are needed to clarify the still unknown and 
complex gene and environment interactions.
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1.3 APR a n d  P e r i o d o n t a l  D is e a s e
1.3.1 P e r io d o n t a l  I n f e c t io n  
D e f in it io n
Periodontitis is a chronic infection which differs from gingivitis by loss of the 
connective tissue attachment to the teeth and resorption of the alveolar bone (Williams 
1990). The process is initiated by the accumulation of a dental plaque biofilm on the 
tooth surface near the gingival margin (Page 1991; Page & Komman 1997). Moderate 
forms of periodontal disease are thought to be highly prevalent (40-50% of the adult 
population) whereas severe forms affect only a minority o f adults (10%) (Papapanou 
1996; Papapanou 1999).
P a t h o b io l o g y
The aetiology and pathogenesis of periodontitis are still incompletely understood even 
though microbial plaque is considered the crucial factor in the initiation of the gingival 
inflammation (De Nardin 2001). Supra- and subgingival plaque, once colonized by 
specific gram negative microbes (e.g. Prophyromonas gingivalis, Tannerella 
forsythensis, Actinobacillus actinomycetemcomitans, Campylobacter rectus, Prevotella 
intermedia and some spirochetes) directly elicits a defensive inflammatory response 
within the gingival tissue (Moore & Moore 1994; Socransky 1984). The individual host 
response to the bacterial insult represents therefore the other essential component in the 
pathogenesis o f periodontitis.
Bacteria or their toxic products (LPS) within the gingival sulcus may gain access to the 
gingival tissue and recruit a local inflammatory infiltrate characterized by neutrophils, 
lymphocytes and macrophages. Local macrophage activation results in production of 
pro-inflammatory cytokines such as IL-1 a  and p, TNF-a and IL-6 in order to 
contain/clear the insult (Ebersole et al. 1993; Kinane et al. 1991; Lamster & Novak 
1992; Page 1991; Page & Komman 1997). The pathognomonic feature o f periodontitis,
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i.e. attachment loss, occurs as the result of matrix metalloproteinase activation in 
response to cell stimulation by pro-inflammatory cytokines (Birkedal-Hansen 1993; 
Page 1991). IL-1 in particular has been involved in bone resorption and amplification of 
the inflammatory infiltrate (Offenbacher 1996). IL-6 is also involved in the 
pathogenesis of periodontitis and is highly represented in inflamed periodontal tissues 
(Irwin & Myrillas 1998).
Periodontal infection also causes a specific local immune response characterized by 
increased local infiltration of T helper and suppressor lymphocytes together with raised 
circulating levels o f IgG antibodies (Ebersole et al. 1987). Due to possible sequence 
homology between human and bacterial components (e.g. heat shock proteins, HSP), 
immuno-complexes formation and deposition both in the local vasculature and 
connective tissue may also induce a self-perpetuating local autoimmune reaction 
independent of the presence of the bacterial trigger (Offenbacher 1996; Page 2002). 
Because of the loss o f connective tissue attachment secondary to the activation of the 
host matrix-metalloproteinases, there is a pathologic migration of the gingival epithelial 
attachment along the root surface that may reach the apex o f the tooth rendering tooth 
loss inevitable. The deepened gingival sulcus (periodontal pocket) represents the 
pathognomonic lesion o f periodontitis. A new local environment is produced and 
bacterial colonization increases. Micro-colonies o f oral bacteria deposit on soft and hard 
tissues being selected by the new anaerobic environment (Socransky et al. 2002; 
Socransky & Haffajee 2002). Based on the degree o f the inflammatory reaction, an 
ulceration of the epithelium lining the pocket may also facilitate pathogens’ invasion of 
the periodontal tissues (De Nardin 2001; Wank et al. 1976). Once in the gingival tissues 
some bacteria may well find their way into the bloodstream especially during tissue 
stressing events such as chewing, brushing or dental treatment (Bein et al. 2003; Bender 
1995; Daly et al. 1997; Daly et al. 2001; Lofthus et al. 1991; McLaughlin et al. 1996;
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Ramli 1998; Waki et al. 1990; Wampole et al. 1978). Despite their limited quantity and 
the rapid host reaction in clearing the insult, little is known about the potential harmful 
effect that such ephemerous bacteraemia can exert on systemic health.
The clinical course of periodontitis is characterized by alternating phases o f active tissue 
destruction and phases o f quiescence (Offenbacher 1996). Its insidious onset may not be 
evident to the individual affected who is often unaware of any symptoms until the later 
stages of the disease. Consequently the disease may remain untreated and progress for 
several months or even years. Clinical manifestation (localization of periodontal 
lesions), ethnic background and the presence o f specific bacteria (A. 
actynomycetemcomitans) however have been associated with more severe or aggressive 
forms of periodontitis. High variability in the individual local inflammatory response to 
the same triggering bacteria has also been reported (Komman 1999). Different genetic 
background seems to be the crucial determinant o f such variability in some populations 
(Komman et al. 1997). Common polymorphisms in inflammatory cytokine genes, for 
example, have been associated with more severe forms o f periodontal infections 
(Komman et al. 1997). Hyper-responding individuals or subjects with deficiencies in 
immune function (leucocytes PMN activity) also manifest with clinically more 
advanced disease (Genco 1996).
Periodontal treatment relies upon the elimination of the local dental plaque biofilm by 
mechanical instmmentation (sub-gingival) usually performed with local anaesthetic 
using hand and/or machine-driven (ultrasonic) instruments. Significant improvement of 
periodontal status occurs after combined therapy of oral hygiene instruction and 
thorough supra- and sub-gingival scaling and root planing in patients with periodontal 
infections. Local periodontal inflammation subsides with disappearance of the gingival 
swelling and bleeding. Recession of the gingival margin often occurs. Extractions of
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teeth ultimately represent the last stage of periodontal treatment often because of little 
connective tissue attachment and alveolar bone remaining.
1 .3 .2  S y s t e m ic  I m p l ic a t io n s  o f  P e r io d o n t a l  D is e a s e
The concept that oral infections might influence systemic health is not new and has 
always been one of great interest. The term “oral sepsis”, later called “focal infection”, 
circulated among physicians at the beginning of last century (O'Reilly & Claffey 2000). 
At that time it was postulated that distant “foci” of tissue infections (e.g. complicated 
carious lesions, advanced periodontitis) might be harmful for other body areas and 
therefore a tremendous effort in removing them (indiscriminate tooth extractions) 
developed (O'Reilly & Claffey 2000). With time and new clinical evidence the focal 
infection theory collapsed, since such an approach proved not beneficial in treating 
serious systemic diseases (rheumatism, arthritis, kidney diseases) (O'Reilly & Claffey 
2000).
The focal hypothesis has seen new light in the past decade since a series of research 
investigations have associated periodontitis with various systemic diseases 
(cardiovascular disease, diabetes, pulmonary infections and adverse pregnancy 
outcomes).
1.3.3 D ia b e t e s
Diabetes mellitus and periodontitis have been associated for many years (Taylor et al. 
1996; Taylor 2001; Zambon et al. 1988). Diabetic patients show a significantly higher 
likelihood o f developing periodontal diseases than non diabetics and many physicians 
are aware o f this relationship. For several years though this relationship has been 
examined only in one direction (uncontrolled or poorly controlled diabetes increases 
risk o f periodontitis). Some reports however have shown how periodontal therapy may 
affect glycaemic control (Grossi et al. 1997; Grossi & Genco 1998; Taylor et al. 1996)
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raising a new hypothetical association: periodontal chronic infections may increase the 
risk of developing type-2 diabetes or may well aggravate the metabolic homeostasis in 
diabetic patients.
It is widely recognized that chronic infections may produce endocrine-metabolic 
changes resulting in poorer glycaemic control and insulin resistance (see section 1.2.1). 
Independent epidemiologic surveys moreover have demonstrated that the prevalence of 
type-2 diabetes and its complication are higher in subjects with periodontitis when 
compared with unaffected populations (Grossi & Genco 1998). A bidirectional 
relationship between periodontitis and in particular type-2 diabetes seems therefore 
significant.
Diabetes in adulthood is often preceded by a status of insulin resistance, elsewhere 
called glucose intolerance (Fernandez-Real & Ricart 2003). Diabetic patients might be 
suffering from a defect of the innate immune system perhaps triggered by a chronic 
low-grade inflammatory systemic state (Fernandez-Real & Ricart 2003). In spite of the 
fact that obesity represents the more studied among type-2 diabetes risk factors (e.g. 
age, diet, smoking), the common underlying pathogenetic mechanism of insulin 
resistance is often associated with systemic inflammation (Fernandez-Real & Ricart
2003). As already mentioned in section 1.2.1, systemic inflammation is influenced by 
insulin action at different levels and vice-versa. Insulin resistance syndrome may 
represent the consequence of repeated acute phase responses in predisposed individuals 
whenever they are challenged by external pathological insults (Fernandez-Real & Ricart 
2003; Yudkin et al. 2004). Chronic infections such as periodontitis can trigger a 
systemic inflammatory response by different means: i) haematogenous dissemination of 
periodontal pathogens and ii) local excessive production of pro-inflammatory cytokines 
(TNF-a, IL-1 and 6) dumped into the bloodstream (Page 1998). Impaired glucose 
tolerance may therefore develop and precede the onset o f type-2 diabetes. Recent
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investigations have demonstrated a significant association between local periodontal 
infection, systemic markers o f inflammation and glycaemic regulation in individual 
suffering from severe periodontitis (Saito et al. 2004).
1.3.4 A d v e r s e  P r e g n a n c y  O u t c o m e s
Preterm low birth-weight (PLBW) delivery (before 37th week o f gestation and < 2500g 
of weight) represents a possible consequence o f maternal young age, alcohol, drug, 
tobacco use and genetic background (Smith 2004). However a large body of clinical 
evidence suggests that infections (mainly of the genitor-urinary tract) can account for a 
significant number of prematurities through an inflammatory reaction involving the 
uterus and annexes (Smith 2004). Direct bacterial invasion o f the feto-placental unit and 
an excessive production of pro-inflammatory mediators may affect gestational age and 
predispose to PBLW (Madianos et al. 2001; Offenbacher et al. 1998b; Offenbacher et 
al. 2001; Offenbacher et al. 1996). Interest on the possible role of not just local but also 
distant tissue infections has therefore increased.
In this respect, an investigation suggested that maternal periodontal infections can 
significantly increase the risk (nearly 8 times) of PBLW delivery and intra-uterine 
growth restriction (Offenbacher et al. 1996). A large prospective trial (1300 patients) 
confirmed that maternal periodontitis was an independent risk factor for PBLW 
(Jeffcoat et al. 2001) while a more recent case-control study failed to support this 
conclusion (Davenport et al. 2002).
Some evidence however has been produced investigating the effect o f periodontal 
therapy during pregnancy. A cohort study led to the conclusion that achieving 
periodontal health during pregnancy would have a beneficial effect on gestational age 
and infant birth weight (Mitchell-Lewis et al. 2001). Similar results were reported from 
a randomized intervention trial showing a significant difference between the incidence
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of prematurity among women who were treated for periodontal disease and those who 
were not ( 10 vs 1.8 % incidence of gestational age < 3 7  weeks respectively) (Lopez et 
al. 2002).
Although local infections (such as vaginosis), maternal age, smoking alcohol still 
represent the leading cause, periodontal experimental models (hamster) demonstrated a 
significant association between presence of periodontal pathogens, experimental 
periodontitis and feto-placental toxicity including foetal weight (Collins et al. 1994a; 
Collins et al. 1994b).
Periodontal infections may also cause other adverse pregnancy events such as pre­
eclampsia, which commonly results in maternal hypertension, proteinuria and affects 
maternal mortality and morbidity (Boggess et al. 2003). In a large cohort of pregnant 
women when periodontitis was present and showed progression, the risk of pre­
eclampsia increased significantly and independent of other recognized risk factors 
(maternal age, smoking etc) (Boggess et al. 2003). Investigators concluded that maternal 
periodontal disease would represent a foetal stressor acting directly through 
haematogenous dissemination of pathogens (or their toxins) and produce placental 
damage or indirectly by a stimulated maternal inflammatory-immune reaction (Boggess 
et al. 2003). An increased concentration of pro-inflammatory cytokines and mediators 
has been reported both in maternal and foetal circulation (Offenbacher et al. 2001).
1.3.5 Ca r d io v a s c u l a r  D ise a se s
Many studies in the 1990s have linked dental infections with increased risk of CVD 
(Table 2 ). Since the first case-controlled studies were published in 1989, significant 
positive associations between various cardiovascular diseases (myocardial infarction, 
hospitalization, cardiac sudden death and peripheral vascular disease) and measures of 
oral health (alveolar bone loss, CPTIN, Russell Index, etc.) have been reported. Two
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recent meta-analysis indicated that periodontitis (defined by all measures reported in 
literature) resulted in a small significant increased risk of developing cardiovascular 
events (OR=1.19 (95% Cl, 1.08 1.32) (Janket et al. 2003), (OR=1.13, 95%CI 1.01-1.27) 
(Khader et al. 2004) independent of age, gender, smoking and other confounders.
Table 2 Epidemiological evidence o f periodontal-CVD “connection”
S t u d y D e s ig n E n d p o in t R a t io
(Mattila et al. 1989) Case/control Fatal MI or new MI 1.3
(Mattila 1993) Case/control Fatal MI or new MI 1.4
(Mattila et al. 1995) Follow up Fatal MI or new MI 1.2
(DeStefano et al. 1993) Longitudinal Admission to hospital/ fatal CHD 1.7
(Beck et al. 1996) Longitudinal New or fatal CHD, Stroke 1.5,1.9, 2.8
(Joshipura et al. 1996) Longitudinal Fatal/non Fatal MI CSD 1.0
(Grau et al. 1997) Case/control Non fatal ischemic Stroke 2.6
(Loesche et al. 1998) Cross-sectional CHD 2.6
(Morrison et al. 1999) Retrospective Fatal CHD Stroke 3.4
(Arbes, Jr. et al. 1999) Cross-sectional History of heart attack 2.2*
(Wu et al. 2000a) Longitudinal Incident non hemorrhagic Stroke 2.1
(Hujoel et al. 2000) Longitudinal Admission to hospital/ fatal CHD, Revascularization 1.1
(Howell et al. 2001) Longitudinal Fatal CHD, non fatal MI, stroke 1.1
(Jansson et al. 2001) Longitudinal Fatal CVD 2.7
(Buhlin et al. 2002) Cross-sectional Self-reported CVD and Stroke 1.6
(Joshipura et al. 2003) Longitudinal Ischemic Stoke 1.3
* Crude OR for individuals with 1/3 of the sites s lowing CAL > 3mm
The National Health and Nutrition Epidemiologic follow-up Study (NHANES) 
(DeStefano et al. 1993) was one of the large cohorts analysed. Different periodontal 
research groups however reported contrasting conclusions. Although the first analysis 
demonstrated a strong association of both, periodontal disease and poor oral hygiene, 
with total mortality for CHD, particularly among young and middle-aged men (aged 25- 
49 years) a different analysis from a database with longer follow-up o f the same cohort 
showed no association (Hujoel et al. 2000). A larger prospective study (Joshipura et al. 
1996) involving 44119 male health professionals who self reported their oral health 
status led to the same conclusions. On the other hand a strong association has been
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repeatedly found between periodontal disease and tooth loss with ischemic stroke (Grau 
et al. 1997; Joshipura et al. 2003).
The controversial association between periodontitis and atherosclerosis perhaps is 
strongly confounded by many common risk factors that the two inflammatory diseases 
share (age, male gender, diabetes mellitus, host susceptibility, stress, smoking poor 
socio-economic status) (Genco et al. 2002; Genco & Slots 1984; Kinane 1998a; Kinane 
1998b). Certainly among them the role of cigarette smoking perhaps represents the 
strongest confounder (Hyman et al. 2002).
Nevertheless, biological plausibility of this association is supported by many lines of 
research: i) periodontitis together with other chronic infections (C. pneumoniae, H  
pilory , CMV) have been associated with increased odds of future cardiovascular events; 
the relative risk observed for the various infections was of similar magnitude (Danesh 
1999), ii) experimental animal and in vitro evidence have been produced about the 
potential role o f periodontal pathogens on the atherosclerotic lipid deposition process 
(Jain et al. 2003; Lalla et al. 2003; Li et al. 2002) and thrombo-embolic complications 
(Herzberg & Weyer 1998), iii) periodontal pathogens (P.gingivalis) have been localized 
within atherosclerotic plaque in analogy with C. pneumoniae (Haraszthy et al. 2000), iv) 
P. gingivalis is able to invade vascular tissues (Dorn et al. 2000) and facilitate 
macrophage transition to foam-cells (Miyakawa et al. 2004; Qi et al. 2003), v) finally, 
the presence of several intraoral pathogens (pathogen burden) has been associated with 
an increased host inflammatory response measured by elevated serum concentrations of 
acute phase markers (Noack et al. 2001).
Despite the number of reports that show a positive association between periodontal 
infections and cardiovascular events, these investigations do not prove any causal 
relationship between those two diseases. A recent systematic review on the matter 
concluded that although moderate levels of evidence have been produced on this
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association, additional larger epidemiological and interventional studies are necessary 
(Scannapieco et al. 2003).
1.3.6 Systemic Host Response
Pro-inflammatory cytokines are significantly elevated within the gingival tissue during 
the active phase of periodontitis (Offenbacher et al. 1981). Increased concentrations of 
many inflammatory mediators have been detected in the gingival crevicular fluid (an 
exudate originating at the dento-gingival junction) presumably due to the local bacterial 
challenge and the local host defence activity (Offenbacher et al. 1981). Bacteria or their 
toxic products may easily gain access to the circulatory system. Brief episodes of 
bacteraemia have been detected after normal activity such as chewing, brushing or more 
clearly as a consequence of periodontal therapy (Bender 1995; Carroll & Sebor 1980; 
Coulter et al. 1990; Daly et al. 2001). Individuals with severe generalized forms of 
periodontitis are at greater risk of showing such episodes, even though the systemic host 
response overall neutralizes bacterial activity efficiently and without showing clinical 
signs. A serum antibody response is therefore observed and in particular an increase in 
specific IgG against common periodontal pathogens has been reported after successful 
standard periodontal therapy (Ebersole et al. 1987). Similar to bacterial dissemination, 
an excessive local production o f pro-inflammatory cytokines can be dumped into the 
blood stream and trigger a systemic acute-phase response.
In the last 5-7 years many reports focused on the possible link between severe 
periodontitis and systemic acute phase response. Consequently a renewed interest on the 
possible harmful role of the systemic host reaction to periodontal chronic infections has 
been produced. In table 3 are listed some of the investigations that reported increased 
concentrations o f acute phase reactants in serum of individuals suffering from severe 
periodontitis as opposed to healthy subjects. Kweider and co-workers found in a 
population of periodontitis patients that acute phase markers, such as fibrinogen and
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WBC, were elevated in comparison with unaffected individuals (Kweider et al. 1993). 
Since that investigation few scattered reports have confirmed such findings in small 
case control studies. Periodontitis patients have higher CRP and IL-6 levels when 
compared with matched periodontally healthy populations (Amar et al. 2003; Ebersole 
et al. 1997; Glurich et al. 2002; Loos et al. 2000; Noack et al. 2001). This perturbation 
of the physiological homeostasis is also accompanied by a lower number of 
erythrocytes and haemoglobin concentrations (Hutter et al. 2001), higher values of 
haptoglobin, moderate leukocytosis (Fredriksson et al. 2002) and increased cholesterol, 
LDL and glucose levels (Katz et al. 2002; Losche et al. 2000; Wu et al. 2000b).
Some reports concluded also that the extent and severity of periodontitis was positively 
associated with greater systemic acute phase response. The acute phase response 
observed in periodontal patients was also associated with the presence of local 
periodontal pathogens (Noack et al. 2001) and was independent from other systemic 
chronic infections (seropositivity to C. pneumoniae, H pilory, CMV) (Loos et al. 2000). 
Due to the limited number of individuals, however, the main criticism raised to these 
investigations was the inability to efficiently account for a series of possible 
confounders (age, smoking, diet, diabetes) that may well affect the acute phase response 
as mentioned earlier. Nevertheless recent larger cohort longitudinal studies provided 
new evidence that periodontal disease is associated with systemic and cardiovascular 
risk factors including acute phase proteins (Joshipura et al. 2004; Slade et al. 2000; 
Slade et al. 2003; Wu et al. 2000b). Using data from the NHANES III, the ARIC, 
Health Professional Study populations, investigators have found that individuals with 
periodontitis have increased systemic levels o f CRP, Fibrinogen, t-PA and LDL 
cholesterol. These differences were also significant when the analyses accounted for a 
series o f possible confounding factors (age, sex, smoking, socioeconomic status, 
diabetes, body mass index, alcohol use).
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Table 3 Periodontitis and APR
St u d ie s D e s ig n
S u b je c t s
(c o n t r o l s )
H e a l t h y P e r io d o n t it is
(Ebersole et al. 1997) RCT 40 (35) 2.17± 0.41 9.12 ± 1.61
(Fredriksson et al. 2002) Case/Control 83(43) 0 2
(Loos et al. 2000) Case/Control 150(43) 0.90 1.45
(Slade et al. 2000) Prospective 12949(2253) 3.3 ±0.1 4.5 ±0.3
(Noack et al. 2001) Case/Control 174 (65) 1.70 ± 1.91 4.06 ±5.55
(Glurich et al. 2002) Case Control 80(44) 1.68 ± 1.42 2.40 ± 1.89
(Amar et al. 2003) Case Control 55(29) 1.0± 1.0 2.3 ±2.3
(Slade et al. 2003) Prospective 4504(4250) 5.8 ±0.13 7.6 ±0.65
(Joshipura et al. 2004) Cross/Sectional 468 (377) 1.8 ±3.0 2.2 ±2.5
Until now, only limited evidence has been reported from intervention studies aimed at 
establishing the nature of the association. Conflicting results have been observed after 
small pilot intervention studies. In some trials, the results of a negative association have 
been questioned because of the limited effect of the delivered periodontal therapy. In 
others high variability in terms of changes in acute phase markers was observed after 
therapy (Christan et al. 2002; Ide et al. 2003; Iwamoto et al. 2003; Mattila et al. 2002).
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C h a pte r  2. 
Ex pe r im e n t a l  H y po th esis
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2 .1 . E x p e r i m e n t a l  H y p o t h e s i s
Periodontitis has been associated with a series of systemic diseases (atherosclerosis, 
cardiovascular events, adverse pregnancy outcomes and metabolic control of type-2 
diabetes). The underlying pathogenetic mechanism(s) might lie in the host APR to 
periodontitis with its local inflammatory and infectious burden. Results of the 
association studies, the chronological consistency of the exposure, the biological 
plausibility, and data from animal models support the existence of a causal link between 
severe periodontal infections and a systemic inflammatory response of magnitude 
similar to that considered predictive of future development of systemic diseases such as: 
atherosclerosis, hypertension, or adverse pregnancy outcomes. The periodontal local 
infectious stimulus and the host inflammatory response associated with it might 
generate a systemic APR. Among the possible mechanisms through which periodontitis 
might influence systemic homeostasis we hypothesise: i) an excessive local production 
of pro-inflammatory cytokines (IL-1, TNF-a) which triggers systemic production of IL- 
6 and therefore induces a systemic APR; ii) periodontal pathogenic bacteria (Pg, Tf,Aa) 
or their toxic products (i.e. LPS) might invade local tissue and directly stimulate IL-6 
production or can directly disseminate into the bloodstread (ephemerous bacteraemias)
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Figure 6. Possible triggers of APR
Periodontitis may represent a moderate stimulus for a systemic acute 
phase response. Recognized inflammatory stimuli are obesity, vascular or 
myocardial tissue damage. Adapted from (Rader 2000)
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producing a systemic APR; iii) a combination of the two.
A chronic systemic inflammatory state can predispose individuals to future serious 
events (CVD, diabetes, stroke, PBLW) (see chapter 1).
The experimental hypothesis of this work was that periodontitis contributes to the 
overall inflammatory burden of the subject.
We selected to quantify in serum and blood both crude and sensitive markers that we 
assumed would represent a reliable method o f assessing the individual inflammatory 
burden (WBC, CRP, IL-6). If the association between systemic inflammation and the 
local periodontal infection were causal in nature, successful treatment o f periodontitis 
would lead to a significant decrease in these inflammatory markers. In order to assess 
the hypothesis we selected patients with severe and generalized forms o f periodontitis 
based on previous evidence indicating a dose response between exposure and 
cardiovascular events in an association study (Slade et al. 2000; Slade et al. 2003; Wu et 
al. 2000b).
The influence o f individual genetic susceptibility (polymorphisms in genes encoding 
cytokines) and of well recognized individual confounding factors (age, gender, 
ethnicity, body mass index, cigarette smoking) on patient response to periodontal 
therapy was also explored.
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2.2  S p e c if ic  A im s
• to assess, using a multi-level analysis approach, the overall efficacy and relative 
contribution of patient, tooth and site-associated factors in determining the 
clinical outcomes of standard periodontal therapy consisting of sub-gingival 
debridement performed with a machine-driven instrument. (Chapter 4)
• to assess whether the degree of individual response to periodontal treatment was 
associated with changes in serological markers of systemic inflammation (CRP, 
IL-6) in a cohort of otherwise healthy individuals (Chapter 4)
• to preliminary explore the effects of periodontal therapy on changes in the 
recently defined CRP-associated CVD risk in a group of otherwise healthy 
individuals. (Chapter 4)
• to investigate the possible association between specific cytokine polymorphisms 
and the systemic inflammatory response (estimated as serum CRP and IL-6) in 
individuals suffering from severe generalized periodontitis. (Chapter 4)
• to describe the changes in systemic inflammatory parameters consequent to an 
intensive periodontal treatment regimen, and to determine the kinetics of 
changes in inflammatory markers and mediators (CRP, IL-6, IL-IRa) in the 
early days following the delivery of periodontal treatment, an event that has 
been associated with bacteraemia. (Chapter 5)
• to evaluate the effect of a novel polymorphism (+1444C>T ) on CRP acute 
release after intensive periodontal therapy and its dependence from the IL-6/- 
174G>C polymorphism and standard cardiovascular (CV) risk factors. (Chapter 
5)
• to test in a 3-arm randomized, controlled intervention trial the short term effects 
o f different regimens of periodontal therapy on the systemic inflammatory status 
o f medically healthy individuals suffering from severe, generalized 
periodontitis. (Chapter 6)
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• to investigate in a randomized controlled trial whether different periodontal 
therapy regimens (standard vs intensive) were associated with a better control of 
the local and systemic inflammatory response. (Chapter 7)
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2 .3  E x p e r i m e n t a l  P l a n
Five interventional studies (three cohort studies and two randomized controlled clinical 
trials, Chapter 4, 5, 6, 7) were designed to ascertain whether the control of periodontal 
infection by different treatment modalities would affect the individual systemic 
inflammatory burden.
Chapter 4 describes the preliminary association between systemic inflammation and 
severe periodontitis in a cohort of 94 otherwise healthy individuals. We assessed the 
correlation between changes in serum levels of acute phase markers and individual 
genetic susceptibility, severity and extent of periodontal infection, and outcomes of 
standard periodontal therapy. (The candidate acted as periodontal examiner and 
collected biological samples. He performed serum quantification of IL-6).
With the second small intervention trial (chapter 5) we wanted to explore the acute 
phase response to a moderate inflammatory stimulus (represented by the delivery of 
periodontal therapy). This study also allowed the description of periodontal therapy as a 
novel non drug-induced model to study systemic inflammation (The candidate acted as 
therapist and performed serum quantification of IL-6, IL-IRa).
We then performed a larger cohort study to confirm the data obtained from this trial and 
in particular we addressed the question of whether or not genetic variation 
(polymorphisms) may contribute to the inter-individual variation in response. (The 
candidate acted as therapist and performed IL-6 quantification).
We then performed a randomized controlled pilot intervention trial (chapter 6) to 
evaluate the short term impact o f two different periodontal treatment regimens (sub­
gingival machine-driven instrumentation with or without local administration of an 
antimicrobial) compared to supragingival scaling and polishing alone on the control of 
the local and systemic inflammatory response associated with severe chronic 
periodontitis. (The candidate acted as therapist and performed IL-6 quantification).
The second randomized controlled trial (chapter 7) was designed to test the hypothesis 
o f a causal association between severe periodontitis and systemic inflammation. 
Changes in inflammatory markers were monitored for 6 months after treating
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systemically healthy individuals affected by severe generalized periodontitis with either 
a standard periodontal treatment regimen or an intensive one. (The candidate acted as 
therapist and performed IL-6 quantification).
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C h a pt e r  3.
G e n er a l  M a t e r ia l  a n d  M eth o d s
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3.1 S t u d y  C o n d u c t
3.1.1 L o g i s t i c s
All clinical intervention trials presented in this thesis were performed at the Eastman 
Clinical Investigation Centre (ECIC) of the Eastman Dental Hospital and Institute 
(EDI), University College London (UCL). The staff of the centre have been trained and 
dedicated only to clinical research trials. Each clinical trial taking place at the centre 
was conducted in accordance with the declaration o f Helsinki on experimentation 
involving human subjects. Study protocols were peer reviewed and approved by the 
joint local Ethical Committee of the Eastman Dental Hospital and UCL Hospitals. Each 
trial was also registered with the Research and Development Directorate of the UCL 
Hospital Trust.
3.1.2  C l i n i c a l  t r i a l  D e s ig n  a n d  O r g a n i z a t i o n
The screening phase of possible candidates for the trials took place within the new- 
patients clinics o f the department of periodontology. Individuals referred for periodontal 
therapy to the hospital were first examined by the department consultants. A general 
clinical periodontal examination was performed. If the subjects fulfilled the specific 
inclusion/exclusion criteria for the specific trial (Table 4) the information was presented 
by the attending consultant with the assistance of an information sheet (See Appendix 1 
for example).
The study was presented verbally to the patient by the consultant presenting the benefits 
and risks of participation. The patient was advised that the choice to participate was 
voluntary and their decision would not affect their future care in the hospital in any way. 
The patient was given the opportunity to ask questions. The trial information sheet was 
given to the patient to take home. They were advised to read it and be sure that they 
understood it fully. Following a minimum period of one week, the clinical research
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coordinator contacted the patient to ask if they had any questions regarding the 
information sheet and if  they had made a decision concerning participation. The 
consultant and members of the research unit were available to answer any possible 
query that the subjects asked. Based on a verbal agreement the baseline visit of the trial 
was scheduled and the patient, after signing a consent form (see Appendix 2 for 
example), was then re-examined.
Table 4 Inclusion/Exclusion Criteria
Inclusion  C r it er ia E xclu sio n  C r it e r ia
Between the ages of 35 and 60 and in good 
general health. Pregnant or lactating females.
Ability and willingness to follow study 
procedures and instructions.
Patients chronically treated (i.e., two weeks or 
more) with any vasoactive medication (e.g., 
anti-hypertensive), lipid lowering therapy or 
anti-inflammatory therapy (steroids, NSAID).
Must have read, understood and signed the 
Informed Consent.
Diagnosis of uncontrolled metabolic diseases 
including diabetes, kidney, liver, or 
cardiovascular diseases.
Individuals must have generalized, moderate to 
advanced chronic periodontitis as measured by 
the presence o f a 40 periodontal pockets with 
bleeding on probing.
Use of systemic antibiotics in the preceding 3 
month or patients who require antibiotic pre­
medication for the performance o f periodontal 
examination or treatment.
Patients suffering from chronic infectious 
diseases such as hepatitis B, HIV and TB.
Absence of other significant oral infections. Patients who received a course o f periodontal treatment within the last 6 months.
A comprehensive clinical periodontal examination was then performed by the study 
examiner who confirmed that the inclusion criteria were met. All data were recorded on 
study forms with the help of nursing staff. The subject was formally included in the trial 
and assigned a study number. Collection of biological (dental plaque, blood) samples 
was performed by the examiner. At the end of the baseline visit the patient left with a 
schedule o f all subsequent study dates according to the specific experimental design. A 
reasonable time allowance was given for each study visit depending upon the 
informations required. If it was planned, randomization was performed by the Clinical 
Trial Coordinator and treatment allocation was concealed using opaque envelopes. The 
study therapist opened the treatment assignment envelope only at the study treatment
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visit and only after having completed treatment common to both treatment groups. 
Clinical examiners remained blind to treatment allocation for the entire length of the 
study and subsequent data analysis.
3 .2  C l in ic a l  e x a m in a t io n  d a t a  a n d  E x a m in e r  C a l ib r a t io n
At the baseline visit, a full medical history interview was first performed to ascertain 
whether there were any risks for the individual or to verify the specific 
inclusion/exclusion criteria for participation to the study. A detailed intra-oral 
examination was then performed. Standard periodontal clinical parameters were 
recorded in full mouth fashion by a single calibrated examiner at six sites per tooth
FGM
• FGM
CEJ
FGM
Figure 7. PPD and REC recording procedures
A: Healthy periodontium, B: Initial lesion, negative REC recording, C: 
Advanced lesion, positive REC recording
(disto-mid-mesio -buccal and -lingual) using a manual, UNC-15 periodontal probe 
(PCPUNC15, Hu-Friedy, Leimen, Germany) with light force. Full mouth probing 
pocket depths (PPD) from the free gingival margin to the deep end of periodontal 
pockets were recorded (Figure 7.). Whenever a clinical measure fell between two 
millimetre markings on the periodontal probe it was rounded up. At proximal areas the 
probe was placed against the contact surface and the tip was as close as possible to the 
interproximal space. With the periodontal probe inserted into the gingival pocket and
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after calling the pocket depth reading, the examiner recorded the recession (REC) from 
the free gingival margin to the cemento-enamel junction (CEJ) by lifting the tip of the 
probe angled at 45° to the long axis of the tooth and seeking the tactile stop of the CEJ. 
Based upon the examiner discretion a different reference landmark (restoration margin, 
crown margin, incisal edge) was adopted and 
carried over at each examination visits whenever 
the location of the CEJ could not be detected.
REC data were recorded as positive or negative 
numbers if the CEJ was exposed or covered by 
the free gingival margin respectively.
Clinical attachment levels (CAL) were 
calculated subsequently from the formula PPD 
plus REC (Machtei et al. 1993). A total of 10 non-study subjects were recruited and 
used for calibration of the examiner. These subjects had periodontal disease and the 
examiner recorded on two different occasions full mouth PPD and recessions at six sites 
per tooth (excluding third molars) using a manual, UNC-15 periodontal probe. The two 
sets of measurements were recorded at least 30 minutes apart. CAL was algebraically 
calculated from PPD and REC according to the above formula. Upon completion of all 
sets of measurements, intra-examiner repeatability for CAL measurement was assessed. 
The examiner was judged to be reproducible after meeting a percentage of agreement 
within ± 2 mm between repeated measurements of at least 98% for CAL.
Full mouth plaque scores (FMPS) were recorded at six sites per tooth as the percentages 
of surfaces which revealed the presence of plaque over the total number of surfaces 
examined (O'Leary et al. 1972). After recording PPD and REC the examiner waited up 
to 25 seconds to score the presence/absence of any signs of gingival bleeding. Bleeding 
upon probing (BoP) was recorded at six sites per tooth and full mouth scores were
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Figure 8 Periodontal examination tray. 
Source: Hu-Friedy, Leimen, Germany
calculated as above (FMBS) (Tonetti et al. 2002). Furcation involvement was graded as 
described by Hamp et al using a Nabers probe (PQ2N, Hu-Friedy, Leimen, Germany) 
while tooth mobility was assessed according to the Miller scale(Hamp et al. 1975). All 
clinical data were entered at the end of the trial in an electronic spreadsheet by research 
staff blind to the trial and error-proofed by the clinical trial coordinator.
Standard periapical radiographs were obtained for all patients from the Radiology 
service of the EDI using a long cone parallel technique and aiming devices (Updegrave 
1951).
3 .3  M ic r o b io l o g ic a l  S a m p l e  C o l l e c t io n
Samples of subgingival periodontal plaque were collected by the examiner at the 
baseline visits before recording any periodontal parameters and according to the study 
protocol. Sites were identified based on the clinical charting performed during the 
screening visit. Using a sterile curette (Gracey, Hu-Friedy, Leimen, Germany) the 
examiner collected subgingival plaque samples from the 4 deepest pockets, one in each 
quadrant (questionable teeth planned to be extracted, as defined in section 3.5.2, were 
not included) (Grossi et al. 1994; Socransky et al. 1994). At each sampling site 
supragingival plaque was gently removed with a scaler (SM13/14S6 Hu-Friedy, 
Leimen, Germany), the site isolated from saliva with cotton-wool rolls (Paul Hartmann, 
Lancashire, United Kingdom) and the curette inserted in the pocket. With a gentle 
stroke the curette was moved upwards from the bottom o f the periodontal pocket to the 
free gingival margin. Samples were pooled and placed into 1 ml o f reduced transport 
fluid (Syed & Loesche 1972)(see Appendix 3 for details). Specimens were immediately 
transported to the Department of Microbiology at the EDI for analysis. At each follow 
up visits scheduled, plaque samples were re-collected by the examiner from the same 
pockets irrespectively of the changes in probing pocket depth.
3 .4  B l o o d  C o l l e c t io n
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Blood samples were collected from a single, clean venepuncture with minimal stasis 
from the antecubital fossa. Patients were seated in a comfortable reclined position and 
rested 5 minutes before the collection which took place before any dental procedure or 
examination was performed. Trained clinical staff located sites for collection 
(superficial veins of the upper limb: median cubital, basilic, cephalic) on the patient’s 
arm with the help of a tourniquet (ToumiClip Blue, Timesco, London, England)(Figure 
9). A single needle-stick procedure was performed after disinfecting the skin (Swab 
saturated with Isopropyl Alcohol 70%, Seton Healthcare Group pic, Oldham, United 
Kingdom ) and the samples needed drawn using a 23 Gauge Butterfly Needle with a 
luer adaptor (Vacutainer® Systems, Blood Collection Set, ref 367263, Becton
Dickinson, New Jersey, USA). The tourniquet was removed as soon as the blood
appeared in the tube to minimize any local venous stress.
The first tube of blood was drawn for full blood count analysis in a 1 x 5ml K2EDTA 
spray dried plastic tube (Purple top, BD 
Vacutainer®, Becton Dickinson, New Jersey,
USA) or discarded. The tube was labelled 
with patient information (name, hospital 
number, date and time of collection) with a 
water insoluble permanent marking pen with 
fine tip (Greiner Bio-One, Staedtler,
Lumocolor) and sent for same day analysis to 
the Haematology Laboratories at the UCL 
Hospital Trust. A second sample for specific 
serological analysis was collected into 1 x 
10ml glass tube with no additive (Red top, BD Vacutainer®, Becton Dickinson, New 
Jersey, USA) and an additional sample of blood (6ml K2EDTA plastic tube, Pink top,
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Figure 9 Blood collection sites.
Source: BD Becton Dickinson, New Jersey, USA
BD Vacutainer®, Becton Dickinson, New Jersey, USA) was collected for DNA 
extraction and subsequent genetic analysis. Tubes containing anticoagulant were 
inverted gently for 8 to 10 times after collection. All samples were then maintained 
upright, at room temperature (18-22°C) until centrifugation (the plain glass tube was 
allowed to clot for 30 minutes prior to centrifugation). Plain glass tubes were 
centrifuged at approximately 3800 rpm in a laboratory bench-top centrifuge (BR401, 
Denley, England) at 4°C for 10 minutes within 2 hours of collection. The supernatant 
serum was then removed, avoiding disturbance of the buffy coat, with a polypropylene 
transfer pipette (Brand Pasteur Plastic Pipette, Aldrich, Steinheim, Germany), and 
delivered into polycarbonate cryovials tubes in aliquots of 0.5ml (2.0 ml Cryogenic 
Vials, Cat. No. 5000-0020, Nalgene, Rochester, NY, USA). All cryovials were 
previously labelled using laser printed water and low-temperature resistant labels 
(L6008™, Heavy Duty Labels, Avery Dennison Corporation, Berkshire, United 
Kingdom). The aliquots of serum and the plastic K2EDTA pink tubes were frozen 
rapidly by transferring them to a -70°C freezer (U725, New Brunswick Scientific, 
Hertfordshire, United Kingdom), where they were maintained until processed. The 
samples were allowed to freeze rapidly, not placed in polystyrene racks.
Serum samples were thawed at room temperature and assayed in blind fashion in 
batches at the end of each clinical trial.
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3.4.1 S erum  a n a l y s is
Quantification of serum inflammatory markers (CRP) was performed on an automated
analyzer (Cobas Integra 700, Roche AG 
Diagnostics, Mannheim , Germany) at the 
Chemical Pathology Laboratories of the 
University College Hospital Trust.
The immuno-turbidimetric assay for serum 
quantification of CRP was standardized
against CRM (Certified Reference Material) Figure ,0. CRP Immunoassay Description
Source: Roche AG Diagnostics, Mannheim ,
470, 91/0619 RPPHS (Reference Preparation Germany
for Proteins in Human Serum) with a lower detection limit of 0.25 mg/L (Figure 10). 
Full blood counts were performed by means of automated haematology procedure 
(Automated Haematology Analyser SE-9000 RET/SYSMEX, Milton Keynes, United 
Kingdom).
3.4.2 C y t o k in e s  A ssa y
Cytokines assay (IL-6, IL-IRa) procedures were performed on first time thawed serum 
samples by means of a high sensitivity quantitative two-stage sandwich enzyme 
immunoassay technique (Quantikine R&D Systems, Inc., Minneapolis, USA). Same 
patient samples collected at different time points were all analysed in a blind fashion on 
the same plate to minimize variability. Each plate consisted of a 96 well polystyrene 
microplate (12 strips of 8 wells); wells were coated with a mouse monoclonal antibody 
against the cytokine to be studied. We describe the laboratory procedures for 
quantification of IL-6 in serum providing informations according to the manufacturer 
instructions. IL-IRa assay was performed in a similar fashion according to the 
manufacturer instructions.
70
3.4.2.1 R e a g e n t s  p r e p a r a t io n
All reagents were brought to room temperature before use and prepared as follows: 
Wash buffer: 100 mL of wash buffer concentrate were diluted into distilled water to 
prepare 1000 mL of wash buffer.
Substrate Solution: Solution was reconstituted from lyophilized substrate in 6 mL of 
substrate diluent.
Amplifier Solution: Solution was reconstituted from the lyophilized amplifier in 6 mL
of amplifier diluent and thoroughly mixed.
IL-6 Standard: A stock solution
of 10 pg/mL of standard was
reconstituted with 5 mL of the
calibrator diluent RD6-11.
Standards were allowed to sit for a
minimum of 15 minutes with Figure „  IL.6 standards preparation.
Source: R&D Systems Inc., Minneapolis, USA
gentle agitation prior to making
dilutions. 500 pL of the calibrator diluent RD6-11 concentrate were pipetted into each 
tube. The standard stock solution was used to produce a dilution series mixing each tube 
thoroughly before each transfer (10, 5, 2.5, 1.25, 0.625, 0.312, 0.156 pg/mL). Calibrator 
diluent served as the zero standard (0 pg/mL) (Figure 11).
3.4.2.2 A s s a y  p r o c e d u r e
After removing the microplate strip, 100 pL of assay diluent RD1-75 was added to each 
well. 100 pL of standard were added as duplicate into wells A-B 1 to 8. 100 pL of 
serum per well was afterward placed in duplicates in each consecutive well. Once the 
plate was full a cover adhesive strip was applied and incubated overnight at room 
temperature. The following morning the plate content was removed by inversion and
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decantation. Any excess of liquid was carefully removed by rapping the plate inverted 
on a clean paper towel at least 5 times. Each well was then filled with 400 pL of wash 
buffer using a multi-channel pipette (Finnipipette Digital - Multichannel Runcorn, 
United Kingdom). The liquid was then removed from the wells by inverting the plate 
and decanting the contents. A washing procedure followed and repeated 3 to 5 times.
200 pL o f IL-6 conjugate were then added to each well, covered with a new adhesive 
strip and left incubating for 2 hours at room temperature. After a washing step to 
remove any unbound conjugate (as described above) each well was filled with 50 pL of 
substrate solution and incubated this time for 60 minutes at room temperature. The 
amplifier solution (50pL) was then added to each well, covered and left for 30 minutes 
at room temperature. The reaction was stopped by adding 50 pL of stop solution to each 
well. Optical density of each well was determined within 30 minutes using a microplate 
reader (Titertek, Multiskan Plus MKIII, Labsystem, Finland) set to 490 nm.
Duplicate readings for each standard and sample were averaged and the zero standard 
optical density was subtracted for each one using Excel function (Excel XP, Microsoft 
Co., USA) (Figure 12).
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A linear graph was then created in
the same spreadsheet in order to plot
optical density of the standards
versus the concentration of the
standards. A linear regression
equation was then calculated where
the IL-6 concentration (y) equals
optical density reading (x) times
linear coefficient (m) plus or minus
intercept (z) (y = mx± z). If samples
were diluted the reading of the
concentration was multiplied by the
dilution factor. Intra-assay
coefficient of variation was
calculated from the formula:
Standard Deviation (between _ . , , . ,Figure 12 Optical density readings and IL-6
concentrations calculation.
duplicate concentration results) A First OD readings then averaged and final results after linear
regression correction
.• 1AA i- • .  j i .i   __  B Line Plot o f OD and IL-6 concentration, regression equationtimes 100, divided by the average mdcoefflcielrtsllsed
concentration result. Mean CV was calculated for each plate and inter-assay CV was 
calculated in a similar manner.
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3 .5  P e r i o d o n t a l  T h e r a p y
3 .5 .1  O r a l  H y g ie n e  I n s t r u c t io n s
Plaque control by self-performed daily oral hygiene procedures results in significant 
improvement of oral inflammation as evaluated from reductions in both dental plaque 
and superficial gingival inflammation (Axelsson & Lindhe 1981b; Axelsson & Lindhe 
1981c; Axelsson & Lindhe 1981a). All individuals enrolled into the intervention trials 
received individual oral hygiene instructions given by trained staff. A minimum of two 
to three appointments (within two weeks) 
were always reserved to monitor patients’ 
oral hygiene improvements with the help of 
plaque disclosing devices, instruction 
brochures of successful techniques, as well as 
providing patients with tooth brushes, 
interdental brushes and other hygiene aids as necessary(Figure 13). At each visit 
following periodontal instrumentation patients received reinforcement of oral hygiene to 
predispose for a favourable response (Axelsson & Lindhe 1981b; Axelsson & Lindhe 
1981c; Axelsson & Lindhe 1981a).
3 .5 .2  P e r io d o n t a l  T r e a t m e n t
Based on baseline clinical periodontal parameters and a full set of long-cone periapical 
x-rays, a proper tooth by tooth periodontal diagnosis was formulated for each individual 
by a consultant. We investigated for the presence of any carious process with or without 
pulpal pathology, periapical area of radiolucency, and where a possible resolution was 
predicted we sent written recommendation to the patients’ referring general dental 
practitioner to provide the necessary dental care. Periodontal instrumentation was 
performed only when such treatments were completed. We produced a prognostic chart
Figure 13 Oral Hygiene Aids 
Source: Dentocare Supplire, UK
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in which teeth were classified as secure, questionable or irrational to treat according to 
the extent of periodontal destruction, presence of severe furcation involvement and 
radiographic residual bone height based on the standard procedures of the Department 
of Periodontology of the EDI. Briefly, seriously involved teeth with Class III furcation 
involvement and/or 3+ mobility, and/or with periodontal 
lesions approaching within 3 mm of the apices were 
considered hopeless and extracted as part of therapy.
All individuals enrolled received periodontal treatment 
including complete subgingival debridement with scaling 
and root-planing under local anaesthesia (2% xylocaine 
with epinephrine 1:100,000, Astra Pharmaceuticals ltd.,
Hertfordshire, England).
Expert trained periodontists performed the necessary 
scaling and root planing using exclusively a piezoceramic device (Piezon Master 400, 
EMS, Nyon, Switzerland) (Figure 14) with 
continuous water irrigation and a selection of fine 
subgingival metallic tips (P, PS, PL2, PL3, PL4,
EMS, Nyon, Switzerland) (Figure 15). There was 
no time limitation for treatment: instrumentation had 
to be completed to the satisfaction of the therapist.
Particular emphasis on debridement was on furcation sites to meticulously remove any 
residual calculus since this has proven to result in good clinical results (Matia et al. 
1986) (Figure 16). At the treatment visits we also preformed extractions of teeth 
deemed to be “hopeless” or “irrational to treat” according to standard clinical 
parameters (eg., with advanced class III furcation involvement and/or mobility of grade 
III or less than 3mm of remaining periodontal support). In the context of these studies,
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Figure 15 Subgingival Piezon Tips
Source: Ems Nyon, Switzerland
Figure 14 Piezon Master 400 
Source: Ems Nyon, Switzerland
Figure 16 Subgingival instrumentation by Piezon Master
Source: Ems Nyon, Switzerland
we intended to control the local periodontal infection without using conventional 
periodontal flap surgery since a series of clinical investigations failed to demonstrate 
significant differences between thorough subgingival scaling and root planing and 
periodontal surgical procedures in patients with periodontitis (Becker et al. 1988; 
Kaldahl et al. 1996b; Kaldahl et al. 1996a; Knowles et al. 1979; Lindhe et al. 1982; 
Lindhe & Nyman 1985; Pihlstrom et al. 1983; Pihlstrom et al. 1984; Ramfjord et al. 
1982; Ramfjord et al. 1987; Westfelt et al. 1985).
At each follow-up visit following periodontal instrumentation, all individuals received 
standard supragingival prophylaxis together with reinforcement of oral hygiene. After 
follow-up clinical periodontal parameters were recorded, if any tooth exhibited 
progression of clinical attachment loss of > 2 mm from baseline, or if any clinical 
complications occurred (e.g. periodontal abscess) for the patients’ own safety the site 
was treated with an appropriate “rescue” procedure as decided upon by the staff. Any 
analysis of attachment loss between follow-up visits, included all teeth that had 
exhibited progressive CAL loss > 3 mm.
3 .6  G e n e r a l  S t a t i s t i c a l  A n a l y s e s
All data recorded were entered in computer database on a daily basis by staff blind to 
any clinical procedures and stored until the end of each trial. Two main statistical 
software packages were utilized to explore and analyse data (SAS version 8.1, Chicago, 
USA and SPSS, vl 1, Chicago, Illinois USA).
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All continuous variables entered were tested for normality by Shapiro-Wilk test. If 
normality assumptions were met data were reported by means and standard deviations. 
Parametric statistical tests were utilized to compare different time points outcomes by 
paired t-test, one-way ANOVA or ANCOVA or repeated ANOVA as appropriate. 
Whenever the primary outcome was to assess the efficacy o f a specific treatment we 
also performed independent t-test to assess the differences among subgroups (treatment 
-  control). Respective analyses for non normally distributed variables were, Wilcoxon 
rank-sum paired test, non parametric ANOVA (Kruskal-Wallis), Mann-Whitney test. 
These variables were reported as median and interquartile ranges.
Association between variables was assessed by non parametric correlation analysis 
(Spearman). Linear multiple regression analyses were performed to assess any 
significant contribution on primary outcome measures by all recorded covariates (e.g. 
age, smoking, gender, ethnicity, body mass index). Multicollinearity tables were also 
produced and variables affected were removed from the models (backward elimination). 
Non continuous variables were analysed by Chi-square test or McNemar test, the latter 
for paired comparisons.
Logistic regression models (binary or multinomial) were also utilized and OR with 
95%CI reported.
All analyses were performed with an intention to treat approach. Whenever a patient 
missed a follow-up or exited early from the trial the last recorded parameters were 
carried over.
A significant difference was set at p<0.05.
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C h a pte r  4.
Sever e  P e r io d o n t it is  and  
Sy stem ic  In f l a m m a t io n :
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4 .1  I n t r o d u c t i o n
In the last half century, dentists and physicians have emphasized that periodontal 
infections are localized to the marginal periodontium and that, as such, they rarely have 
systemic implications in healthy individuals. More recent evidence, however, has 
indicated that patients with severe periodontitis have increased serum levels of CRP, 
hyper-fibrinogenaemia, moderate leukocytosis, as well as increased serum levels of IL-1 
and IL-6 when compared with unaffected control populations (Amar et al. 2003; 
Ebersole et al. 1997; Fredriksson et al. 2002; Glurich et al. 2002; Hutter et al. 2001; 
Loos et al. 2000; Noack et al. 2001; Slade et al. 2000; Slade et al. 2003; Wu et al. 
2000b). These data have received considerable attention but fall short of indicating that 
periodontitis was the cause for the observed serum acute phase responses and thus of 
establishing that periodontitis may play a role in the etiologic pathway of systemic 
inflammatory diseases such as the metabolic syndrome and/or atherosclerosis. 
Atherosclerosis, with its consequent cardiovascular diseases, represents one of the 
leading causes of death in the industrialized world. Its aetiological pathway is one of a 
chronic inflammatory disease. However the stimuli of the invoked inflammatory 
reaction remain incompletely understood (Ross 1999). In the past fifteen years, many 
investigators, unable to attribute a large part of cardiovascular events to the well 
recognized risk factors (cholesterol, lipids, smoking etc), gave support to the old theory 
that chronic infections may cause atherosclerosis (Leinonen & Saikku 2002).
Several reports and a recent meta-analysis have shown increased odds ratios for 
cardiovascular events in large populations of subjects harbouring hypothetical triggering 
chronic infective agents (H. pylori, C. pneumoniae). The role of chronic infections on 
atherosclerotic cardiovascular diseases is now supported by a bulk of validating 
evidence that has also generated a series of antimicrobial intervention trials to establish
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causality in the association (Anderson et al. 1999; Danesh 1999; Fong 2000; Gupta & 
Camm 1998; Stone et al. 2002).
While the debate on the strength and nature of the association between periodontitis and 
cardiovascular diseases will continue for some time, recent evidence has changed the 
definition of periodontitis. Recognized risk factors include the important effect of 
cigarette smoking, and systemic diseases such as diabetes present also in the panel of 
the etiological agents for cardiovascular diseases (Genco et al. 2002; Genco 1996; Page 
& Komman 1997; Page et al. 1997; Page 1998). Subjects affected by periodontitis share 
common polymorphisms in specific genes considered important in the regulation of the 
inflammatory response (Komman et al. 1999; Komman 1999; Komman & Duff 2001). 
Genetic variations within IL-1, TNF-A, IL-6 genes, in different populations and 
settings, have been associated also with raised serum concentrations of CRP or other 
inflammatory markers (Berger et al. 2002; Vickers et al. 2002).
Two mechanistic hypotheses have been proposed regarding the aetiological pathways of 
the association between periodontitis, systemic inflammation and systemic diseases: one 
focuses on the chronic infectious burden that periodontitis may represent for the 
organism due to repeated challenges of either micro-organisms or endotoxin during 
mastication, tooth brushing etc.; the other sees the diseased periodontium as a source of 
systemic inflammatory mediators which are dumped into the systemic circulation and 
are capable of inducing a mild chronic low-grade inflammatory status (Graves 1999; 
Offenbacher et al. 1981). Either way the possibility that periodontitis can affect 
systemic health remains a matter of great interest.
We designed a pilot cohort interventional trial whereby severe periodontitis would be 
treated by machine driven devices (piezo-ceramic) and our aim was to explore the 
relationship between periodontal infections and systemic inflammation assessed by a 
cluster of inflammatory markers. We were also interested in investigating whether there
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was any dose-effect relationship between these two conditions and whether periodontal 
therapy would then affect the individual inflammatory basal state. We investigated the 
possible influence of recognized critical factors for systemic inflammation (age, gender, 
body mass index and smoking) and genetic variations (polymorphisms in inflammatory 
and pattern recognition encoding genes) on this association. Finally the relative 
importance of patient, tooth and site associated covariates on the variability of the 
clinical periodontal response of this cohort was also evaluated.
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4 .2  M a t e r i a l s  a n d  M e t h o d s
4.2 .1  E x p e r im e n t a l  P o p u l a t io n
The study was a prospective, single blind pilot intervention trial with 6 months follow- 
up. Participants were recruited from subjects referred to the Department of 
Periodontology of the EDI, UCL. Subjects presenting with severe (probing pocket 
depths greater than 6 mm and marginal alveolar bone loss greater than 30%), 
generalized (at least 50% of teeth affected) periodontitis were invited to participate in 
the study without any other systemic infection or disease. These levels of extent and 
severity of disease were chosen to increase probability of detection of a systemic burden 
from the local periodontal infection (Slade et al. 2000; Slade et al. 2003). Because of the 
advanced clinical condition, however, having an untreated control group was not 
possible (unethical) and a longitudinal cohort design was used to test the principle. 
Inclusion and exclusion criteria for screening of suitable candidates for the trial have 
already been reported in section 3.1.2. All patients gave written informed consent; the 
study had been reviewed and approved by the Eastman/University College London 
Hospitals joint ethics committee.
4 .2 .2  S t u d y  O u t l in e  
A baseline visit was conducted 
by a blind calibrated examiner 
who collected a complete 
medical history, standard 
clinical periodontal parameters,
blood and microbial samples.
A periodontal treatment phase 
followed and it was carried out by a periodontist. The patients were re-examined 2 and 6
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Figure 17 Study Experimental Design
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months after the completion of treatment when the same clinical and serological 
parameters were collected. After 6 months of therapy a subgroup o f individuals, who 
showed no needs for immediate further periodontal therapy, were monitored for a 
further six months (total of 12 months follow-up since their initial periodontal therapy). 
These individuals were re-examined and a blood sample was also collected.
4 .2 .3  P e r io d o n t a l  P a r a m e t e r s  a n d  E x a m in e r  C a l ib r a t io n
At the three study visits (baseline, 2 and 6 months) site (PPD, REC, CAL), tooth 
(furcation involvement, mobility) and patient (full mouth BoP and plaque scores) were 
recorded as described in section 3.2 by one calibrated examiner.
4 .2 .4  P e r io d o n t a l  t r e a t m e n t
Patients were treated for periodontitis by means of non surgical periodontal therapy 
delivered by a periodontist. Oral hygiene instructions and subgingival scaling and root 
planing under local anaesthesia were performed using a piezoelectric instrument 
equipped with appropriate subgingival tips (EMS, Switzerland). The therapist, without 
limitations in terms of time or number of visits, completed this phase within 1-3 months 
of the baseline visit. All other dental treatments (extractions of hopeless teeth, 
restorative and endodontic treatments) were carried out before completion of the 
periodontal treatment phase.
4 .2 .5  B l o o d  C o l l e c t io n  a n d  A n a l y s is
Serum samples were collected and processed as mentioned earlier (section 3.4) at 
baseline and 2 and 6 months after completion of treatment. Serum was obtained by 
centrifugation and stored at -70°C until analysis. CRP serum levels were assessed by an 
automated immunoturbidimetric high-sensitivity assay (Cobas Integra, Roche, lower 
detection limit o f 0.25 mg/L); IL-6 was measured by means of a commercial high- 
sensitivity ELISA kit (Quantikine HS, R&D System, Minneapolis, lower detection limit 
of 0.04 ng/L) ( section 3.4.1 for details).
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4 .2 .6  G e n e t ic  P o l y m o r p h is m s  A n a l y s e s
Patients’ DNA was extracted from peripheral leukocytes collected at baseline and stored
in an EDTA vacutainer tube in a -70°C freezer. A commercial kit was used according
to the manufacturer’s instructions (Nucleon® BACC2 kit, Nucleon Bioscience,
Coatbridge, UK). Blood samples were thawed at room temperature and 30 ml of reagent
A (red cell lysis buffer; 10 mM Tris-HCL pH 8; 0.32 M sucrose; 5 mM MgC12; 1%
Triton X-100) added to 10 ml of blood in a 50 ml polypropylene centrifuge tube. The
contents were mixed by inverting several times and then centrifuged at 1300g for 5 min
to sediment the leukocytes. The supernatant was discarded and 2.0 ml of reagent B
(white cell lysis buffer) and 300 jug of
proteinase K (Invitrogen, UK) were added to
the cell pellet. After vortexing, the tubes were
incubated at 37° C for 30 min and 0.5 ml
sodium perchlorate (0.5 M) was added, the
contents mixed by inversion, then 2.0 ml
chloroform was added and mixed again. 300
pi of Nucleon® resin was added and the tubes
centrifuged at 1300g for 3 min to separate the
phases, followed by removal of the upper
aqueous phase containing the DNA, which was
transferred to a fresh tube. Two volumes of cold ethanol were added to precipitate the
DNA and the DNA was resuspended in 250 pi of sterile water. The DNA concentration
was estimated by measuring absorbance at a wavelength of 260 nm using a
spectrophotometer.(Pharmacia Biotech, UK) 10 ng of DNA were subsequently used for
polymerase chain reaction (PCR) for common polymorphisms in: the IL-1A (Komman
et al. 1997): IL-1B (Komman et al. 1997; Komman et al. 1999): IL-6 (Fishman et al.
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C.fi CC GC
Figure 18 IL-6(-174) G stands for common 
allele, C is the rare allele.
1998):TNF-A (Gonzalez et al. 2003). TLR-4 (Lorenz et al. 2001) and IL-10 (Aithal et 
al. 2001).
Table 5 Primer sequences, PCR conditions and restriction enzymes used to amplify each marker and 
determine the genotypes___________________________________________________________________
M a r k e r P r im e r  s e o u e n c e s
IL -l A  (-889)
5 ’-AAGCTTGTTCTACCACCTGAACTAGGC -  3 ’
5 ’-TTACATATGAGCCTTCCATG -  3 ’
95°C 4 min, 45 cycles; 94°C 1 min, 50°C 1 min, 72°C 1 min, 
Nco 1 enzyme digest.
IL1 B (-511)
5 ’-TGGCATTGATCTGGTTCATC -  3’
5 ’ -GTTT AGG A AT CTT CCC ACTT -  3 ’
95°C 4 min, 35 cycles; 95°C 1 min, 53°C 1 min, 74°C 1 min 
Bco 1 enzyme digest
IL -l B (+3954)
5 ’-CTCAGGTGTCCTCGAAGAAATCAAA 3 ’
5 ’-GCTTTTTTGCTGTGAGTCCCG 3’
95°C, 4 min; 35 cycles; 95°C for 1 min, 67,5°C 1 min, 74°C 1 min 
Taq 1 enzyme digest.
IL -6 (-174)
5’ T G ACTT C AGCTTT ACT CTT GT 3 ’
5’ CTGATTGGAACCCTTATTAAG 3 ’
95°C, 4 min; 35 cycles; 95 °C, 45 sec; 63 °C, 1 min; 72 °C, 75 sec 
Hsp 211 enzyme digest.
T LR 4 (-299)
5 ’ -G ATT AGC AT ACTT AG ACT ACT ACT ACCTCCTCC ATG-3 
5 ’-GATCAACTTCTGAAAAAGCATTCCCAC-3 ’
95°C, 4 min; 30 cycles; 95°C, 30sec; 55°C, 30sec; 72°C, 30sec. 
Nco 1 enzyme digest.
T LR 4 (-399)
5 ’-GGT TGC TGT TCT CAA AGT GAT TTT GGG AGA A-3’ 
5’-ACC TGA AGA CTG GAG GAG TGA GTT AAA TGC T-3’ 
95°C, 4 min; 30 cycles; 95°C, 30sec; 55°C, 30sec; 72°C, 30sec 
Hin fl enzyme digest.
T N FA (-308)
5 -AGG CAA TAG GTT TTG AGG GCC AT-3'
5 -TCC TCC CTG CTC CGA TTC CG-3'
94 °C, 4 min; 35 cycles; 94 °C, 2 min; 60 °C, 1 min; 72 °C, 1 min. 
Taq 1 enzyme digest.
IL -10(-627)
5 ’-CTTAGGTCACAGTGACGTGG-3 ’
5 ’ -GTG AGC ACT ACCT G ACT AGC-3 ’
94 °C, 4 min; 35 cycles; 94 °C, 1 min; 50 °C,1 min; 72 °C, 1 min 
Rsa I enzyme digest
Each PCR reaction was performed in a 25 pi volume containing 1 pi of DNA in buffer
containing 10 mM Tris-HCl, pH 8.3, 50 mM KC1, 500 pM of each dNTPs (dATP, 
dCTP, dTTP, dGTP), 50 pmol of each of the primers and 1U of taq polymerase 
(Abgene, UK). The MgCh concentration varied for different primers. Sequences of the 
oligonucleotide primers used for PCR amplification, the size of the predicted PCR 
products and the PCR amplification program used were described previously and are 
listed in table 5. Alleles were identified following digestion with restriction 
endonucleases on a 3% agarose gel containing 0.5 mg/ml ethidium bromide in 1 TBE
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buffer at 100 V for 2 h. The bands were visualised using a UV transilluminator (Alpha 
Innotech Ltd., UK)
4 .2 .7  M ic r o b ia l  S a m p l e s  a n d  A n a l y s is
Samples of subgingival periodontal plaque were collected at baseline and two and six 
months after completion of periodontal treatment. Details of the procedure can be found 
in section 3.3.
Bacterial DNA was isolated from the plaque samples by the use of a commercial DNA 
extraction kit (Puregene, MI, USA). The DNA was then used as a template to carry out 
amplification of the bacterial 16S rRNA gene to confirm the presence of bacterial DNA 
in each sample. This 16S rRNA gene product was then used as a template using species 
specific primers to amplify regions of DNA specific to one o f three different periodontal 
pathogens by the use of multiplex-polymerase chain reaction (Tran & Rudney 1999). 
The use of these primers produced three different sized DNA products for Tannerella 
forsythensis (Tf) [formerly Bacteroides forsythus], Porphyromonas gingivalis (Pg) and 
Actinobacillus actinomycetemcomitans (Aa). PCR products were then visualised on an 
agarose gel. The presence of a DNA band at the expected size allowed confirmation of 
the presence of the pathogen within the plaque sample. Two rounds of PCR were 
performed with specific primers in order to produce a detection limit as low as 10 
cells/ml (Gafan et al. 2004; Tran & Rudney 1999).
4 .2 .8  S t a t is t ic a l  a n a l y s is
4.2.8.1 G e n e r a l  A n a l y sis
As this was a pilot intervention trial, the sample size of this study was not based on 
formal power calculations but on logistic considerations. No other study was found in 
the literature at that time to perform a sample size analysis. All data were entered in a 
computer file, proofed for entry errors and analysed with a two statistical packages 
(SAS version 8.1, Chicago, USA; SPSS, v l l ,  Chicago, Illinois USA). Continuous
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variables are presented as mean and standard deviation or as median and interquartile 
range if  data were not normally distributed. A logarithmic transformation was necessary 
to normalize IL-6 and CRP serum concentrations prior to any parametric analysis. The 
Shapiro-Wilk test was used to validate the normality assumptions of both Log[IL-6] and 
Log[CRP] concentrations. Whenever aggregate variables are reported (average of 
averages) standard errors are utilized to describe specific variability. Differences in 
periodontal parameters among various subgroups and between visits were analyzed by 
one way ANOVA or t-test as appropriate. The Chi-square test was utilized to determine 
significant association among categorical variables. Significant correlations among 
inflammatory markers were tested by non parametric analysis (Spearman’s rank 
analysis). Clinical and microbiological outcomes were defined in terms of changes in 
PPD, REC, CAL and presence of specific periodontal pathogens at different time points. 
Paired differences in categorical variables were determined by McNemar paired test 
(e.g. presence or absence of periodontal pathogens after two and six months).
The statistical plan included an analysis on clinical periodontal parameters using both a 
standard and multilevel (site, tooth, patient) approach. Inflammatory markers basal 
concentrations and changes after periodontal therapy were analysed with standard 
statistical procedures including the influence of different genetic polymorphism on 
basal and post-treatment serum parameters concentrations.
4.2.S.2 I n f la m m a t o r y  M a r k e r s
Changes in serum concentrations of CRP and IL-6 following periodontal therapy were 
used as the primary outcome variables. Due to previously reported intra-individual 
variations in terms of serum CRP concentration, the association of independent 
variables with serum IL-6 and CRP concentrations was assessed by linear multiple 
backward elimination regression analysis. The effects o f various genotypes on serum 
Log[IL-6] and Log[CRP] were analysed by means of ANOVA or independent t-test, as
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appropriate. Serum IL-6 and CRP concentrations were preliminarily adjusted for age, 
body mass index, gender, ethnicity and smoking. The individual response to periodontal 
therapy in terms of changes in inflammatory markers was assessed by constructing a 
generalized linear model (using the SAS PROC GLM and REPEATED statement) that 
included the following confounding factors: age, gender, body mass index, cigarette 
smoking and cytokine polymorphisms. The null hypothesis was o f no changes in CRP 
and IL-6 concentrations following periodontal therapy. Bivariate and multivariate 
logistic regression analyses were also used to compare the effect of periodontal 
treatment on changes in CRP concentrations. Odds ratios (95% Cl) were calculated after 
correcting for potential confounders such as age, gender, ethnicity, body mass index and 
cigarette smoking.
4.2.8.3 M u l t il e v e l  A n a l y sis
In order to assess the variance attributable to the different levels o f the clinical 
periodontal data, i.e. the patient, the tooth and the site, a multilevel approach was 
utilized to fully respect the data hierarchy as well as the nested structure of the 
variability: site within the tooth, teeth within the patient (Gilthorpe et al. 2000a; 
Gilthorpe et al. 2000b; Gilthorpe et al. 2001). 3 levels o f variability were defined (the 
patient, the tooth and the site) (see table 6) to construct specific equations essentially 
representing an evolution of multiple linear regression models (Raudenbush & Bryk 
2002). All variables entered into the analysis are listed in table 6. Site and tooth 
parameters described in section 4.2.3 were included in each model with an additional 
tooth variable (tooth type = molars, premolars and incisors including canines). The 
following patient information was also entered into the analysis: age (years), gender, 
smoking status, body mass index (in Kg/m2), ethnicity, diagnosis (chronic periodontitis 
vs. aggressive periodontitis, as defined by the American Academy of Periodontology 
guidelines)(2000b; 2000c; 2000a; Califano 2003). The time o f subgingival
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instrumentation (in minutes) was noted and aggregate variables were calculated for each 
subject by averaging specific site information: full mouth plaque (FMPS) and bleeding 
on probing (FMBS) scores were considered as the percentages of total surfaces which 
revealed the presence of plaque or bleeding within each subject. The average number of 
periodontal pockets 5 mm or deeper (NPPK) as well as full mouth averages of PPD and 
CAL were derived. The carriage of one or two copies o f the rare alleles in several 
polymorphisms was also included (see Table 6 for classification details).
Two separate variance components models (or null model) were constructed using 
changes in PPD, and CAL between baseline and 6 months (APPD, ACAL) as the 
dependent variables first without inserting explanatory variables. The null model was 
used to estimate the overall variability of changes in the dependent variables tested and 
to attribute it to the patient, tooth and site levels. A series o f explanatory variables were 
then entered into each model (covariate model). This further step allowed examination 
of the relationship between each covariate and the dependent variable.
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Table 6 MLM clinical covariates selection according to three different level o f variance (patient, tooth 
and site)__________________________________________________________________________________
V a r ia b l e  a t  b a se l in e  Ch a r a c t e r is t ic s
Age Continuous, years
Gender Female=0, Male=T
Ethnicity Caucasian=l, Non Caucasian=0
Smoking Current Smoker=l, Non Smokers=0
Diagnosis Chronic Periodontitis=0, Aggressive=l
BMI Continuous, kg/m2
FMBS Continuous (average full mouth)
FMPS Continuous (average full mouth)
NPPK Continuous (average full mouth)
Pg
Presence at Baseline of Pg=l, Absence of
Patient Pg=0
AA Presence at Baseline of Aa=l, Absence ofAa=0
Tf Presence at Baseline of Tf=l, Absence ofTf=0
Treatment Time Continuous, minutes
N° Teeth Extracted Continuous, number
IL-6 (-174) GG allele=0, GC-CC alleles=l
IL-10(-627) CC allele=0, CA-AA alleles=l
TNFA(-308) TLR-4(-299, -399), 1.1 allele=0, 1.2-2.2 alleles=lIL-lA(-889), IL-1B(-511, +3954),
Mobility Categorical, Grade 0,1,2,3
Tooth Furcation Furcation Present=l, Furcation Absent=0
Type: Incisors, Premolars, Molars Categorical, Incisors (including canines) =0, Premolars=l, Molars=2
Plaque Plaque present=l, Plaque Absent=0
Site BoP BoP present=l, BoP Absent=0Mesio-Distal Mesio-distal sites=l, Bucco-Lingual=0
APPD (Baseline-6 Months) Continuous, mm
The normality assumption criterion for inclusion o f the dependent variables were 
verified with the Kolmogorov-Smimov test (Goldstein 1986; Goldstein 1989; Goldstein 
et al. 2002). Furthermore an analysis of model residuals was done to confirm the 
validity of the procedure(Goldstein 1986; Goldstein 1989; Goldstein et al. 2002; 
Goldstein & Goldstein 1995; Goldstein et al. 2001; Goldstein 2002). A multi- 
collinearity analysis was performed for each explanatory variable derived. Every linear 
association was corrected by eliminating the specific variable until the final model 
fulfilled standard criteria(Bryk & Raudenbush 1992). Regression estimates were
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calculated by means of the iterative generalized least square (IGLS) algorithm using 
dedicated software(A//wz7V v2.0) (Rasbash et al. 2000). The fit change of each model (-  
2Log Likelihood) including/excluding explanatory variables was calculated and the 
significance tested by Chi-square analysis (Goldstein & Goldstein 1995). A significant 
difference was set to be at p < 0.05.
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Se v e r e  P e r io d o n t it is  a n d  
M a r k e r s  o f  s y s t e m ic  
In f l a m m a t io n
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4 .3 .1  S u m m a r y
Severe periodontitis is associated with elevated inflammatory markers in otherwise 
healthy populations. However the nature of this association has not been determined. 
The aim of this specific analysis was to assess whether the degree of response to 
periodontal therapy was associated with changes in serological markers of systemic 
inflammation. Periodontal parameters and inflammatory markers CRP IL-6 were 
evaluated prior, and 2 and 6 months after delivery of standard non surgical periodontal 
therapy in a cohort of 94 systemically healthy subjects with severe generalized 
periodontitis participating in a prospective 6 months intervention trial. 6 months after 
treatment, significant reductions in serum IL-6 (p<0.001, median decrease 0.2 ng/L, 
95% Cl 0.1-0.4 ng/L) and CRP (p<0.0001, median decrease 0.5mg/L, 95 % Cl 0.4-0.7) 
were observed. In a multivariate model, serum CRP levels were significantly associated 
with the outcome of periodontal treatment after correcting for common covariates (age, 
body mass index, gender, smoking) and polymorphisms in the IL-6 (-174 C/G) and IL­
IA (-889) genes. Subjects with above average response to periodontal therapy (<30 
residual pockets and <30% of sites bleeding on probing) accounted for the observed 
improvement in serum CRP after correcting for possible confounders. Control of 
periodontitis, achieved with non surgical periodontal therapy, significantly decreased 
serum mediators and markers of acute phase response. Periodontitis may add to the 
systemic inflammatory burden of affected individuals.
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4 .3 .2  I n t r o d u c t io n
Support for the hypothesis that periodontitis driven inflammatory responses are of 
significance for otherwise healthy individuals is at least threefold: i) periodontitis has 
been associated with increased odds of cardiovascular events (Scannapieco et al. 2003), 
of delivering pre-term low birth weight babies (Offenbacher et al. 1998a), and of having 
sub-optimal control of type II diabetes (Grossi & Genco 1998); ii) the strength of 
association between periodontitis or other chronic infections and cardiovascular events 
seems to be of similar magnitude (Danesh 1999); iii) experimental pre-clinical models 
have indicated that chronic infection with periodontal pathogens leads to thickening of 
the carotid intima (Lalla et al. 2003; Li et al. 2002) to cause metabolic changes 
(hyperlipidemia) capable of increasing the risk of atherosclerosis (Jain et al. 2003) and 
to induce foetal growth restriction (Collins et al. 1994b).
In recent years an increasing number of epidemiological studies have indicated that 
subjects with periodontitis may have increased risk o f experiencing future 
cardiovascular events (Beck & Offenbacher 2001). There are however some reports 
which did not find any significant association (see Table 2). Critics have underlined the 
fact that both periodontitis and atherosclerosis share commonalities in terms of 
established risk factors, and that the association, even if  established, could be spurious. 
If the association were firmly established, however, the critical question of its nature in 
terms of possible causality will remain central to understanding the medical significance 
of periodontal infections.
Independently of the underlying mechanism(s), systemic inflammation seems to be 
central for explaining the nature of the link between chronic infections and 
atherosclerosis (Danesh et al. 2000; Libby et al. 2002; Pearson et al. 2003). In this 
respect, CRP is generally considered as the most sensitive marker of the APR to
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infectious burdens and/or inflammation (Gabay & Kushner 1999). As a consequence of 
its kinetics, it best describes the inflammatory status of the individual (de Maat & Kluft
2001) (see section 1.1.4). CRP hepatic production is usually elicited by an inflammatory 
stimulus and mediated through a complex network of cytokines (mainly IL-6) (Ablij & 
Meinders 2002). CRP serum concentrations in the upper quartiles of normality, 
moreover, have assumed a significant role as predictors for future coronary events in 
healthy populations (Ridker et al. 1997). Systemic low grade infections with their 
moderate acute phase responses may accelerate the formation of atheromatous plaques 
with consequent increased risk of future cardiovascular events (Danesh et al. 2000). 
This body of emerging evidence, however, has left unanswered a series of questions on 
the debated link between chronic infections, e.g. periodontitis, and atherosclerotic 
events.
The aim of this first analysis was to assess whether the degree of individual response to 
periodontal treatment was associated with changes in serological markers of systemic 
inflammation, i.e. CRP and IL-6, in otherwise healthy individuals. Clinical periodontal 
and microbiological outcomes were also analysed to validate the level of efficacy of 
periodontal treatment.
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4 .3 .3  R e s u l t s
94 subjects agreed to participate in the study and all reached the 6 months follow up. 
Overall subjects were 46 ± 9 years of age, 54 % were females, 42 % were current 
smokers and 26 % had a family history of cardiovascular diseases (see Table 7). The 
sample population included 75% chronic periodontitis patients while 25% were affected 
by a generalised aggressive form (2000b; Califano 2003). Their average body mass 
index was 25.3 ± 3.7 kg/m2.
Table 7 Baseline Patients Characteristics
V a r ia b l e M ea n  ± SD
Age (years) 46 ± 8
Gender Female 54%
Smoking Current smokers 42%
Body Mass Index kg/m2 25.3 ±3.7
Family history of CVD Positive 26%
Periodontal Diagnosis Chronic 75% Aggressive 25%
Nr o f teeth at Baseline 27 ± 3
Nr of teeth extracted 2 ± 2
During the 6 months study period none of the subjects reported any change in diet, 
medication or smoking habits. After the 6 months follow-up examination 34 individuals 
were allocated to receive further periodontal treatment whereas 60 individuals were 
monitored for another 6 months.
The recorded clinical periodontal parameters emphasize the severity and extent of the 
periodontal infection (Table 8). Participants presented with high levels of gingival 
inflammation (full mouth bleeding scores of 63.5 ± 16.4%) and severe widespread 
periodontitis (average of 77 ± 23 periodontal lesions per subject with an average clinical 
attachment level loss of 3.1 ±2.5 mm)(Figure 19).
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Multiplex PCR detectable levels of specific anaerobic pathogens were found in the 
majority of the cases as follows: 76.3 % of the subjects were positive for T f 72.8 % for 
Pg and 43.8 % for A.a, indicating the high prevalence o f infection with recognised 
periodontal pathogens in this population.
4 .3 .3 .2  E f f e c t s  o f  T r e a t m e n t  o n  P e r io d o n t a l  O u t c o m e s  
The clinical periodontal outcomes of treatment are displayed in Table 8. Oral hygiene 
was significantly improved with 2 and 6 months FMPS averaging about 20% at both 2 
and 6 months. FMBS also reached averages of 16 and 17% at 2 and 6 months, 
respectively. Subjects showed a significant reduction in the number of periodontal 
pockets (probing 5 mm or more) from 77±23 at baseline to 28±16 at 2 months and 
23±15 at the 6 months follow up (PO.OOOl, t-test). Changes in full mouth patient 
averages in terms of PPD, REC but not CAL were also significant at the different time 
points (PO.OOOl, t-test) (Table 8).
Table 8 Clinical periodontal parameters before and after treatment.
B a s e l in e 2 M o n t h s 6  M o n t h s
M e a n SD M e a n SD M e a n SD
FMPSJ 58.04 20.70 20.90f 14.29 20.08f 10.42
FMBSJ 63.57 16.39 15.80t 11.57 17.10t 11.91
N r Pockets* 77.08 23.23 27.82| 16.36 22.91t 15.04
PPD mm 4.36 0.59 3.25f 0.47 3.19 | 0.47
REC mm 0.56 0.88 1.56f 0.94 1.72| 0.94
CAL mm 4.93 1.13 4.74 1.14 4.85 1.13
*Number o f pockets with PPD>4mm. PPD, REC and CAL represent full mouth 
averages o f each subject.
X FMPS = Full mouth plaque score, FMBS = Full mouth bleeding score 
f  PO.OOl t-test compared to baseline.
A significant reduction in the prevalence of Pg positive subjects, from 72.8% at baseline 
to 34.2% at 2 months was achieved (pO.OOOl Me Nemar test). After six months of 
standard periodontal therapy the number of individuals positive for all three periodontal 
pathogens significantly decreased. Pg positive subjects remained significantly lower 
than baseline (36.0 % pO.OOOl Me Nemar test ). T f and Aa samples although did not
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reach statistical significance after two months, at 6 months were both significantly 
reduced (52.6 % p=0.030 and 25.4% p=0.025 respectively).
Figure 19 Patient clinical features before and after periodontal therapy
A Baseline clinical pictures (frontal and lateral views) B Baseline periapical full mouth radiographical assessment 
C 6 months clinical pictures (frontal and lateral views)
4 .3 .3 .3  E f f e c t  o f  P e r io d o n t a l  T r e a t m e n t  o n  S e r u m  In f l a m m a t o r y  
P a r a m e t e r s
The baseline median level of CRP was 1.9 mg/L (3.6 IQR, Figure 20) whereas the level 
of IL-6 was 1.8 ng/L (1.5 IQR, Figure 20. No significant differences in concentrations 
were found among different groups according to age, gender, periodontal diagnosis 
(chronic vs aggressive periodontitis) and smoking status.
Both inflammatory markers had a positively skewed distribution curve. A significant 
decrease in serum IL-6 concentration was found at 2 and 6 months after completion of 
periodontal treatment (p=0.021, p=0.006, respectively Wilcoxon test). CRP serum
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concentration decreased significantly only at the 6 months follow up (p< 0.0001, 
Wilcoxon test, Figure 20). The median change in CRP concentration between baseline 
and six months was of 0.5 mg/L with a distribution free 95 % confidence interval of 0.4 
to 0.7 mg/L.
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Figure 20 Box and whiskers plots showing CRP serum levels before and 2 and 6 months following 
treatment of periodontitis (N=94).
The box refers to the 25th (bottom) and 75th (up) percentiles and the median is the horizontal line inside. 
See text for details
The difference in median concentration of IL-6 was 0.18 ng/L (0.02 -0.44 95%CI) 
between baseline and 2 months and 0.22 ng/L (0.06-0.44 95%CI) between baseline and 
6 months (Table 9)
Table 9 Median differences o f systemic inflammatory markers at 2 and 6 months follow up.__________
A B a s e l in e -2  m o n t h s *!* A B a s e l in e -6  M o n t h s *!*
M e d ia n  ± IQ 95% Cl* M e d ia n  ± IQ 95% Cl*
CR P (m g/L) 0.1 ± 1.0 -0.3 0 0.5 ± 1.3 0.4 0.7
IL-6 (ng/L) 0.18 ± 1.0 0.02 0.4 0.22 ± 1.0 0.06 0.4
* 95% Confidence Interval distribution free 
f  A = Difference o f serum systemic markers between visits.
Improvements in serum IL-6 and CRP concentrations were observed comparing 
baseline and 6 months values in 73% and 62% of subjects, respectively.
Due to heterogeneity of response to periodontal treatment (in terms of clinical 
periodontal parameters) and to the presence of well established covariates such as
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smoking, age, gender, and body mass index, data were further explored using a repeated 
measure analysis of covariance model with Log CRP as the dependent variable (Table 
10). For the purposes of this analysis subjects were classified in terms of their level of 
response to periodontal therapy based on the median number of residual pockets and the 
median percentage of bleeding sites 6 months after treatment. The group with the better 
response to periodontal therapy was characterised by the persistence of less than 30 
pockets 5 mm or deeper and less than 30% bleeding on probing. Among these subjects 
with the better periodontal response, 79.2% displayed a decrease in serum CRP.
Table 10 Association of changes in serum CRP and IL-6 with the degree o f clinical response to 
periodontal therapy after controlling for tested confounders_________________________________________
LOG [CRP] (MG/L) N =94 LOG [IL-6] (n g /L ) N=94
3 ± S E P 3 ± S E P
Modela <0.001 0.001
Intercept -0.859 ± 0.181 <0.001 0.034 + 0.146 0.817
Periodontal Treatment Effect=0b -0.022 + 0.012 0.069 -0.007 + 0.010 0.500
Periodontal Treatment Effect=lb -0.030 ± 0.009 <0.001 -0.014 + 0.007 0.041
AGE (years) 0.009 ± 0.002 <0.001 0.007 ± 0.002 <0.001
Body Mass Index (Kg/m2) 0.024 ± 0.004 <0.001 0.003 ± 0.004 0.355
SMOKING
[smokers vs. non smokers] 0.112 + 0.043 0.010 -0.006 ± 0.035 0.861
IL-6 (-174 G/C) [CC vs GC]C 0.189 + 0.065 0.004 0.010 + 0.053 0.853
IL-1A (- 889) [2.2 vs l . l ] c -0.109 + 0.056 0.054 -0.033 ± 0.046 0.478
IL-1A (- 889) [2.2 vs 1.2]c 0.095 ± 0.054 0.082 0.021 + 0.044 0.637
IL-1B (-511) [2.2 vs l . l ] c -0.039 ± 0.065 0.551 -0.165 + 0.054 0.002
IL-1B (-511) [2.2 vs 1.2]c 0.017 + 0.062 0.783 -0.134 + 0.051 0.009
IL-1B (+3954) and GENDER NS NS
a Generalized Linear Model testing the association of changes in Log[CRP or IL-6] between 0 and 6 months with the 
level o f response to periodontal treatment, age, gender, body mass index, smoking status, tested cytokine
polymorphisms. Model: Log [CRP] Adj. R2 = 0.312; Log [IL-6] Adj. R2 = 0.134 
Periodontal Treatment Effect indicates better than median (1) or worse than median (0) outcomes of periodontal 
therapy in terms of clinical parameters (number of residual pockets less than 30 and full mouth bleeding less than 
30%).
0 The analysis compared the effect of being homozygous for the rare allele (2.2 or CC for IL-6) with either being 
heterozygous or homozygous for the common allele (1.2 or 1.1, and GG or GC for IL-6)
A highly significant model was constructed that explained 31% of the observed
variability in Log CRP in terms of effectiveness of periodontal treatment, age, body
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mass index, smoking status, and carriage of specific cytokine genotypes (Table 10). 
Data indicated that there was a significant interaction between the treatment outcome 
and the overall CRP levels (baseline, 2 and 6 months), and that the decrease in CRP was 
significant in those subjects who had the best outcomes in terms of periodontal 
parameters. The effect was significant after correcting for other known covariates such 
as age, gender, body mass index and smoking. Furthermore, the analysis indicated that 
serum CRP concentrations were significantly associated with carriage of specific 
polymorphic functional alleles in the promoter region of the IL-6 (-174G/C) and IL-1A 
(-889) genes. Carrying different alleles at the polymorphic sites of IL-1B gene (-511 and 
+3954) did not reach significance in the model. These polymorphisms were included in 
the analysis since they have shown to influence basal level of CRP serum 
concentrations (Berger et al. 2002; Vickers et al. 2002).
A similar analysis using Log IL-6 as the dependent variable indicated that serum IL-6 
changes were also associated with the outcomes of periodontal treatment as well as with 
covariates such as age o f the subjects and a specific polymorphism in the IL-1B gene (- 
51 l)(Table 10).
When we examined after 12 months a subgroup o f 60 subjects, CRP serum 
concentrations were still significantly lower than their baseline values. This subgroup 
had a baseline CRP value of 1.8 mg/L (95%CI 1.1-4.3) and showed a significant 
reduction after 6 months (median decrease 0.4 mg/L, 95%CI 0.0-1.1) in line with the 
results of the whole population. After 12 months of completion of therapy, the median 
CRP value was 1.4 mg/L (95%CI o f 1.0-2.7) and it was significantly lower than 
baseline (P=0.003 Wilcoxon rank-sum test) (Figure 21). The significant median change 
between baseline and 12 months concentrations was 0.4 mg/L with a 95%CI of 0.3-1.2.
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Figure 21 Box and whiskers plots showing CRP serum levels before 
and 2 and 6 and 12 months following standard periodontal treatment 
(N=60)
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4 .3 .4  D is c u s s io n
Effective control of periodontal infection reduced serum inflammatory markers (CRP, 
IL-6) in a relatively small population (N=94) with severe generalized periodontitis. 
Significant decreases in IL-6 were observed already 2 months after therapy, while 
decreases in CRP were observed only after 6 months. In a subgroup analysis, 
furthermore, concentrations of CRP remained significantly lower than their baseline 
levels up to 12 months from the initial periodontal therapy. O f particular relevance, 
given the preliminary nature of this trial and the lack of a control group, was the 
observation that reductions in both CRP and IL-6 were significant in subjects who 
responded better than average to the delivered periodontal therapy. Indeed, 79.2% of the 
subjects who responded better to periodontal therapy showed an improvement in serum 
CRP. Within the limits of the cohort uncontrolled design, the data indicated that, in this 
systemically healthy population, there might be a strong association between 
periodontitis and the systemic inflammatory status. These data also indicated that 
maximizing the potential response to periodontal therapy is critical in the context of the 
design and implementation of a definitive trial.
In this respect it seems relevant to emphasise that serum CRP and IL-6 levels detected 
at baseline were in the upper quartiles of the current definition of normality when 
determined with a high sensitivity assay, rather than being in ranges usually associated 
with acute infections or systemic inflammatory diseases. These data confirm previous 
observations that otherwise healthy subjects suffering from chronic periodontitis display 
a moderate increase in systemic inflammation (Loos et al. 2000). This is important in 
providing a proper interpretation of these findings: in the context of infections 
physicians have considered frankly elevated CRP values as an indication of a systemic 
infectious burden requiring appropriate therapeutic measures. More recent data from
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longitudinal studies, however, have indicated that acute phase response markers such as 
CRP and/or IL-6 in the upper distribution of normality seem to be predictive of 
atherogenesis and cardiovascular events (Danesh et al. 2000; Ridker et al. 1997). 
Periodontitis patients have higher CRP and IL-6 levels when compared with matched 
periodontally healthy populations (see Table 3). However it has become clear that some 
confounding factors (e.g. cigarette smoking) may be underlying these associations.
We observed a linear positive correlation between the severity o f periodontitis and the 
serum concentrations of CRP, indicating that the effect of periodontitis on systemic 
inflammation seems to be dose dependent (Table 10).
Renewed interest has been placed in understanding the role of chronic, low grade 
infections and their associated inflammatory responses. Atherosclerosis is a 
multifactorial disease. The infection hypothesis has been on the scene since the early 
years of last century. Many sero-epidemiological studies have supported an association 
between specific infections and cardiovascular events. C. pneumoniae, H  piilory, 
cytomegalovirus, and oral/dental infections have been implicated (Danesh 1999; 
Leinonen & Saikku 2002). The theory is based upon the presumed noxious effect that 
these pathogens may have acting directly and/or indirectly (through the inflammatory 
response) causing: pro-coagulant activity, reduced fibrinolysis, increased leukocyte 
adhesion, increased cytokine production, and ultimately enhanced LDL and cholesterol 
deposition in the arterial wall (Libby et al. 2002). Among the possible mechanisms one 
is that the pathogens may sustain a low grade inflammatory response in the 
atherosclerotic plaque (mediated by macrophages, endothelial cells, etc.). The 
intravascular infection may induce an endothelial injury and activate a local 
inflammatory response. In this vicious circle the activation of inflammatory cells and 
the production of inflammatory cytokines as well as of adhesion molecules may 
increase the risk for thrombogenesis. The increased values of systemic inflammation
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markers reported in the literature would therefore be an indicator o f the atherosclerosis 
(endothelial damage) progression rather than the effect of distant infections. However a 
prospective study (Rotterdam Study) indicated that atherosclerosis free individuals with 
chronic low grade infections had an accelerated progression of atherosclerosis 
suggesting that there was chronological consistency, with infection preceding the 
development of atherosclerosis (van, I et al. 2002). Another good example of a clear 
association between chronic infections (including periodontitis) and atherosclerosis 
comes from an ongoing prospective study (Kiechl et al. 2001). In atherosclerosis-free 
individuals the presence of a chronic infection predicted nearly 40 % of new 
atherosclerotic lesions. This risk was also higher among subjects who showed an 
increased systemic inflammatory reaction. Whether this was due to particular virulence 
of pathogens involved or to an abnormal host reaction to them has not been 
demonstrated yet. More support to this “infectious” hypothesis comes from two of the 
larger antibiotic secondary prevention trials. A beneficial effect o f the antimicrobial 
therapy in terms of both serum levels of inflammatory markers (reduction at 6 months) 
and improvement in the endothelial function has been clearly reported (Anderson et al. 
1999; Gupta & Camm 1998; Stone et al. 2002; Wiesli et al. 2002) in different 
population samples (mainly with pre-existing cardiovascular disease). More challenging 
has been demonstrating that antimicrobials are also effective in reducing the risk of new 
cardiovascular events. Properly sized randomised controlled clinical trials are currently 
under way to establish in a definitive way the nature of the association between chronic 
infections and cardiovascular events. It should be emphasised, however, that these trials 
will not be able to assess the role of biofilm centred infections such as periodontitis. 
Several lines of evidence support the causative role of chronic infections and/or the 
associated inflammatory responses in atherosclerosis: i) increased odds ratios; ii) 
chronological consistency between infection and atherosclerosis; iii) data from
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experimental models; and in the end iv) emerging results of intervention trials. Data 
supporting the role of periodontal infections have been limited to the first three lines of 
evidence. In the majority of studies, subjects with severe generalized periodontitis 
displayed increased odds ratios of cardiovascular events.
Periodontitis is an infection caused by gram negative bacteria that are organized in a 
biofilm in a sub-gingival location between the diseased root surface of the tooth and the 
junctional epithelium. As such, it is relatively insensitive to the effect of systemic 
antibiotics and its treatment requires, in the first instance, the removal of the biofilm by 
mechanical professional instrumentation. Following successful treatment, bacterial load 
is significantly reduced while antibody titres and avidity to the specific pathogens are 
improved. As a result of these changes, local inflammation significantly decreases and 
there is a significant improvement in clinical parameters (probing pocket depths, 
bleeding on probing, etc.).
Reports from large prospective studies have associated periodontitis and tooth loss with 
an increased risk for carotid atherosclerosis (1mm thickening of the intima) after 
correcting for possible confounding factors (Beck et al. 2001; Desvarieux et al. 2003). 
In cell culture studies, Pg , one of the most important periodontal pathogens, has shown 
the ability to invade endothelial cells (Dom et al. 2000; Genco et al. 1999). Periodontal 
pathogens have been identified in carotid atheromatous plaques of patients undergoing 
endarterectomy (Haraszthy et al. 2000). Furthermore Pg chronic inoculations in the 
ApoE +/- mice increased the lipid profiles, enhanced atheroma formation and produced 
calcifications of the aortal atherosclerotic plaques (Li et al. 2002). The current study 
expands this evidence to include the results of an initial intervention trial focusing on 
inflammatory responses. The data generated pose the basis for a controlled intervention 
trial leaving only the question of whether the delay of the systemic response was to 
attribute to the nature of the treatment adopted.
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Previous to this investigation, only two small trials had reported the impact of non 
surgical periodontal therapy on systemic inflammation. Christgau et al did not find any 
effect of periodontal treatment in a mixed small population (20 diabetics and 20 
healthy) in terms of changes in CRP levels. One of the reasons may lie in the assay they 
used for quantification of the acute phase marker (detection limit 2.8 mg/L) and 
secondly in the extent and severity of periodontitis in their population (Christgau et al. 
1998). Non surgical periodontal therapy had a significant effect on white blood counts 
(specifically in terms of number of neutrophils and thrombocytes) but was strongly 
confounded by the effect of smoking (Christan et al. 2002).
Since our trial was completed we identified three other studies that investigated the 
same topic. The first one included a population of 39 patients suffering from 
periodontitis, all non smokers who were randomly split between a test group (24 
subjects) consisting of periodontal therapy and a control group (15 subjects) whose 
therapy was delayed for three months. No differences in changes were noted comparing 
CRP concentrations 6 weeks after therapy for the test and 3 months for the control 
group (Ide et al. 2003). A Finnish group led by Mattila also reported on the effects of 
periodontal therapy (even including systemic antibiotics in some patients ) in a group of 
35 individuals suffering from chronic periodontitis that experienced a reduction in CRP 
concentrations after 6 weeks of completion of therapy. This difference just approached 
statistical significance (p=0.05) and they also reported high degree of variability in the 
individual response (Mattila et al. 2002). Both studies did not report any association 
between clinical response and CRP level changes leaving also some unanswered 
questions about the efficacy of the treatment adopted. Finally a small case series of 14 
individuals showed a significant reduction in CRP and TNF-a serum concentrations 
after 1 month of periodontal therapy consisting of mechanical instrumentations and 
repeated adjunctive local antimicrobial (minocycline) therapy (Iwamoto et al. 2003).
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The limited number of patients however combined with the presence of important 
confounding factors (9 of the 14 subjects were type-2 diabetic) do not allow easy 
interpretation of these results.
One aspect of our results worth emphasising in view of future studies is the indication in 
the multivariate analysis (Table 10) that CRP decreases following treatment were 
associated with the clinical outcomes of the delivered periodontal therapy: subjects that 
had better outcomes than the median at 6 months (in terms of number of residual 
pockets and bleeding on probing) seemed to account for the observed decrease in CRP 
after correcting for all the other covariates. Although we lack o f any informations of a 
control untreated group this preliminary observation seems to indicate that there may be 
a dose dependent effect of periodontal therapy in terms of systemic parameters. 
Moreover incomplete control of periodontitis (as estimated by persistence of pockets 
and bleeding on probing) following non-surgical periodontal therapy alone may have 
precluded achieving an even bigger decrease in serum CRP levels. This observation 
raises the issue of new end-points in periodontal therapy in the context of prevention of 
systemic inflammation and possibly atherosclerosis as well as the need to assess the 
possible benefits of additional periodontal therapy.
The size of the observed improvement in CRP at 6 months is also noteworthy. The 
reported data indicated that in this population the observed median decrease in serum 
CRP was 0.5 mg/L. The 95% confidence interval, furthermore, was relatively narrow 
indicating that the “true” uncorrected median decrease is likely to be in the 0.4 to 0.7 
mg/L range. O f further interest was the observation that the magnitude of such 
difference after periodontal therapy remained constant (0.4 mg/1) in the subgroup of 60 
individuals who were re-examined 12 months since their periodontal therapy. Within 
the limitations of this design, a decrease of this magnitude in terms of CRP is 
comparable to those observed with some of the most promising medications such as
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statins and anti-inflammatory agents (Ridker et al. 1998; Ridker et al. 1999). The 
medical significance of these changes if proven in larger controlled long-term 
intervention trials, would substantially decrease the predicted risk for future 
cardiovascular events based on serum CRP concentrations (Ridker et al. 1998).
Given the low number of reports in which the same microbiological technique has been 
adopted, we reported a high rate of detection of periodontal pathogens in patients 
suffering from periodontitis (Gafan et al. 2004; Tran & Rudney 1999). We justify such 
results based on the fact that the PCR assay used in this study has been shown to detect 
levels as few as 10 cells of specific periodontal pathogens and therefore much sensitive 
of any other molecular approaches where the lower detection reported was in the order
• j  o
of 10 to 10 cells (Chuba et al. 1988). Colonization of periodontal pathogens detected 
with this tecnique in young children has been reported in the range of 30-40 % (Gafan et 
al. 2004). This would suggest that other factors, such as pathogen numbers might cause 
disease rather than only presence, giving strength to the ecological plaque hypothesis 
(Marsh 1994). Furthermore, because patients enrolled in this study suffered from 
generalized severe forms of periodontitis, this does not allow us to compare our results 
with previous populations studied due to the difference in the extent and severity of the 
disease.
Standard periodontal therapy resulted in significant reduction of samples positive for all 
periodontal pathogens after 6 months. These results are difficult to interpret with other 
reports due to the different microbiological technique utilized. It has been shown that 
species are not distributed uniformly throughout the oral cavity, sampling strategy can 
have affected detection rates and our samples were pooled. Future research is needed in 
this matter in order to confirm these results.
In this study a significant decrease in serum IL-6 was observed 2 and 6 months after 
completion of periodontal therapy. A significant decrease in CRP, however, could only
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be detected at the 6 months evaluation and 12 months in a small subgroup. This finding 
is in agreement with the periodontal data reported from literature and described earlier 
whereby standard periodontal therapy did not induce any change in CRP concentrations 
after 6 weeks of periodontal therapy (Ide et al. 2003; Mattila et al. 2002).
The results of this study do not offer insights on the possible reasons for this delay. 
Interestingly, however, looking at the results published from antibiotic intervention 
trials in patients with cardiovascular diseases this time lag has also been reported 
(Anderson et al. 1999; Stone et al. 2002). Our original hypothesis, also confirmed by the 
later studies we performed (see chapter 6 and 7), is that the standard treatment approach 
utilized, without using any antimicrobial or anti-inflamamtory agent or advanced 
corrective (periodontal surgery) techniques, is not capable of controlling the local 
infectious/inflammatory burden and therefore only after a period of time (6 months) a 
re-established healthy gingival environment produces a significant systemic benefit. 
Some limitations in these results have to be reported. Obesity is also a major source of 
inflammatory mediators’ production (de Maat & Kluft 2001; Yudkin et al. 2000; Kluft 
& de Maat 2001). We cannot exclude that lifestyle or diet changes in our population, 
even if not reported, could have affected our serological results. Another point could be 
related to CRP biological variability. Recognized determinants of CRP “physiologic” 
levels include weight, smoking, statin and hormone replacement therapies, alcohol 
consumption and antibiotic treatment (Cushman et al. 1999; de Maat & Kluft 2001). 
There are controversial opinions with regards to biological variability. CRP is thought 
to have a low biological variation with few outliers (as reported in longitudinal studies) 
(Macy et al. 1997).
There is no diurnal variation and these outliers may presumably occur for inflammatory 
stimuli but their clearance should not take more than 3 days (Gabay & Kushner 1999). 
However a relatively wide variability (-30%) has been also reported (de Maat et al.
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1996).(See Section 1.1.4) More research is needed in this matter. In this respect, our 
data, especially in view of the results observed at 12 months, confirm that CRP is a 
stable inflammatory marker and open new doors in clinical periodontal research 
investigating the systemic impact of periodontal therapy. The possibility of having a 
controlled healthy population sampled at the same time-points of the patients suffering 
from periodontitis, would better clarify the impact of the CRP individual and seasonal 
variability on the preliminary outcome we have reported.
The overall limit of this study originated from the cohort design and its preliminary 
nature. We therefore urge caution in inferring from these results any definite 
conclusions. These will be addressed by future studies already included in the a priori 
experimental plan (see Chapter 6 and 7).
I l l
P e r i o d o n t i t i s  A n d  CRP A s s o c i a t e d  R is k
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4.4 .1  S u m m a r y
Periodontitis has been associated with a moderate systemic inflammatory response. 
Successful periodontal therapy could decrease serum inflammatory parameters. We 
aimed to explore the outcomes of periodontal therapy in terms of changes in CRP- 
associated CVD risk as defined in a recent American Heart Association consensus 
conference.
At baseline subjects with more severe and widespread periodontitis had a higher chance 
of having high CRP associated CVD risk (OR 5.6, 95% Cl 1.2-27.4). Age and body 
mass index were also significant in the analysis. After therapy, a significant decrease in 
the number of subjects associated with a medium and high CRP-associated risk was 
observed (p<0.001x2) with 40 of 94 subjects displaying a decrease in their class of risk. 
Patients who had a better oral response to periodontal therapy were also more likely to 
have decreased their inflammatory risk category (OR 4.8, 95%CI 1.4-15.8) after 
correcting for age, gender, ethnicity and cigarette smoking. This analysis indicated that 
periodontitis may add to the inflammatory burden of the individual and may result in 
increased levels of cardiovascular risk based on serum CRP concentrations. These 
observations will need to be confirmed in a definitive trial. Given the high prevalence of 
periodontitis in the population, these data would caution physicians to be aware of the 
possible oral source of an increased inflammatory burden.
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4 .4 .2  I n t r o d u c t io n
The systemic implications of chronic and acute infections have attracted increasing 
attention in the past decade. Common pathogens (e.g. C. pneumoniae, H. pilori, E. coli, 
cytomegalovirus) have been associated with atherosclerosis and cardiovascular events 
(Epstein et al. 2000; Shah 2002). Reports from preliminary intervention trials assessing 
the impact of antimicrobial therapy on cardiovascular disease have supported the 
hypothesis that the observed association may be causal in nature. Some of these pilot 
studies (ACADEMIC, ROXIS, and STAMINA) showed a significant effect of antibiotic 
therapy on the occurrence of clinical events (cardiovascular complications) but the 
matter has not been fully resolved (Anderson et al. 1999; Stone et al. 2002; Wiesli et al.
2002). Furthermore, insufficient evidence has been produced on the potential 
mechanisms. An intriguing but hypothetical model is based on the systemic 
inflammatory response subsequent to chronic low-grade infections (Libby et al. 2002). 
Within this context great interest has arisen from the discovery that even minimally 
raised concentrations of inflammatory markers may accurately predict future CV events. 
IL-6 and CRP represent the most sensitive makers used to evaluate the inflammatory 
status of an individual and appear to be useful predictors for future cardiovascular 
events in a variety of populations (Pearson et al. 2003; Ridker et al. 1997). Preliminary 
intervention trials showed a significant effect of systemic antibiotic therapy in reducing 
systemic inflammatory markers (Stone et al. 2002; Wiesli et al. 2002). A recent joint 
consensus conference of the American Heart Association (AHA) and the Center for 
Diseases Control (CDC)has focused on the clinical utility of these markers in the 
management of CVD risk (Pearson et al. 2003). In addition to the classical risk 
estimation based on well defined markers (such as smoking, obesity, hyperlipidemia, 
hypertension, diabetes, age, gender), and due to the available evidence on the role of
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inflammation in the pathogenesis of atherosclerosis, the consensus conference identified 
3 different risk categories based on serum CRP levels. Pooled epidemiological data 
from 40,000 subjects have shown that different levels o f serum CRP predict future 
cardiovascular events in otherwise healthy individuals. Based on these observations, 
subjects with CRP concentrations less than 1 mg/L are considered to be at low risk, 
while those with concentrations in the 1 to 3 mg/L range are assigned a medium risk 
level and those with more than 3 mg/L in serum CRP are considered to be at high risk 
for future cardiovascular disease and events. Periodontitis is a prototype of low grade 
local infection associated with a moderate systemic inflammatory response. Patients 
suffering from severe forms of this disease seem to have a perturbation of their systemic 
homeostasis (Ebersole & Cappelli 2000). Not all periodontitis patients manifest with the 
same systemic response. It is reasonable to believe that the individual systemic response 
to periodontitis may be modulated by different genetic (polymorphisms) and 
environmental (e.g. cigarette smoking or obesity) factors. Periodontitis has been 
repeatedly associated with increased odds of atherosclerotic events (Danesh 1999). 
Systemic inflammation may represent the underlying mechanism that links these two 
common chronic diseases. This analysis focuses on the effects of periodontal therapy on 
changes in the recently defined CRP-associated CVD risk in a group of otherwise 
healthy individuals. Results indicated that 6 months following completion of non- 
surgical periodontal therapy a significant decrease in CVD risk was observed.
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4.4.3 R e s u l t s
Categorizing the population according to the AHA/CDC guidelines at baseline, 12 
patients were in the low, 47 in the medium and 35 in the high risk group.(Figure 22) A 
logistic regression model with the AHA/CDC three categories as dependent variable 
was performed to ascertain the probability of individuals falling in a different category 
of risk. Estimates and odds ratios (95% Cl) were calculated (Table 11). Patients 
presenting with more widespread periodontitis (expressed by the presence of greater 
than median number of periodontal pockets 5 mm or deeper) had an OR of 5.6 (95% Cl 
1.2-27.4, p<0.04) and an OR of 3.5 (95% Cl 1.2-10.1, p<0.02) of being in the highest 
category of risk compared to the lowest and medium respectively.
Table 11 Logistic multinomial regression analysis of CRP associated CVD risk categories in patients
suffering from severe periodontitis.
A v e r a g e  (CRP<1 m g/L ) 
vs H ig h  (CRP>3 m g/L )
M e d iu m  (1 m g /L < C R P < 3  m g /L ) 
vs H ig h  (C R P > 3 m g /L )
P±SE P OR 95% C l P±SE P OR 95% C l
Constant 3.911±2.574 0.129 1.879±1.586 0.236
AGE -0.153±0.053 0.004 0.858
0.774 to 
0.953 0.057±0.030 0.060 0.945
0.891 
to 1.003
GENDERa 0.953±0.811 0.240 2.593 0.529 to 12.71 0.654±0.520 0.208 1.923
0.695
to5.326
SMOKING b -0.939±0.806 0.244 0.391 0.081tol.898 0.619±0.536
0.248 0.538 0.188 to 1.540
ETHNICITYc -0.083±0.840 0.921 0.921
0.178
to4.772 0.229±0.548 0.676 1.257
0.430
to3.678
BMI-1 d 2.163±1.072 0.044 8.696 1.064to71.10 1.692±0.670 0.012 5.431
1.460
to20.20
BMI-2 e 1.306±1.016 0.199 3.692
0.504
to27.06 0.385±0.583 0.509 1.470
0.469
to4.609
Periodontal 
pocketsf 1.724±.810 0.033 5.605
1.146
to27.41 1.262±0.535 0.018 3.533
1.238 
to 10.08
Model P<0.01, -2 Log Likelihood=147.590, Chi-Square 31.325, Pseudo R-Square 0.331 
a Male vs Female.b Smoker vs Non Smoker.c Caucasian vs Non Caucasian. Body Mass Index-1: 3rd 
Tertile (>26.3 Kg/m2) vs 1st(<23.4 Kg/m2) . e Body Mass Index-2: 3rd Tertile (>26.3 Kg/m2) vs 2nd (>23.4 
Kg/m2) . f Patients who presented with a baseline number of periodontal pockets 5 mm or deeper greater 
than median (79).
Age and body mass index were the only other significant factors in the model. The 
analysis accounted for other common confounders such as gender and cigarette 
smoking.
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Non surgical periodontal therapy resulted in a significant improvement of all clinical 
periodontal parameters after six months. A mean reduction of 57 ± 24 in the number of 
periodontal pockets greater than 4 mm (p<0.0001 t-test) was obtained together with a 
significant reduction in full mouth bleeding (45 ± 17%, p<0.0001 t-test) and plaque 
scores (38 ± 18%, p<0.0001 t-test). Six months after therapy a significant reduction in 
the number of plaque samples positive for periodontal pathogens (p<0.001 Mc-Nemar 
test) was observed.
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Figure 22 Bar chart showing baseline and 6 Months frequency (number) o f individuals in each 
CRP-associated CVD risk category.
Serum concentrations of inflammatory markers were also significantly reduced after 6 
months for both CRP (median decrease 31%, 54 IQ, p<0.0001 Wilcoxon test) and IL-6 
(median decrease 12%, 50 IQ, p<0.0001 Wilcoxon test).
A significant correlation was observed between the difference in IL-6 and the difference 
in CRP (r = 0.38, p=0.001 Spearman rank test).
At 6 months a significant reduction in the number of subjects in the high and medium 
CRP-associated CVD risk classes was observed (p<0.0001x test). 13 subjects moved 
from the high to the medium category, 25 from the medium to the low, 2 from the high 
to the low, 4 from the medium to the high and 50 individuals remained in the same 
category (12 in the low, and 19 each in the medium high categories). Differences in the
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number of observations before and 6 months after therapy in each category were 
significant (low category p<0.0001, medium p<0.05, high p<0.05, Me Nemar Test).
To further explore the effect of periodontal treatment on CRP-associated CVD risk 
categories a binary logistic regression analysis was performed with a dependent variable 
describing the difference in categories defined as follows: reduced CRP-associated 
CVD risk (1), no change or increased CRP-associated CVD risk (0) (Table 12). The 
analysis controlled for potential confounders (age, gender, ethnicity, smoking, body 
mass index).
Table 12 Logistic regression analysis of the CRP-associated risk reduction after periodontal therapy
P±SE P OR 95% Cl
Constant -0.705 ± 2.355 0.764 0.494
AGE 0.008 ± 0.030 0.777 1.008 0.951 to 1.069
GENDERa -0.931 ±0.563 0.098 0.394 0.131 to 1.188
ETHNICITY15 -0.104 ±0.256 0.686 0.813 0.298 to 2.220
SMOKING0 1.080 ±0.603 0.073 2.944 0.903 to9.596
BM Id -0.085 ± 0.076 0.260 0.918 0.791 to 1.065
Extracted teeth (N )e 0.333 ±0.140 0.017 1.395 1.060 to 1.834
AFMPSf 0.029 ±0.018 0.103 1.030 0.994 to 1.067
AFMBS 8 -0.011 ±0.018 0.540 0.989 0.954 to 1.025
PPK-EFFECTh 1.557 ±0.613 0.011 4.746 1.428 to 15.773
Pg change1 0.139 ±0.536 0.796 1.149 0.402 to 3.286
Tf changej -0.604 ±0.619 0.329 0.546 0.163 to 1.837
Aa change k 0.363 ±0.578 0.530 1.438 0.463 to 4.463
Model P=0.01, -2 Log Likelihood 94.938, Chi-square 24.819, Pseudo R-square 0.337
a Male vs Female b Caucasian vs Non Caucasian c Smoker vs Non Smoker dBody Mass Index (kg/m2) e Number of 
hopeless teeth extracted during treatment f Difference in Full Mouth Plaque Scores between 0 and 6 Months g 
Difference in Full Mouth Bleeding Scores between 0 and 6 Months h Patients who presented with a reduction in 
number of periodontal pockets (5 mm or deeper) greater than the median (56 pockets) 6 months after therapy. 1 
Patients with undetectable Pg at six monthsj Patients with undetectable Tf at six months k Patients with undetectable Aa 
at six months
Individuals who responded better to periodontal treatment (defined by a pocket 
reduction at 6 months greater than median) were 4 times more likely (95% Cl 1.4-15.8, 
p<0.02) to reduce their risk category compared to those who did not achieve the same 
clinical response. Participants who also received extractions of hopeless teeth after 
baseline had an odds of 1.4 (95% Cl 1.1-1.8, p<0.02) to have a reduction of serum CRP 
of significant magnitude.
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4.4 .4  D is c u ssio n
A significant association exists between the number of periodontal pockets and 
increased CRP-associated CVD risk according to a recent AHA/CDC classification 
(Pearson et al. 2003). Otherwise healthy individuals, affected with severe periodontitis 
had significantly increased odds of being at above average risk (i.e. medium or high 
risk) for cardiovascular diseases if they presented with more widespread periodontitis 
defined as higher number of periodontal pockets. This finding is strengthened by the 
observation that successful non-surgical periodontal therapy resulted in a significant 
decrease of the CRP-associated CVD risk. Individuals who responded better to 
periodontal therapy (i.e. those who had above median decreases in the number of 
periodontal pockets) had increased odds of displaying a decrease in their CRP- 
associated cardiovascular risk. Accumulating evidence has associated severe 
periodontitis with increased odds of future cardiovascular events (Danesh 1999). 
However a clear etiologic pathway has not been proven yet. This analysis suggests a 
possible role of untreated severe periodontitis on future atherosclerotic processes via 
systemic inflammation. However, the design of our cohort study do not allow us to 
conclude that there is a causal relationship between periodontitis and systemic 
inflammation. Experimental animal data support this hypothesis (Dorn et al. 2000; Jain 
et al. 2003; Qi et al. 2003; Lalla et al. 2003; Li et al. 2002). A wide range of 
pathological stimuli (infection, tissue damage) can cause local host production of 
inflammatory cytokines that may exert a distant effect and alter the normal vascular 
homeostasis (Libby et al. 2002). This insult, also called endothelial dysfunction, 
represents a possible mechanism by which chronic infections such as periodontitis, 
directly via pathogens or indirectly via their products and host inflammatory defences, 
may initiate and modulate intravascular accumulation of inflammatory cells and lipids 
(atherosclerosis) (Libby et al. 2002; Shah 2002).
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Patients suffering from severe periodontitis have an increased local production of 
inflammatory cytokines (IL-ip, TNF-a, IL-6) (Gorska et al. 2003; Offenbacher 1996) 
and a moderate systemic inflammatory response (defined by raised concentrations of 
CRP, fibrinogen and moderate leukocytosis) (Table 3). Whether this is mainly due to a 
local excessive production of cytokines that may gain access to the circulation or to a 
metastatic dissemination of periodontal pathogens and their antigenic products through 
the bloodstream is still unknown. IL-6 local production in the gingiva may exert its 
systemic anti-inflammatory activity by stimulating the hepatic synthesis of acute phase 
proteins in order to protect the host against local pathological stimuli (Irwin & Myrillas
1998). CRP is the prototype of these proteins and it is increasingly assuming the leading 
role of future predictor for CVD events (Gabay & Kushner 1999; Ridker et al. 1998). 
Furthermore CRP may play a direct active role in the atherosclerotic process (Pepys & 
Hirschfield 2003; Ridker et al. 1998). The recent AHA/CDC conference confirmed the 
potential relevance of small serum changes of the concentrations of this marker in 
healthy individuals or in those already suffering from CVD. However on the basis of the 
evidence, the clinical utilization of CRP as a predictive tool for future cardiovascular 
risk is still considered optional.
This analysis indicated that successful periodontal therapy may reduce CRP-associated 
cardiovascular risk. Caution is needed in interpreting these results due to the limited 
number of cases, the variability observed among all participants and the study design. 
These observations will need to be confirmed in a definitive, prospective, randomized 
controlled clinical trial. In the meantime given the high prevalence o f periodontitis in 
the population, these data would caution physicians to be aware of the possible oral 
source o f an increased inflammatory burden both in the context of differential diagnosis 
and in the context of selection of appropriate therapeutic intervention.
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G e n e t ic  d e t e r m in a n t s  o f  t h e  L o c a l
AND SYSTEMIC INFLAMMATORY
R e s p o n s e s  t o  C h r o n ic  
P e r io d o n t a l  In f e c t io n s
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4.5.1 S u m m a r y
The inflammatory response to chronic infections such as periodontitis may be central to 
the systemic implications of these diseases. This analysis aimed to investigate the 
degree of exposure between periodontitis and systemic inflammation and explore the 
possible association between specific gene polymorphisms and the systemic 
inflammatory response in a cohort of individuals suffering from severe generalized 
periodontitis. 94 subjects with periodontitis were genotyped for polymorphisms in IL­
IA (-889), IL-1B (-511, +3954), TNF-A (-308), IL-6 (-174) and TLR-4 (-299,-399) 
genes. We found that the genotypes for IL-1A or IL-6 are associated with higher levels 
of serum IL-6 (P<0.03) and serum CRP (P<0.05), similarly the TNF-A genotype is 
associated with higher levels of serum IL-6 (P<0.05) after correction for age, body mass 
index, gender, ethnicity and cigarette smoking. Systemic inflammatory responses are 
higher in severe periodontitis patients carrying rare alleles for functional inflammatory 
gene polymorphisms. These results suggest that cytokine genotypes are important 
determinants of the systemic inflammatory response in subjects with periodontitis. 
Genetic polymorphism therefore, may in part explain the reported association between 
periodontitis and systemic disease.
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4.5.2 In t r o d u c t io n
Periodontitis is an opportunistic mixed infection of the tooth supporting tissues. Its 
aetiology recognizes a synergistic role between specific anaerobic bacteria organised in 
a biofilm, sub-gingival dental plaque, and an exaggerated inflammatory response in 
susceptible individuals. Periodontitis is highly prevalent affecting 10 to 15% of the adult 
population and, represents the major cause of tooth loss in adults leading to long term 
disability and increased treatment needs (Albandar & Rams 2002; Papapanou 1996; 
Papapanou 1999; Ridker et al. 1998).
As such chronic periodontitis is a recurrent disease that alternates between active and 
quiescent phases. The individual inflammatory response induced by the pathogens 
seems to play a critical role in the disease pathogenesis (Genco & Slots 1984). High 
levels of inflammation of the periodontium have been associated with the actual 
progression of the disease (Offenbacher et al. 1981). Evidence has indicated that 
specific hyper-inflammatory traits are present in patients affected with severe 
periodontitis (Offenbacher 1996). These include carriage of the rare alleles of functional 
polymorphisms in the interleukin-1 gene complex (Komman et al. 1997) and TNFA 
gene (Qian et al. 2002).
In the last decade, the discovery of an association between periodontal infections and 
other diseases (pre-eclampsia, atherosclerosis, diabetes, and respiratory diseases) has 
placed increased emphasis on the systemic implications of periodontal infections 
(Danesh 1999; Shay 2002). Recent evidence has indicated that patients with severe 
periodontitis have a perturbation of their systemic inflammatory status manifested by 
increased serum levels of IL-6, IL-1, CRP, fibrinogen and moderate leukocytosis when 
compared with unaffected control populations (Table 3). Independent of the underlying 
mechanism(s), the best approach to test this hypothesis would be to explore all possible
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influential factors acting on the systemic inflammatory response in patients suffering 
from periodontitis. In this context, IL-6 and CRP are generally considered to be the 
most sensitive markers of the acute phase response to infections and inflammation (see 
section 1.1). The production of IL-6 is elicited at the site of the infection directly by 
bacterial (LPS) or cytokine (TNF-a, IL-lp) stimulation (Irwin & Myrillas 1998; Shay 
2002; Graves 1999). IL-6 as a pleiotropic cytokine is responsible for the synthesis of 
CRP and other acute phase proteins in order to contain the local infection (see section 
1.1.3). Serum concentrations of both inflammatory markers have also assumed a 
significant role as predictors for future cardiovascular events in healthy populations (see 
section 1.2.3). Significant evidence indicates that the individual inflammatory response 
is modulated by specific polymorphisms at inflammatory genes. Genetic variants in the 
IL-1A (-899) IL-6 (-174) and TNF-A (-308) genes have been linked to enhanced 
systemic inflammatory responses based on serum levels of specific mediators (Gonzalez 
et al. 2003; Shay 2002; Fishman et al. 1998; Vickers et al. 2002). Little is known, 
however, about the relationship, if any, between cytokine polymorphisms and the 
systemic inflammation associated with periodontal infections.
The aim of this analysis was to investigate first whether there was a linear positive 
association between severity of periodontitis and magnitude of individual systemic 
inflammation defined by serum concentrations of IL-6 and CRP. Second we explored 
the possible association between specific cytokine polymorphisms and the systemic 
inflammatory response (estimated as serum CRP and IL-6) in individuals suffering from 
severe generalized periodontitis. The data indicated that, in patients with severe 
periodontal infections, increased serum IL-6 was associated with carriage of allele 2 for 
IL-1A (-899), TNF-A (-308) and IL-6 (-174), while serum CRP was associated with 
allele 2 for IL-1A (-889) and IL-6 (-174) after correcting for age, body mass index, 
gender, ethnicity and cigarette smoking.
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4.5.3 R e s u l t s
4 .5 .3 .1  S y s t e m ic  I n f l a m m a t io n  a n d  S e v e r it y  o f  P e r io d o n t it is
Median serum IL-6 was 1.8 ng/L (1.5 IQ) while CRP was 1.9 mg/L (3.5 IQ). The serum 
concentrations of the two inflammatory markers were significantly correlated (r=0.34 
p<0.001, Spearman’s rank correlation test). No significant differences in these markers 
were observed among subgroups categorised by ethnicity, gender, smoking or bacterial 
detection.
Logarithmic transformations of IL-6 concentrations were significantly associated with 
age and periodontitis severity assessed as the individual mean PPD (pockets greater 
than 5 mm) by backward elimination multiple regression analysis (Table 13).
T able  13 Linear Regression Model predicting IL-6 concentrations
LOGlIL-61a T P
U n s t a n d a r d i z e d  C o e f f i c i e n t s  b ± SE
Intercept -1.231 ±0.452 -2.724 0.008
Age 0.008 ± 0.003 2.618 0.011
PPD 6MMC 0.117 ±0.053 2.203 0.031
a Adj R square 0.344, F<0.0001.b Unstandardized coefficients are expressed as Log of IL-6. 
c Full mouth average of probing pocket depths greater or equal to 6 mm.
Similarly, Log CRP concentrations were significantly associated with age, body mass 
index, Log concentration of IL-6 and severity of periodontitis evaluated as the 
individual average full mouth clinical attachment level (Table 13).
T able  14 Linear Regression Model predicting CRP concentrations
LOG 1CRP1 * T P
Va r ia b l e U n s t a n d a r d i z e d  C o e f f i c i e n t s  b ± SE
Intercept -0.784 ±0.258 -3.043 0.003
Log [IL-61 ng/L 0.394 ±0.146 2.689 0.009
CAL mmc 0.082 ± 0.030 2.774 0.007
BMI Kg/m2 d 0.023 ± 0.009
« « « <  b T T .  1 l'
2.658 0.009
t  C t-» 11 . _^1a Adj R square 0.292 FO.OOOl. Unstandardized coefficients are expressed as Log of CRP.c Full mouth 
average clinical attachment level (mm).d Body Mass Index.
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Figure 23 Scatter plot o f CAL levels against adjusted Log CRP 
concentrations.
V alues produced after linear regression model (see Table 13)
4.53.2 G e n e  P o l y m o r p h is m s  a n d  S y s t e m ic  In f l a m m a t io n  in  P e r io d o n t it is
The observed allele frequencies and genotypes o f the tested cytokine polymorphisms 
are reported in table 15 and are in accordance with previous reports (see section 4.2.6).
Table 15 Genotype and Allele Frequencies o f the Tested Polymorphisms
P o l y m o r p h is m 1.1
N (%)
1.2
N (%)
2.2
N (%)
A l l e l e  2 
F r e q u e n c y
IL-1A (-889) 36 (39) 35 (37) 22 (24) 0.45
IL-1B (-511) 35 (37) 46 (49) 13(14) 0.36
IL-1B (+3954) 63 (67) 25(27) 5(6) 0.21
TNF-A (-308) 67 (74) 22 (25) K D 0.15
IL-6 (-174) 52 (56) 29 (31) 12(13) 0.27
1L-10 (-627) 49 (55) 34 (38) 6 (7 ) 0.26
TLR-4 (-299) 76 (87) 11(13) - 0.07
TLR-4 (-399) 86 (94) 6(6) - 0.03
IL-6 serum concentrations (adjusted for age, body mass index, gender, ethnicity and
smoking) were compared in subjects homozygous for the common alleles and subjects
carrying one or more copies o f the rare allele (Figure 24). Periodontitis patients carrying
one or two copies o f the rare allele o f IL-1A (-889), TNFA (-308) or IL-6 (-174)
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polymorphisms displayed significantly higher serum IL-6 concentrations. The observed 
mean difference in serum IL-6 between 1.1 subjects and 1.2 or 2.2 subjects was 0.9 ±
1.1 (SE) ng/L for IL-1A (P=0.031), 0.8 ± l.l(SE) ng/L for TNF-A (PO.OOl) and 0.8 ±
1.1 (SE) ng/L for IL-6 (PO.OOl). No significant differences in serum IL-6 were 
observed in subjects with different genotypes in the promoter region of IL-1B (-511, 
+3954) and TLR-4 (-299, -399 -  data not displayed in the figure) in this population.
3.0
P<0.0001 •P=0.031 aP<0.0001a
□  1.2 - 2.2
IL-6 (-174) IL-lA(-889) IL-lB(+3954) IL-1B(-511) TNF-A(-308)
Figure 24 Box and whiskers plots show different concentrations of IL-6 according to different genotypes. 
Box and whiskers plots show different concentrations of IL-6 according to different genotypes in 
inflammatory gene polymorphisms after controlling for age, gender, ethnicity, body mass index and 
smoking. The box refers to the 25th (bottom) and 75th (up) percentiles and the median is the horizontal line 
inside. Black dots refer to outliers. For the exact number of subjects in each subgroup refer to Table 15. 
a Significantly different comparing 1.1 to 1.2 and 2.2 (t-test). Statistics performed on logarithmic values 
whereas in the figure back transformed values are reported for clarity. 
b GG for IL-6 (-174) and TNF-A(-308) 
c GC-CC for IL-6 (-174), GA/AA for TNF-A(-308)
A similar analysis conducted to compare serum CRP concentrations (adjusted as for IL-
6) indicated that subjects carrying one or two copies of the allele 2 at IL-6 (-174) and
IL-1A (-889) had significantly higher CRP serum levels than subjects homozygous for
127
1.1 (Figure 25). The observed difference in serum CRP between 1.1 subjects and 1.2 or
2.2 subjects was 0.8 ± l.l(SE) mg/L for IL-1A (P=0.048) and 0.8 ± l.l(SE) mg/L for 
IL-6 (P=0.023). All other polymorphisms tested were not significant.
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P=0.048'P=0.023 * □ 1.2 - 2.2
IL-6 (-174) IL-lA(-889) IL-lB(+3954) IL-1B(-511) TNF-A(-308)
Figure 25 Box and whiskers plots show different concentrations of CRP according to different genotypes 
Box and whiskers plots show different concentrations of CRP according to different genotypes in 
inflammatory gene polymorphisms after controlling for age, gender, ethnicity, body mass index and 
smoking. The box refers to the 25th (bottom) and 75th (up) percentiles and the median is the horizontal line 
inside. Black dots refer to outliers. For the exact number of subjects in each subgroup refer to Table 15. 
a Significantly different comparing 1.1 to 1.2 and 2.2 (t-test). Statistics performed on logarithmic values 
whereas in the figure back transformed values are reported for clarity. 
b GG for IL-6 (-174) and TNF-A(-308) 
c GC-CC for IL-6 (-174), GA/AA for TNF-A(-308)
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4.5.4 D is c u s s io n
Patients with severe periodontitis recruited for this trial showed a positive association 
between serum inflammatory markers and clinical measures of extent and severity of 
periodontitis independent of age, body mass index, gender and cigarette smoking. 
Serum IL-6 concentrations were also significantly associated with the carriage of allele 
2 for functional polymorphisms in the IL-1A, TNF-A and IL-6 genes after correcting 
for age, gender, ethnicity, and smoking status. Similarly, serum CRP concentrations 
were associated with allele 2 in the IL-1A and IL-6 genes. In this subject group no 
medical condition other than severe generalised periodontitis was detected, furthermore 
no subjects reported taking any systemic medication.
Previous investigations have associated the severity of periodontitis with the carriage of 
a composite genotype that included allele 2 of the IL-1A (-889) and IL-1B (+3954) 
(Komman et al. 1997). This composite genotype has also been associated with the 
detection of higher concentrations of IL-1 in both the gingival tissues and the 
inflammatory exudates originating from the marginal periodontium (Engebretson et al.
1999). The current data extend these observations indicating that specific cytokine 
polymorphisms are associated with the extent of the systemic inflammatory response to 
periodontitis.
These genetic variations might produce an imbalance between agonist inflammatory 
mediators and influence the individual response to pathogens as well as to the treatment. 
Berger et al in a population with significant atherosclerosis found that the 3954 hyper- 
inflammatory type 2 allele for IL-1B markedly influenced (2-3 fold increase) baseline 
CRP serum levels. A similar but weaker effect was found in subjects carrying allele 2 at 
the polymorphic site (4845) of the IL-1 A gene that is in 99% agreement with the IL-1 A 
(-889) polymorphism (Berger et al. 2002). In the present report, this specific genotype
129
(IL-1 A -889) showed a significant association with serum CRP levels whereas 
differences in the 3954 loci did not reach statistical significance. Furthermore this study 
detected a significant association between IL-6 (-174 G/C) polymorphisms and both 
pre- and post-treatment serum values of CRP. CRP and IL-6 baseline levels have been 
associated already with this specific genotype. A recessive effect of the C allele on the 
mean levels of IL-6 was reported (Margaglione et al. 2001) whereas a dominant effect 
of the same was associated with increased baseline CRP levels (Vickers et al. 2002). We 
also found a significant association between the -511 IL-1B polymorphism and serum 
IL-6 levels.
An expanding literature has associated the carriage of specific cytokine polymorphisms 
with the outcome of a variety of infections (Emonts et al. 2003; Holmes et al. 2003; 
Tabrizi et al. 2001). This is proposing a novel explanation o f the individual variability 
in response to similar pathological stimuli. Genetic polymorphisms of antigen 
recognition pathways (TLR) and pro-inflammatory cytokines (IL-1, TNF-a, IL-6) have 
been extensively analysed (Waterer & Wunderink 2003). These polymorphisms often 
have been associated with increased local and systemic cytokines production. CRP 
synthesis rate, that represents a reliable marker of the persistence of a noxious stimulus, 
has also been linked to IL-1 and IL-6 polymorphisms in different populations and 
settings(Berger et al. 2002; Pankow et al. 2001; Vickers et al. 2002). The mechanisms, 
however, are still being investigated.
A recent report has stressed the role of cytokine polymorphisms, and the IL-6 (-174) in 
particular, in determining the levels of systemic inflammation associated with chronic 
low grade infections leading to an increased risk of atherosclerosis (Georges et al.
2003). This study indicated that the association between atherosclerosis and pathogen 
burden was modulated by the IL6/G -174C polymorphism and appeared to be mediated 
by variations in serum IL-6 levels (rare allele showing the highest concentrations). In
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the current study, serum IL-6 levels were associated with the tested genotypes, and 
highly correlated with serum CRP levels. These data and previous findings support the 
hypothesis that the systemic inflammatory responses to chronic infection might be 
modulated by host genetic factors and that the local production of inflammatory 
mediators determines the serum concentration, of acute phase reactants such as CRP. 
Caution is needed, however, in interpreting these results given the relatively small 
number of subjects included.
In recent years, chronic, low grade infections such as periodontitis have been associated 
with systemic inflammatory diseases like atherosclerosis (Danesh 1999). A variety of 
mechanistic models linking chronic infections with an increased risk of atherosclerosis 
have been proposed, but inflammation is central to all of them. If inflammation is the 
key mechanism of this association, the present findings indicate that the risk of 
developing atherosclerosis may be modulated by an individual’s genotype and that 
carriers of the rare alleles of specific cytokine genes may represent a higher risk group 
for developing systemic disorders associated with chronic infections like periodontitis.
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R e l a t iv e  C o n t r ib u t io n  o f  P a t ie n t , 
T o o t h  a n d  S it e -A ss o c ia t e d  
V a r ia b il it y  o n  t h e  C l in ic a l  
O u t c o m e s  o f  S u b g in g iv a l
D e b r id e m e n t
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4.6.1 Su m m ary
The objective o f this analysis was to assess the relative contribution of patient, tooth and 
site associated variables on changes in PPD and CAL following delivery of a standard 
non surgical phase of periodontal therapy.
The relative contribution of patient, tooth and site associated variables was evaluated 
with a hierarchical multilevel analysis. 80% of variability in PPD and CAL reductions 
was attributed to site level parameters, while 12% (14% for CAL) was at the tooth and 
8% (7% for CAL) at the patient level. The multilevel analysis associated PPD 
reductions with patient factors [cigarette smoking status and carriage of the rare allele of 
a specific polymorphism for the IL-6 gene], tooth factors (tooth mobility and tooth 
type), and site factors (mesial and distal location, as well as baseline probing depth). In 
particular, smokers and carriers of the C allele (-174, IL-6) had significantly less 
reductions in probing pocket depths. Further confirmation of their effect was the 
discovery of a similar effect on CAL changes. Significant determinants on changes of 
CAL were also ethnicity (Caucasian), polymorphisms of TLR-4 and TNF-a genes and 
the presence of a periodontal pathogen (Pg). Incisors and canines responded better than 
premolars and molars. A dose dependent effect of mobility was observed: teeth with 
higher baseline mobility resulted in significantly greater decreases in PPD. Presence of 
furcation involvement at baseline negatively affected changes in CAL. At the site level, 
greater reductions were observed at interdental sites (compared to facial or oral), and at 
deeper sites (1.2 mm for 4-5 mm pockets and 2.4 mm for 6 mm or deeper).
These data provided an estimation of the relative contribution of site, tooth and patient 
associated variables in terms of PPD and CAL reductions following a standard course of 
machine-driven subgingival debridement.
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4.6.2 I n t r o d u c t i o n
The initial, infection control phase of periodontal therapy is the critical component in 
the treatment of periodontitis. Summaries of the evidence provided at the World 
Workshop of 1996 and the European Workshop on 2002 indicate that the combination 
of sub-gingival debridement with oral hygiene instruction is effective in reducing 
probing pocket depths and inflammation (Cobb 1996; Van der Weijden & Timmerman 
2002). The expected magnitude of the observed decrease in pocket depth at the site 
level ranged between 1.3 mm in shallow (4-5 mm) and 2.2 mm in deep (^6 mm) 
pockets. (Cobb 2002; Cobb 1996)
Traditionally, periodontists have performed their sub-gingival debridement using 
primarily hand instruments but improvements in machine-driven instruments over the 
last decade have significantly expanded the scope for using sonic, ultrasonic or 
piezoelectric instruments with fine tips specifically designed to reach the root surfaces 
at sites with deep pockets. A recent systematic review discussed at the 2002 European 
Workshop compared the clinical efficacy of sub-gingival debridement performed with 
hand or machine-driven instruments (Tunkel et al. 2002). Results indicated that “with 
respect to clinical outcome measures, the available data do not indicate a difference 
between machine-driven and manual debridement in the treatment of chronic 
periodontitis for single-rooted teeth”. The retrieved evidence to support this statement, 
however, was considered to be “not very strong”. From the systematic analysis of the 
data, it also emerged that machine-driven sub-gingival debridement to the satisfaction of 
the treating clinician required 37% less time than hand instrumentation.
With respect to the external applicability of these observations, some evidence indicates 
that the level of response may be lower in specific patient groups (e.g. smokers, 
diabetics), and at areas that are difficult to treat (e.g. molars, furcations, very deep
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pockets). The validity of some of these data, however, has been questioned since the 
majority of the classical studies did not provide patient based data and did not account 
for the lack of independence of the outcomes of different sites/teeth in the same patient 
(Tonetti & Cobb 2002).
It is also noteworthy that, to date, no research has addressed the issue o f the relative 
importance of patient, tooth and site specific parameters in determining the observed 
variability of outcomes of sub-gingival debridement.
The objective of this analytical approach was to assess, using a multi-level analysis, the 
relative contribution of patient, tooth and site-associated factors in determining the 
clinical outcomes of sub-gingival debridement performed with a machine-driven 
instrument.
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4.6.3 R e s u l t s
A total of 2589 teeth and 15498 sites were included in the multilevel analysis(Tables 
16-18). The discrepancy between the number of teeth and sites was due to the presence 
of un-recordable information at some appointments. Previous data indicate that this 
does not undermine the validity of the analysis (Gilthorpe et al. 2001).
Table 16 Baseline clinical and periodontal parameters
V a r ia b l e
Pa tie n t s
(N=94)
Age, years 46±9
Gender, Females 52%
Smokers, Current 42%
BMI, Kg/m2 25±4
Ethnicity:
Caucasians
African/Caribbeans
Asians
62
18
14
Diagnosis, Chronic Periodontitis 75%
FMBS 63%±16%
FMPS 58%±20%
Number of pockets >4mm: 77± 23
Aa detectable (patients) 44%
Pg detectable (patients) 72%
Tf detectable (patients) 76%
Treatment Time, minutes 193±38
Table 17 Baseline clinical and periodontal 
parameters according to tooth level
Va r ia b l e
T o o t h
(N=2589)
Tooth Type:
Incisors 550
Premolars 654
Molars 1385
Mobility, Grade
0 1582
I 740
II 201
III 66
Furcation involvements:
Molars 58%
Upper First Premolars 25%
Table 18 Baseline clinical and periodontal 
parameters according to site level.
V a r ia b l e Sit e  (N =15498)
PPD, mm 4.4±0.4
REC, mm 0.51± 1.70
CAL, mm 4.93±1.13
Plaque Score (1) 58.5%
BoP (1) 64.1%
Non surgical periodontal therapy using a piezoelectric device required an average of 
193±38 minutes and resulted in a significant improvement in all clinical periodontal 
parameters after six months (Table 19). A mean reduction of 57.5±2.4 (mean±se) in the 
number of periodontal pockets greater than 4mm (p<0.0001 t-test) was achieved
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together with a significant reduction in full mouth bleeding (45.5±2.5%, p<0.0001 t- 
test) and plaque scores (37.7±1.9%, pO.OOOl t-test).
Table 19 Differences in patient level clinical outcomes 2 and 6 months following non-surgical 
periodontal therapy_________________________________________________________________
Ba se l in e  - 2 M o n th s B a se l in e  -  6 M o n th s
M ea n  ±  SE 95%  C l P M e a n  ±  SE 95%  C l P
AFMPS 36.9±2.1 32.8-41.1 <0.001 37.7±1.9 34.0-41.4 <0.001
AFMBS 46.8±1.7 43.4-50.3 <0.001 45.5±2.5 42.1 -49.0 <0.001
Anppd >4 52.5±2.5 47.6-57.6 <0.001 57.5±2.4 52.6 - 62.4 <0.001
APPD 1.1±0.5 1.0- 1.2 <0.001 1.2±0.5 1.1 -  1.3 <0.001
ACAL 0.2±0.6 0 1 © L> 0.003 0.1±0.5 -0.04 - 0.2 0.215
FMBS and FMPS stand for full mouth bleeding and plaque scores respectively, nppd>4 refers to the total 
number of periodontal pockets per patient probing more than 4 mm.
4.6.3.1 C h a n g e s  in  PPD
Results from the variance component (null) multilevel model with APPD as dependent 
variable without and with all explanatory covariates included are presented in table 20. 
In the null model variability at each individual level was obtained as a percentage of the 
total variability calculated adding all estimates together.
Table 20 Multilevel Linear Regression Model estimating the relative contribution of patient, tooth and 
site parameters to the observed variability in PPD reduction_____________________________________
APPD B a s e l i n e  6 M o n t h s
N u l l  M o d e l
C l in ic a l  V a r ia b l e s  
in c l u d e d
P±SE P±SE
Intercept 1.053 ±0.046 2.539± 0.442
Patient 0.177±0.029 0.072±0.013(8.0%)* (-59.3%)t
Tooth 0.262±0.017 0.096±0.008(11.6%)* (-63.4%) t
Site 1.806±0.024 0.753±0.011(80.4%)* (-58.3%)t
-2 LL 50312.170 28752.080J
Percentage of variance in the dependent variable APPD attributed by the multilevel model at the 
patient, tooth and site level, f  Difference in percentage of variance in the dependent variable 
APPD at the patient, tooth and site level when explanatory (clinical) variables were included in 
the model. J -2LL change significant (PO.OOOOOOl) tested by x2 •
The majority o f the variance was attributed to the site level (80%), followed by the
tooth (12%) and patient level (8%). On average, adding the tested variables to the model
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explained 60% of the variability at all levels (Table 20). Significant better fit was 
obtained by entering all clinical covariates at all levels (P0.00001 Chi-Square test). 
Regression estimates and significance testing for all clinical covariates were also 
performed (Table 21). Current smokers (p<0.001) and individuals carrying one or two 
copies of the rare allele at the IL-6 (-174) polymorphism (p<0.01) showed a 
significantly less favorable response to periodontal therapy in terms of changes in 
probing pocket depths. All other subject variables were not significant in the final 
model.
Table 21 Multilevel Linear Regression Model assessing the significance o f tested patient, tooth and site 
parameters in explaining the variability in observed PPD reductions_______________________________
APPD B a s e l i n e  6  M o n t h s
V a r i a b l e B ± S E
Age 0.003±0.006
Gender -0.089±0.077
Ethnicity -0.095±0.050
Smoking -0.324±0.081 }
Diagnosis 0.001±0.127
BMI 0.002±0.010
FMBS -0.001±0.003
FMPS 0.002±0.003
NPPK -0.001±0.002
Patient FullMouth CAL -0.099±0.057
Pg 0.045±0.100
AA 0.027±0.077
Tf -0.017±0.091
Treatment Time 0.001±0.001
N° Teeth Extracted 0.010±0.020
IL-6 (-174) -0.226±0.090 f
TNF-A (-308) -0.057±0.098
TLR-4 (-299) -0.119±0.117
IL-1 A, IL-1B, IL-10 NS
Mobility -0.069±0.022 *
Furcation -0.029±0.038i ooin Premolars vs Incisors -0.226dh0.031 §
Molars vs Incisors -0.686±0.045 §
Plaque 0.02±0.022
Q 1 1 A BoP 0.011 ±0.025ol l6 Mesio-Distal 0.428±0.023 §
Normalized baseline PPD 0.633±0.007 §
* P<0.05 fP<0.01 f  PO.OOl § P 0 .0001
At the tooth level, the presence of mobility at the baseline visit was also significantly 
associated with a less favorable PPD reduction (P<0.05) while the model clearly
demonstrated that anterior teeth (incisors and canines) showed the most significant 
decreases in PPD when compared to premolars or molars (P<0.0001). At the site level 
the model confirmed that normalized baseline probing depths were highly associated 
with changes in PPD (P<0.0001) and that mesial and distal sites were the areas where 
PPD changes were greater than those observed at the facial and lingual sites (P<0.0001). 
Analysis o f residuals at each level o f variability confirmed the normality assumptions 
(Figure 26 A-C) and the validity o f the model.
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Figure 26 Unstandardized residuals at site (A), tooth (B) and patient (C) levels o f  variance for APPD 
Baseline-6 months MLM.
Table 22 shows the patient-based changes in PPD according to smoking status and 
carriage of the rare allele at the IL-6 gene. Within each group, PPD changes between 
baseline and 6 months were highly significant (PO.OOl t-test). To compare changes in 
PPD among groups, a standard multiple testing approach with a Bonferroni correction 
was utilized.
Table 22 Patient level analysis o f PPD reductions based on smoking status and carriage o f the rare allele 
of the IL-6(-174) polymorphism (N=94)_______________________________________________________
Baseline 6 Months A BL-6M P
Variable Mean ± SE Mean ± SE Mean ± SE T-TEST
PPD
Smoker 4.47 ± 0 .1 1 3.43 ± 0 .0 9 1.04 ± 0 .0 6 <0.001
Non smoker 4.30 ±  0.07 3.03 ± 0 .0 5 1.26 ± 0 .0 7 <0.001
nppd >4
Smoker 82 ± 4 29 ±3 53 ± 4 * <0.001
Non smoker 78 ± 3 18 ±  2 60 ± 3 * <0.001
PPD IL-6 (-174) GG 4.34 ±  0.08 3.13 ± 0 .0 6 1.21 ± 0 .0 6 <0.001
IL-6 (-174) G C -C C 4.40 ± 0 .1 0 3.27 ± 0 .0 9 1.13 ± 0 .0 8 <0.001
nppd >4
IL-6 (-174) GG 82 ± 3 19 ±  2 63 ± 4 * <0.001
IL-6 (-174) GC - CC 77 ± 3 26 ± 3 51 ± 3 * <0.001
* P<0.05 post hoc comparison (Bonferroni) Nppd>4 stands few total number of pockets 
greater than 4mm per patient.
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This analysis showed a small but significant difference between current smokers and 
non smokers in terms of changes in probing pocket depths (0.22 mm 95% Cl 0.03 to 
0.41). The carriage of the rare allele for the IL-6 (-174) polymorphism was significantly 
associated with a smaller decrease in the number of pockets (mean difference 11 
pockets 95% Cl 2-21).
A tooth based analysis is displayed in table 23. This analysis failed to show a significant 
effect of tooth type (incisors vs. premolars or molars) in terms of APPD.
The effect of tooth mobility, however, was highly significant: at greater baseline 
mobility values corresponded higher the observed decrease in PPD (PO.OOl post hoc 
Bonferroni comparison).
Table 23 Tooth level analysis of PPD reductions based on tooth mobility and tooth type (N=2589)
B a s e l i n e  
M e a n  ± SE
6 M o n t h s  
M e a n  ± SE
A BL-6M
M e a n  ± SE
P
T-TEST
Molars - 
Premolars 4.72 ±0.03 (1494) 3.49 ±0.02 (1335) 1.05 ±0.02 (1330) <0.001
Tooth Incisors 3.86 ±0.04 (1095) 2.79 ±0.02 (1066) 1.03 ±0.03 (1066) <0.001
Type Molars 4.60 ±0.04 (1385) 3.39 ±0.03 (1230) 1.03 ±0.02 (1226) <0.001
Incisors 3.87 ±0.05 (550) 2.78 ±0.03 (539) 1.07 ±0.04 (539) <0.001
Grade 0 3.94 ±0.03 (1582) 3.05 ±0.02(1525) 0.87 ±0.02* (1525) <0.001
Mobility
1 4.71 ±0.04 (740) 3.32 ±0.04 (682) 1.28 ±0.03* (682) <0.001
2 5.63 ±0.10 (201) 3.82 ± 0.11 (138) 1.58 ±0.09* (138) <0.001
3 6.25 ±0.17 (66) 3.78 ±0.20 (29) 1.85 ±0.20* (29) <0.001
* PO.OOl post hoc comparisons (Bonferroni)
Since the majority of previous studies have been reported using flawed site-based 
analyses, results of this trial have also been reported using a site analysis (table 24) to 
allow comparison. In this instance the site based analyses were in agreement with the 
multilevel analysis. Mesial and distal sites showed significantly greater changes in 
probing depths after non surgical periodontal therapy than facial or lingual surfaces 
(PO.OOl t-test mean difference 0.81 mm 95% Cl 0.76 to 0.86). In addition to the
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previous analysis in the same table are reported the significant differences between 
groups of sites according to the standard cut-off values o f the baseline probing depths. 
The deeper the baseline PPD the greater was the decrease in PPD 6 months after 
subgingival scaling. 1.22 mm of PPD reduction was found in sites measuring 4-5mm at 
baseline (PO.OOl t-test 95%CI 1.2 to 1.3); while the APPD was 2.4 mm at sites with 
baseline PPD of 6 mm or more (PO.OOl t-test 95% Cl 2.3 to 2.4).
T ab le  24 Site level analysis of PPD reductions based on site location and classes o f baseline PPD
(N= 15498)
B a s e l i n e  6  M o n t h s  A  B L - 6 M  P  
V a r i a b l e  M e a n  ± SE M e a n  ± SE M e a n  ± SE t - t e s t
Facial-Lingual 3.06 ± 1.86 (5176)
2.40 ± 1.20 
(4794)
0.51 ± 1.34* 
(4786) <0.001
Mesio-Distal 5.01 ± 1.94 (10322)
3.57 ± 1.37 
(9568)
1.31 ± 1.50 * 
(9533) <0.001
PPD <=3mm 2.27 ±0.73 (6271)
2.25 ±0.80 
(6064)
0.02 ± 0.811 
(6064) <0.001
PPD= 4-5 mm 4.57 ± 0.49 (4439)
3.34 ± 1.05 
(4153)
1.22 ± 1.06f 
(4153) <0.001
PPD ^ 6mm 6.89 ± 1.22 (4788)
4.39 ± 1.51 
(4102)
2.39 ± 1.52t 
(4102) <0.001
* PO.OOl independent t-test f  PO.OOl post hoc comparisons (Bonferroni) The 
table is derived from a flawed site-based analysis with the only purpose to
compare these results with the ones derived from the multilevel modeling,
rather than being interpreted on its own.
4.6.3.2 C h a n g e s  in  CAL
A Second MLM model with ACAL as dependent variable and including or not all
explanatory covariates is presented in table 25. The null model, which represents only
the intercept model, refers to the total variance of the model distributed across each 
level of the hierarchy (site, tooth, patient). Each level of hierarchy is highly significant 
and with the inclusion of all clinical parameters the difference in percentage of variance 
explained by the model is also reported (P<0.00001 Chi-Square test). A significant 
reduction in total residual variance was found at the patient and site levels whereas at 
the tooth level the inclusion of all clinical variables did not change significantly the
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residual variation. Regression estimates and significance testing for all clinical covariate 
are reported in table 26.
Table 25 MLM random intercepts for DCAL 0-6 with and without clinical variables included_____
ACAL B a se l in e  6 M o n t h s
N u ll  M o d el C l in ic a l  V a r ia b l e s  in c l u d e d
P±SE P±SE
Constant -0.124±0.046 0.943±0.565
Patient 0.173±0.029  
(7. l%)t
0.097±0.020  
(-43.9% ) f
Tooth 0.346±0.021(14.0% )f
0.338±0.020
("2.3)J
Site 1.951±0.026(78.9% )f
1.362±0.021
(-30.2%)J
-2 LL 49229.620 34803.590§
t  Percentage of variance in the dependent variable ACAL attributed by the multilevel model at the 
patient, tooth and site level.J Difference in percentage of variance in the dependent variable ACAL at the 
patient, tooth and site level when explanatory (clinical) variables were included in the model.
§ -2LL change significant (P<0.0000001) tested by %2.
Similarly to the results for APPD, smoking status and carriage of a specific 
polymorphism (IL-6 gene) where significantly associated with changes in clinical 
attachment levels after six months of periodontal therapy (P<0.001) giving strength to 
the overall analysis.
Subjects of different ethnicity (not Caucasian vs Caucasian) or those individuals 
carrying one or two copies of the rare alleles at polymorphisms of TNF-A and TLR-4 
genes showed a negative association with clinical attachment level changes (table26). 
Furthermore the detection of a specific periodontal pathogen (Pg) at baseline was 
associated with a greater difference in CAL at 6 month follow up. At the tooth and site 
level similar results to the previous model (APPD) were observed for all covariates 
included in the model. Essentially a greater difference in CAL was predicted if there 
was no furcation involvement at baseline (P<0.0001) or if the tooth was an incisor 
(P<0.001 incisors vs premolars, P<0.0001 incisors vs molars). The presence of mobility 
at the baseline visit was not associated with any changes in clinical attachment levels.
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Finally, the model (CAL), one more time, confirmed that the baseline probing depths 
were highly associated not only with changes in PPD (PO.OOOl) as previously reported 
but also with differences in clinical attachment levels (PO.OOOl). Mesio-distal sites 
were the surfaces where these changes happened the most when compared to bucco- 
lingual sites (PO.OOOl).
Table 26 MLM three levels variance model for ACAL 0-6 with all clinical variables included
ACAL Baseline 6 
Months
Variable b ±SE
Age -0.003i0.008
Gender -0.118±0.095
Ethnicity -0.196±0.061 f
Smoking -0.239±0.099 %
Diagnosis -0.214±0.156
BMI -0.006±0.003
FMBS -0.001±0.004
FMPS -0.006±0.003 f
NPPK -0.00 liO.002
Patient FMCAL -0.074±0.070
Pg 0.261±0.122 f
AA -0.019±0.094
Tf -0.169±0.111
Treatment Time -0.002±0.001
N° Teeth Extracted -0.015±0.025
IL-6 (-174) -0.393±0.110 #
TNF-A (-308) -0.326±0.120 §
TLR-4 (-299) -0.286±0.143 t
IL-1 A- IL-B511,3954,IL-10 NS
Mobility -0.064i0.035
Tooth Furcation -0.228±0.061 #Premolars vs Incisors -0.121±0.050 §
Molars vs Incisors -0 .2 0 7 i0 .0 7 2  #
Plaque 0.039i0.030
Site BoP 0.054i0.035Mesio-Distal 0.561±0.122 #
PPD 0.466±0.009 #
f  P<0.05 JP<0.01 § PO.OOl # PO.OOOl
Confirmation of the validity of the model came from the analysis of residuals at each 
level of variability (site, tooth and patient) (Figure 27 A-C).
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We then repeated the analysis o f the above reported significant changes utilizing a 
standard statistical approach that does not account for the intrinsic hierarchy of  
periodontal data (t-test or ANOVA as appropriate). Tables 27-29 show the differences
lt
A • f  1 ------+—  ------------1- f. 1 tr
Figure 27 Unstandardized residuals at site (A), tooth (B) and patient (C) levels o f  variance for ACAL 
Baseline-6 months MLM.
in terms o f CAL between baseline and 6 months after periodontal therapy separately at 
each level o f variance (patient level: table 27, tooth level: table 28 and site level: table 
29).
Table 27 Changes in CAL at patient level (mean full mouth PPD and nPPD> 4 -  N=94) by: smoking,
B a s e l in e 6 M o n t h s A CAL-6M P
V a r ia b l e s (p a t ie n t ) M e a n  ±  S D M e a n  ±  S D M e a n  ±  S E
Smoker 
Non smoker
5.21 ±0.18 5.25 ±0.18 -0.05 ± 0.08 NS
4.76 ±0.15 4.61 ±0.14 0.15 ±0.08 NS
Caucasian 
Non Caucasian
4.57 ±0.12 4.60 ±0.15 -0.03 ±0.10 NS
5.12 ± 0.16 5.00 ±0.16 0.13 ±0.07 NS
Pg Positive 
Pg Negative
5.01 ±0.14 4.99 ±0.14 0.02 ± 0.07 NS
4.63 ± 0.25 4.33 ± 0.24 0.29 ±0.14 NS
TNF-ot(-308) 1.1 
TNF-a(-308) 1.2-2.2
4.76 ±0.12 4.68 ±0.13 0.08 ± 0.07 NS
5.32 ±0.32 5.26 ± 0.29 0.07 ±0.10 NS
IL-6 (-174) GG 
IL-6 (-174) GC - CC
4.81 ±0.13 4.67 ±0.13 0.13 ±0.07 NS
5.10 ± 0.21 5.09 ±0.21 0.01 ±0.10 NS
TLR-4 (-299) 1.1 
TLR-4 (-299) 1.2 - 2.2
4.85 ±0.11 4.78 ±0.12 0.07 ± 0.07 NS
5.21 ±0.43 5.29 ±0.44 -0.07 ±0.12 NS
The rationale behind this supplemental analysis was to demonstrate that using a 
standard statistical approach some informations maybe lost and perhaps different 
conclusions are drawn from the analysis. Nevertheless many o f the findings reported 
from the MLM analysis were confirmed (Table 26).
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Table 28 Changes in CAL at tooth level (mean PPD/tooth N=2589) by: tooth type (incisors vs
premolars/molars) and furcation involvement (present/absent).
Baseline 6 M onths A BL-6M P
Variables (to o th ) M ean ± SE (N) M ean ± SE  (N)
M ean  ± SE  
(N)
Furcation present 
Furcation absent
5.17 ±0.11 (295) 4.67 ±0.11 (232)
0.05 ± 0.09 
(227) <0.001
5.77 ±0.09 (537) 5.29 ±0.09 (466)
-0.01 ±0.05 
(460) <0.001
Molars-Premolars
Incisors
5.14 ±0.05 (1494) 4.87 ± 0.05 (1339)
-0.06 ±0.03* 
(1327) <0.001
4.48 ±0.06 (1094) 4.56 ± 0.06 (1067)
-0.17 ±0.03* 
(1065) <0.001
Molars
Incisors
5.58 ±0.07 (840) 5.11 ±0.06 (705)
0.01 ± 
0.04** (694) <0.001
4.48 ±0.06 (1094) 4.56 ±0.06 (1067)
-0.17 ± 
0.03** 
(1065)
<0.001
* P<0.05 ** PO.OOOl Independent t-test
Table 29 Changes in CAL at site level (CAL at each site N=18048) by mesio/distal vs 
liguo/buccal, and PPD classes at baseline_______________________________________
Baseline 6 M onths A BL-6M P
Variables
(site)
M ean ± SD 
(N)
M ean ± SD 
(N)
M ean ± SD 
(N)
Mesio Distal 
Buccal-Lingual
5.33 ±2.57 
(10086)
5.08 ±2.16 
(9157)
0.03 ± 1.58* 
(9016) <0.001
3.92 ±2.50 
(5095)
4.05 ± 2.05 
(4690)
-0.39 ± 1.53* 
(4636) <0.001
PPD <=3mm 
PPD= 4-5mm 
PPD ^ m ra
2.91 ± 1.62 
(6139)
3.69 ± 1.73 
(5932)
-0.82 ± 1.18** 
(5862) <0.001
5.00 ± 1.78 
(4350)
4.88 ± 1.85 
(3950)
0.07 ± 1.41** 
(3925) <0.001
7.29 ± 2.25 
(4682)
6.24 ±2.15 
(3881)
0.77 ± 1.74** 
(3862) <0.001
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4.6.4 D is c u ssio n
The results of this analysis established that, in a group of 94 systemically healthy 
subjects suffering from severe, generalized periodontitis, the major source of variability 
in terms of decrease in probing pocket depths and CAL, following delivery of a 
standard phase of cause-related periodontal therapy consisting of oral hygiene 
instructions and mechanical subgingival debridement, was attributable to the site level 
(80%), with the tooth and the patient explaining 12% and 8% o f residual variance. This 
analysis associated the extent of decrease of periodontal pockets with patient factors 
(cigarette smoking status and carriage of the rare allele of a specific polymorphism for 
the IL-6 gene), tooth factors (tooth mobility and tooth type), and site factors (mesial and 
distal location, as well as baseline probing depth). A multilevel analytical approach was 
used in order to respect the intrinsic hierarchy of periodontal clinical data (patient, tooth 
and site). Each level of variance was significant in the models as well as significant 
were a series o f covariates that were used in order to predict changes in probing pocket 
depths and clinical attachment levels following initial periodontal therapy. These results 
are significant since they represent a robust confirmation and an expansion of the 
evidence that had been generated before a full understanding of the fact that the 
treatment outcomes at different sites and/or teeth within the same patient are not 
independent (DeRouen et al. 1991; Hujoel et al. 1990). O f interest was also the 
estimation of the fact that the tested clinical variables explained roughly 60% of the 
observed variability at the patient, the tooth and the site level. Given the fact that the 
present study did not involve extensive analysis of the mechanisms by which the tested 
therapy is likely to result in clinical improvements, the percentage of explained 
variability was somehow unexpected and can perhaps be better understood 
hypothesizing that some of the incorporated variables may represent proxy estimations 
of these mechanisms. As an example, PPD may in itself represent an estimation of the
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level of debridement that can be achieved (Rabbani et al. 1981). This study confirmed 
initial observations indicating that cigarette smoking negatively affects the outcome of 
non-surgical periodontal therapy: smokers resulted in 0.23 mm less pocket depth 
reduction than non-smokers. Even though the average amount may seem small, 
clinicians should put this number in the context of the observed decrease for the whole 
population (95% Cl of 1.1.to 1.3 mm). The observation that smokers had also a 0.20 
mm attachment levels loss compared to non smokers further confirms the negative 
influence of this variable. Pocket depth reductions in smokers were decreased by 20% 
compared to the overall population.
A series of polymorphisms in pro-inflammatory genes were evaluated. We did not find 
any correlation between the IL-lA(-889) and IL-1B (+3954) on clinical periodontal 
parameters changes after periodontal therapy. Some evidence suggest that the 
combination of carriage of a copy of the rare allele in both loci is associated with a more 
severe periodontal infection, tooth loss, alveolar bone levels and bleeding on probing 
(Lang et al. 2000; Meisel et al. 2004; Meisel et al. 2003; Meisel et al. 2002; McGuire & 
Nunn 1999). The significant patient associated factor was the carriage of the rare allele 
of a polymorphism in the promoter region of the IL-6 gene.
The analysis assessed the impact of a dominant effect of this functional polymorphism. 
IL-6 is a key regulatory cytokine that has been implicated in the pathogenesis of 
periodontitis. Research from this group has discovered an association between the tested 
IL-6 polymorphism and the severity of periodontal destruction as well as the level of 
systemic inflammatory response associated with periodontitis. The present finding has 
not been reported before and supports the hypothesis that IL-6 is central to the 
homeostasis of the periodontium. People C-carriers for this polymorphism (-174) have 
shown also clinical periodontal infections of greater extent that those carriers of the
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common allele (G) (Holla et al. 2004; Trevilatto et al. 2003). This will require 
confirmation in future investigations.
With respect of changes in CAL after periodontal therapy, the MLM analysis evidenced 
a significant negative effect of the same magnitude for TNF-A and TLR-4 
polymorphisms. Both genetic variants have been preliminarily associated with a clinical 
periodontal phenotype of greater extent and severity perhaps because of an exaggerated 
inflammatory response in one case (TNF-A) or a deficient host innate response in the 
other (TLR-4) (Holmes et al. 2003; Tabrizi et al. 2001). Further research is however 
needed to ascertain whether in larger populations the same effect is repeated.
Despite the limitations arising from the qualitative nature of the microbiological 
analysis, the finding of the positive effect of the presence of a periodontal pathogen at 
baseline (P.g) with a greater change in attachment levels after 6 months deserve some 
comments. Perhaps individuals positive for this pathogen were more susceptible to a 
better clinical response since periodontal therapy is more likely to control the presence 
of this pathogen rather than T f or Aa. The hypothesis is supported by the results that 
showed a greater significance in the difference of Pg already after two months of 
therapy whereas T f and Aa where less detectable only after six months. Confirmation of 
these findings is however also needed and we would caution any extrapolation of these 
results to other populations.
It is important to note that the relatively modest contribution of patient specific 
variables was obtained in a population of systemically healthy subjects. It may be 
expected that, had this study included subjects with significant systemic conditions, 
more patient variability could have been expected.
At the tooth level, the impact of mobility on PPD reductions deserves some discussion. 
The multivariate, multilevel analysis has uncovered a negative impact of tooth mobility 
on PPD reductions. This result was obtained following correction for other possible
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confounders included in the model such as baseline PPD. The result is in apparent 
conflict with the results of the univariate analysis presented in table 23 indicating that 
better probing depth reductions were observed in teeth with a high degree of mobility. 
These apparently divergent results must be carefully interpreted. The multivariate model 
indicates that, after correcting for possible confounders, mobility had an overall 
negative impact on PPD reductions. The univariate analysis, on the other hand, indicates 
that a mobile tooth was associated with better reductions in PPD. Since mobile teeth are 
likely to have lost a significant amount of clinical attachment and present with deep 
pockets, teeth with a higher degree of mobility are likely to display better improvements 
in PPD due to the deep pockets (univariate analysis). After correcting for these 
confounders, however, mobility in itself seemed to have a negative impact on the 
clinical responses following sub-gingival debridement. Multilevel modelling analysis of 
periodontal data has produced contrastant results difficult to interpret as for instance the 
protective effect of the presence of supragingival calculus in terms of long-term 
attachment loss (Gilthorpe et al. 2001). Further research is needed in the matter to better 
elucidate whether there is a biological plausibility of such results.
Of interest was also the finding that incisors and canines responded better than 
premolars and molars. Although no evidence is available on the subject, we hypothesize 
that there might be a higher efficacy of subgingival instrumentation at single rooted 
teeth and a higher likelihood that thinner gingival tissues associated with pockets in 
anterior teeth are likely to heal with more recession and hence pocket reduction than in 
posterior teeth. The presence of furcation involvement did not have a significant impact 
on PPD reduction as previously reported (Loos et al. 1988; Loos et al. 1989; Nordland 
et al. 1987) whereas, CAL changes were highly affected by this covariate. The 
interpretation of this result might have been affected by the fact that this study did not
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specifically address the outcome of sites with furcation involvement (site analysis) but 
rather considered furcation involvement as a tooth level variable.
At the site level, greater reductions in both probing pocket depths and attachment levels 
were observed for interdental sites as compared to facial and/or oral. This is in 
agreement with previous data and consistent with the prevalent location of deeper 
pockets in the interproximal areas.
The impact of baseline pocket depth on the amount of pocket depth reduction was also 
assessed. While the periodontal literature has firmly established that deeper pockets 
have a greater potential for reduction, a recent investigation has warned against the 
effect of mathematical coupling in multivariate models incorporating baseline pocket 
depths as an independent variable (Tu et al. 2002). To assess the effects of this 
important variable and reducing the impact of mathematical coupling, baseline PPD 
measurements were normalized. The site analysis (table 24), agrees well in terms of 
magnitude with the classical studies that have indicated that the magnitude of 
improvement is greater in deeper pockets.
It is also noteworthy that the amounts of PPD reductions observed in the present 
population is in excellent agreement with those reported in previous studies and in 
systematic reviews of non surgical periodontal therapy. In particular, moderate pockets 
showed an average decrease in PPD of 1.2 mm in this study and of 1.3 mm in the 
summary prepared for the 1996 World Workshop(Cobb 1996); similarly deeper pockets 
(>5 mm) showed a 2.4 mm improvement compared to a 2.3 mm. Mean changes in CAL 
after therapy ranged between 0.03 mm and 0.7 of gain in sites with probing pocket 
depths greater than 4 and 6 mm respectively. The interest of these data lies in the fact 
that in this study only machine-driven instrumentation was utilized. The good 
agreement with the published data can be interpreted as a further indication that 
properly performed mechanical instrumentation can lead to excellent clinical outcomes.
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In this respect it is worth noting that the total time o f instrumentation required to 
achieve satisfaction of the clinician exceeded the 3 hours (193 minutes).
G e n e r a l  P o in t s  o f  D is c u s s io n
This preliminary investigation indicated that patients suffering from severe generalized 
periodontitis (affecting at least 50% of their dentition) also present a systemic 
inflammatory reaction assessed by raised IL-6 and CRP serum concentrations. The 
degree of this systemic reaction is positively associated with the extent and severity of 
periodontal infection and it is independent of age, gender, smoking and ethnical 
background. These data enabled us also to explore the possible influence of genetic 
variations on the individual chronic inflammatory response. Specific allele 
combinations were indeed significantly associated with a hyper-inflammatory 
phenotype elicited by the local periodontal infection.
Support for causality in the association between periodontitis and APR lies in the fact 
that standard periodontal therapy produced a significant reduction in serum 
inflammatory markers, which was also correlated positively with the degree of clinical 
response observed. This systemic anti-inflammatory effect was stable in magnitude for 
a period of 12 months somehow minimising the possible confounding arising from 
several systemic factors (age, gender, ethnicity, smoking).
The importance of a different genetic backgrounds however has to be mentioned also 
when we examined the individual response to periodontal therapy. A significant portion 
of the variability in the resulting inflammatory state following periodontal therapy was 
also explained by the carriage of rare alleles at polymorphic sites of pro-inflammatory 
genes (IL-1A, IL-6).
Within the limitation of the design of this trial we can conclude that the association 
between severe periodontitis and systemic inflammation might represent one of the 
missing mechanistic links between periodontal infections and systemic diseases such as
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atherosclerosis, type-2 diabetes and adverse pregnancy outcomes. The individual basal 
inflammatory burden is increasingly assuming the role o f predictor for future serious 
events (myocardial infarction, atherosclerosis, diabetes and hypertension) to the extent 
that new risk categories are being developed based on inflammatory markers.
In particular individuals showing on a single occasion a concentration of CRP above 3 
mg/L are at high risk of developing serious coronary events in the future, especially if 
other risk factors are present (hyperlipidaemia, smoking, diabetes and hypertension). 
Individuals with more severe periodontitis have 4 times more probability to be in this 
high-risk category. The good news however is that if  this observation is proved to be 
real and not just affected by a reverse causality bias (atherosclerosis, hypertension, 
diabetes are the cause of systemic inflammation), successful periodontal therapy might 
reduce the individual CRP-associated cardiovascular risk.
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C o n c l u sio n s
• Severe generalized periodontitis is associated with a moderate systemic 
inflammatory reaction in a dose-dependent way.
• This association is modulated by well recognized cardiovascular risk factors 
(age, body mass index, smoking) and novel genetic variations in pro- 
inflammatory genes (IL-1 A,IL-6, TNF-a).
• Patients suffering from severe generalized periodontitis are more likely to be at 
higher risk for future CRP-associated cardiovascular predicted events.
• Standard periodontal therapy decreases the individual inflammatory burden after 
6 and 12 months. This reduction is greater in those who show a better clinical 
response. Similarly a significant reduction in CRP-associated cardiovascular risk 
is expected.
• Because of the cohort design of this study, these observations will need to be 
confirmed in randomized controlled clinical trials to minimize the risk of bias in 
these findings. Such trials will be described in Chapter 6 and 7.
• Specific gene polymorphisms negatively influence the clinical response of 
individuals receiving exclusively machine driven standard non surgical 
periodontal therapy.
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C h a p t e r  5.
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5.1.1 Su m m a r y
Chronic periodontitis and its treatment can cause a systemic inflammatory response.
The aim of this study was to describe the systemic inflammatory reactions to an 
intensive periodontal treatment regimen. 14 otherwise healthy subjects suffering from 
severe chronic periodontitis were enrolled in a 1 month pilot single blind trial. Intensive 
periodontal treatment, consisting of full mouth subgingival root debridement delivered 
within a 6-hr period, was performed. Periodontal parameters were recorded before and 1 
month after completion of treatment. Blood samples were taken at baseline and 1, 3, 5, 
7 and 30 days after treatment. IL-IRa, IL-6 and CRP erum concentrations were 
determined by ELISA. Complete blood counts were also performed. One day after 
treatment, mild neutrophilia and monocytosis (P<0.05) and lymphopenia (P<0.01) were 
accompanied by a sharp increase in inflammatory markers (IL-IRa, IL-6, P<0.01). A 
ten-fold increase in CRP (P<0.001) was detected on day 1 and its kinetics followed a 
pattern of a classical acute phase response (significantly raised concentrations up to 1 
week, P<0.01). 3 to 7 days after treatment, subjects presented also with a mild tendency 
towards a normocytic anaemic state (PO.Ol) and a degree of lympho-thrombocytosis 
(P<0.05). The observed changes were similar to those expected following the well- 
characterized endotoxin-challenge model of inflammation. Intensive periodontal 
treatment produced an acute systemic inflammatory response of one week duration and 
might represent an alternative to classic endotoxin-challenge or drug-induced models to 
study acute inflammation in humans.
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5.1.2 In t r o d u c t io n
Experimental models to study in vivo acute inflammation have been developed over the 
years; they utilize a variety of stimuli capable of inducing a systemic inflammatory 
response. Among them the endotoxin model (parenteral injection of LPS in healthy 
subjects) represents perhaps the most known and adopted, although the physical training 
model (strenuous exercise) and the vaccination model have been equally useful (Fiuza 
& Suffredini 2001; Martich et al. 1993; Moldoveanu et al. 2001; Parker & Watkins 
2001; Shephard & Shek 1998; Shephard & Shek 1998; Shephard 2002; Suffredini et al. 
1995; Hingorani et al. 2000).
In the reported models, the systemic inflammatory responses to the stimuli are measured 
as changes in concentrations of well-recognized serum markers (CRP, IL-6, IL-1). 
Some of these mediators are thought to exert direct defensive functions (like CRP) 
while others are involved in the amplification/regulation of the local stimulus and 
induction of a systemic response to it (Suffredini et al. 1999).
The concept that periodontitis and its treatment could represent a useful model to study 
human inflammation originates from growing evidence that periodontal infections are 
associated with and contribute to the systemic inflammatory burden of affected 
individuals. Several reports have confirmed that moderate to severe forms of 
periodontitis are associated with a mild systemic inflammatory response, as defined by 
raised serum concentrations of inflammatory markers (CRP, IL-6) (Ebersole et al. 1997; 
Loos et al. 2000; Noack et al. 2001; Slade et al. 2003).
Periodontitis is a prototype chronic low-grade infection. It is caused primarily by 
anaerobic gram negative bacteria organized in a protected biofilm in the subgingival 
portion of the root surface. Its treatment relies upon the mechanical removal of the 
biofilm and subgingival calculus deposits in order to reduce bacterial load and thus local 
inflammation (Williams 1990). Mechanical instrumentation of the subgingival
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environment, however, results in an intense transient bacteraemia as well as significant 
soft tissue damage at the level of the periodontium (Lofthus et al. 1991; Waki et al. 
1990). The fact that periodontitis is caused by a mixed anaerobic gram negative flora 
would suggest that bacteraemia following periodontal instrumentation may challenge 
the systemic inflammatory response in a similar fashion with respect to endotoxin 
injection. Since mechanical periodontal therapy in the absence of administration of 
antimicrobials represents the standard of care delivered to the 10-15% of the adult 
population affected by chronic severe periodontitis, periodontal therapy may represent a 
readily available experimental model to study inflammation.
Improved understanding of the early inflammatory responses following delivery of 
periodontal therapy is also a critical element in designing definitive intervention trials to 
assess the nature of the association between periodontitis and systemic inflammation. 
These trials are designed to uncover a decrease in inflammatory parameters after 
periodontal therapy and such decreases could be masked by the tail of the treatment 
associated increase in inflammation.
The aims of this pilot investigation were i) to describe the changes in systemic 
inflammatory parameters consequent to an intensive periodontal treatment regimen, and 
ii) to determine the kinetics of changes in inflammatory markers and mediators (CRP, 
IL-6, IL-IRa) in the early days and weeks following the treatment associated 
bacteraemia.
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5 .1 .3  M e t h o d s
5 .1 .3 .1  St u d y  P o p u l a t io n  a n d  D e s ig n
The study was a prospective single blind intervention trial with one month follow-up. 
Participants were recruited from subjects referred to the Department of Periodontology 
of the EDI, UCL. Subjects presenting with severe (probing pocket depths greater than 6 
mm and marginal alveolar bone loss greater than 30%), generalized (at least 50% of 
teeth affected) periodontitis were invited to participate in the study. Exclusion criteria 
included: i) known systemic diseases, ii) history and/or presence of other infections, iii) 
systemic antibiotic treatment in the preceding three months, iv) treatment with any 
medication known to affect the serum level of inflammatory markers, v) pregnant or 
lactating females. All patients gave written informed consent; the study had been 
reviewed and approved by the Eastman/UCL Hospitals joint ethics committee.
A baseline visit was conducted by a blind calibrated examiner who collected a complete 
medical history and standard clinical periodontal parameters (presence of plaque, 
bleeding on probing, probing pocket depths, and recession of the gingival margin). 
Subjects thereafter received an intensive session of subgingival mechanical 
instrumentation under local anaesthesia (within a 6 hour period). Instrumentation was 
performed using a 
piezoelectric instrument 
(EMS, Nyon, Switzerland) 
equipped with fine tips for 
access in the subgingival 
environment. Extraction of 
hopeless teeth was 
performed during the same
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session according to standard clinical practice. Periodontal outcomes were re-assessed 1 
month following completion of periodontal therapy (Figure 28).
5 .1 .3 .2  INFLAMMATORY MARKERS AND BLOOD COUNTS ANALYSES
Serial blood samples were drawn into vacutainer tubes (see section 3.4) at baseline, 1,3, 
5, 7 and 30 days after periodontal therapy. Serum was obtained by centrifugation as 
described earlier (section 3.4) and stored at -70°C until analysis in a standardized blind 
fashion. CRP levels were assessed by an automated immunoturbidimetric high- 
sensitivity assay (Cobas Integra, Roche AG Diagnostics, Mannheim , Germany 
detection limit of 0.25 mg/L) essentially as described in section 3.4.2; IL-6 and IL-IRa 
were measured with high-sensitivity 2-site ELISA kits (Quantikine HS, R&D System, 
Minneapolis, USA, detection limit 0.04 pg/mL and 14 pg/mL respectively). Differential 
blood counts were performed using standard clinical haematology procedures on an 
automated analyzer. Body temperature was recorded at each visit using an automated 
thermometer (Thermoscan Plus, Ear Thermometer, Welch Allyn Braun, Thame, UK).
5 .1 .3 .3  S t a t is t ic a l  M e t h o d s
Data are reported as means ± standard deviations (SD) for normally distributed 
variables or median and interquartile ranges (IQR). Non parametric statistical 
comparisons were applied. All statistical comparisons between visits were performed 
with the Friedman ANOVA and the Wilcoxon signed rank-sum test for post-hoc 
comparisons. Concentrations of inflammatory markers were skewed and therefore log 
transformed values were used in all graphical representations for ease of interpretation. 
The alpha value was set at 0.05.
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5.1.4 R e s u l t s
14 subjects (mean age 48±6 years) were included in the trial. With the exception of the 
presence of severe, generalized periodontitis, all subjects were medically healthy. 8 
patients were females, 10 were Caucasians, 2 subjects were smokers and 1 was a former 
smoker. They had an average body mass index of 26±4 kg/m . During the study period, 
all patients remained stable and there were no changes in lifestyle issues and habits 
including exercise, diet, smoking and medications.
In terms of periodontal parameters participants presented with high levels of gingival 
inflammation (full mouth bleeding scores of 65±14%) and severe widespiead 
periodontitis (average of 67 ± 23 periodontal pockets 5mm or deeper per subject with an 
average clinical attachment level loss of 4.8 ± 0.9 mm).
T able 30 Changes in Clinical Parameters after Periodontal Therapy_____
B a s e l in e 3 0  D a y s
NPPD 66.80±23.02 21.33±12.03*
PPD (mm) 4.12±0.76 2.95±0.31*
REC (mm) 0.70±0.46 1.30±0.51*
CAL (mm) 4.82±0.87 4.26±0.62**
FMPS 49.07±22.27 13.79±11.73*
FMBS 65.40±14.60 17.29±7.96*
Values are expressed as mean±SD, * PO.OOOl, ** 
P<0.01 Wilcoxon post hoc rank sum paired test versus 
baseline.
Significant improvements in all clinical parameters were observed (P<0.0001, paired t- 
test) 1 month after completion of treatment (Table 30). Subgingival instrumentation was 
performed for an average of 200±27 minutes over a 6 hour period. A mean of 3±3 
hopeless teeth were extracted per patient at the same visit. At day 1 all participants 
reported a series of symptoms occurring the evening after the treatment, including 
headache, rise in body temperature, tiredness, chills and general malaise. No significant 
changes were observed in participants’ body temperature between the various time 
points (data not shown).
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Box and whiskers plots of the log
transformed concentrations of
inflammatory markers (IL-IRa, IL-6
and CRP) at baseline and 1, 3, 5, 7,
and 30 days after treatment are
displayed in figure 29. IL-IRa
kinetics showed a significant
increase of its concentrations only 1
day after treatment (917.94±569.33
pg/mL compared to 572.91±248.89
pg/mL at baseline, P<0.001
Wilcox on rank-sum test). No
changes were observed at later time
points for this early marker.
IL-6 concentrations were sharply
increased at day 1 (6.98±1.60 pg/mL
compared to 1.78±1.67 pg/mL at
baseline, P<0.001 Wilcoxon rank-
sum paired test) and remained
higher than baseline for the first
Days
week. Figure 29 Box and whiskers plots showing changes in
Log[IL-lRa], Log[IL-6], Log[CRP]before and after
Clear significant changes in CRP periodontal therapy.
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and the median is the horizontal line inside. Open circles 
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Figure 30 Line graphs showing changes in WBC and RBC after periodontal therapy 
(See table 31 for details)
From an initial 1.61±2.11 mg/L, participants showed a significant increase o f CRP 
concentrations at day 1 of 12.49±2.63 mg/L (P0.0001 Wilcoxon signed rank-sum test). 
CRP concentrations remained significantly higher than baseline 3, 5 and 7 days after 
treatment (7.31 ±2.40, 3.63±1.99, 2.59±1.81 respectively, P<0.001 Wilcoxon rank-sum 
paired test).
With respect to haematological parameters, early changes in differential leukocyte 
counts were observed at day 1.
WBC increased on day 1 after therapy even though this was not statistically significant, 
thereafter a significant reduction in WBC were observed after 1 month o f periodontal 
therapy (P<0.05 Wilcoxon rank-sum paired test) (Figure 30).
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Figure 31 Line graphs showing changes in Differential White Cell Blood Counts 
(See table 31 for details)
The changes at day 1 were mainly attributed to an increased pool of circulating 
neutrophils (P<0.01 Wilcoxon test compared to baseline) and an increase in the 
numbers of circulating monocytes was also observed at day 1 and 3 (P<0.05 and P<0.01 
respectively). Lymphocyte numbers however fell (P<0.01) at day 1 and then increased 7 
and 30 days after treatment (P<0.05) (Table 31 and Figure 31).
5 and 7 days after treatment, erythrocyte numbers (figure 30), haematocrit, and 
haemoglobin concentration decreased (Table 2). The number of platelets was 
significantly increased on day 5 (P<0.05).
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Table 31 Differential Blood Counts before and after Periodontal Therapy
D a y s  A f t e r  P e r io d o n t a l  T h e r a p y
B a s e l in e  1 3 5 7 30 P f
WBC
109/L
6.3(1.8) 7.0(2.2) 6.1(1.8) 5.8(2.3) 6.0(1.3) 5.8(1.4)* 0.029
Lymp
109/L
554(189) 346(222)** 587(279) 586(541) 637(242)* 578(354)* <0.0001
Neutr
109/L
887(75) 996(183)** 970(278) 927(219) 900(223) 916(225) 0.04
Mon
109/L
114(39) 138(28)* 150(66)** 136(62) 109(37) 137(37) 0.012
Baso
109/L 5(5)
4(2)* 5(8) 6(6) 7(5) 8(2) 0.01
Eosin
109/L
25(33) 20(14) 35(24) 37(33) 37(26) 40(17) 0.007
RBC
1012/L
4.5(0.9) 4.7(0.5) 4.5(0.6) 4.4(0.6)* 4.3(0.9)** 4.5(0.7) <0.0001
HB g/dL 13.7(2.5) 14.0(1.5) 13.5(2.7)* 13.4(2.1)** 13.3(2.5)** 13.8(2.8) <0.0001
M C V fl 94.1(7.6) 94.0(4.3) 93.5(6.7) 94.4(8.0) 94.2(7.0) 94.0(6.7) NS
HCT L/L 0.42(0.1) 0.43(0.04) 0.42(0.1) 0.41(0.04)* 0.40(0.1)** 0.42(0.1) <0.0001
MCH pg 31.6(2.5) 30.6(2.8)** 30.8(3.3) 31.0(2.5) 31.1(3.5) 30.3(2.8)** 0.033
MCHC
mg/dL
33.1(1.4) 32.3(1.0)** 33.0(1.5) 32.6(1.2) 32.8(2.0) 37.2(1.2) 0.08
PLTS
109/L
290(85)
. .
289(87) 284(78) 309(65)* 291(59) 286(53) 0.005
WBC=White Cell Count, RBC=Red Cell Count, PLTS=Platelets, Lymp=Lymphocytes, Neut=Neutrophils, 
Mon=Monocytes, Baso=Basophils, Eosi=Eosinophils, HB=Haemoglobin, MCV=Mean Corpuscular Volume, 
HCT=Haematocrit, MCH= Mean Corpuscular Hemoglobin, MCHC= Mean Corpuscular Hemoglobin Concentration 
f  Friedman ANOVA
*P<0.05, ** P<0.01 Wilcoxon post hoc rank sum paired test versus baseline.
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5.1.5 D i s c u s s i o n
This report described the effects of an intensive periodontal treatment regimen (full 
mouth subgingival instrumentation delivered within a 6-hour period) on biochemical 
and haematological parameters in the days following therapy. Transient alterations in 
complete blood counts (mild neutrophilia and monocytosis and relative lymphopenia) 
were observed 1 day after treatment. 2 to 6 days thereafter a tendency towards a mild 
normocytic anaemic status developed. Significant changes in inflammatory markers 
accompanied these cellular responses: CRP, a prototype acute phase marker, increased 
nearly 10 fold after 1 day and returned to baseline values only 1 month after treatment. 
Its concentration changes followed the pattern of a classic acute phase marker with a 
rise within 24 hours. Data indicated that IL-6 followed the same pattern with a 
significant increase on day 1 and slower decreases over one week. Serum IL-IRa levels, 
however, followed a different pattern. A relatively modest increase was detected only 
on day 1 after therapy, possibly reflecting the tail of a rapid acute response resolved 
within the first 24 hours.
Given the evidence of significant ingress of bacteria into the systemic circulation 
following periodontal instrumentation (Daly et al. 1997; Daly et al. 2001; Lofthus et al. 
1991; Waki et al. 1990; Lineberger & De Marco 1973), the present data describe the 
systemic inflammatory changes occurring after periodontal treatment. As bactaeremia 
and tissue damage are produced, local and systemic production of pro-inflammatory 
mediators (such as TNFa and IL-ip) has been described as a component of host 
defences (Birkedal-Hansen 1993; Suffredini et al. 1995; Suffredini et al. 1999). In order 
to modulate the process, anti-inflammatory molecules (such as IL-IRa, IL-6) appear on 
the scene to control inflammation and stimulate the hepatic synthesis of acute phase 
proteins (CRP) (Gabay & Kushner 1999). Changes in leukocytes and erythrocytes
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numbers become transiently apparent in the first few days to a week (Suffredini et al. 
1999).
The observed results, although different in magnitude of changes, are in agreement with 
those reported in several models of human inflammation. Intravenous endotoxin 
administration results in a systemic syndrome of several hours with fever and 
constitutionals symptoms. A rapid decrease in leukocyte counts due to peripheral 
vascular margination is observed and it is subsequently followed by a degree of 
neutrophilia. Production of pro-inflammatory mediators (TNF-a accompanied by 
modest IL-lp increase) amplify the reaction against endotoxin, while anti-inflammatory 
cytokines (IL-6, IL-IRa) trigger the hepatic response that, within 24 hours, results in 
raised concentrations of acute phase proteins in order to contain and clear the microbial 
insult (Suffredini et al. 1995; Suffredini et al. 1999).
The mild tendency towards an anaemic status following intensive periodontal therapy 
reported in this study merits some discussion. Previous studies have indicated that 
following acute inflammatory stimuli (minor surgery or strenuous exercise) a post­
operative/trauma anaemia develops with the characteristics of a functional iron 
deficiency (van Iperen et al. 1998; Fallon et al. 1999). A clear shift of the metal from the 
erythropoiesis and circulation to the reticulo-endothelial system might represent the 
pathogenetic mechanism (Weiss 2002). During a systemic inflammatory reaction (as in 
this and other experimental models) increased production of cytokines (IL-1, IL-6) 
might directly affect iron metabolism and inhibit the maturation and synthesis of the 
erythroid progenitor cells (Alvarez-Hemandez et al. 1989; Means, Jr. & Krantz 1992; 
Means, Jr. 1995; Means, Jr. 2003). Furthermore a specific IL-6-induced hepatic 
mediator (hepcidin) could be responsible for iron sequestration in macrophages and a 
reduced iron absorption in the small intestine (Ganz 2003). Patients suffering from 
periodontitis already manifest signs of anaemia of chronic diseases when compared with
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healthy controls (Hutter et al. 2001). Further investigations are necessary to gain insight 
into the nature of the association between periodontitis and anaemia and the 
mechanisms of these observations.
Due to the lack of observations in the early post-treatment hours, this study offers no 
direct evidence on the peak of the inflammatory response generated by periodontal 
therapy. Comparisons with other inflammatory models, however, would suggest that the 
peak of intensity could occur within the first 2-5 hours after treatment. This 
interpretation is consistent with the observation that rapid inflammatory markers such as 
IL-IRa had returned to baseline levels within the first 3 days. Further studies focusing 
on the early inflammatory responses (up to first 6-8 hrs) are needed. On the basis of 
these results, it is concluded that intensive periodontal treatment induced an acute 
systemic inflammatory response. Since the observed response seems to share many of 
the features of the well-characterized endotoxin, vaccination and strenuous exercise 
models, periodontal therapy may represent a useful non drug-induced model to study 
human inflammation. Its relevance may be particularly evident when researchers wish 
to study the functional relevance of specific genetic variants or the effect of 
pharmacological interventions that require relatively large sample sizes and when the 
use of the other established models (such as the endotoxin challenge) may be 
impractical or unethical.
The lack of persistence of the acute systemic inflammatory response following 
treatment until the first post-operative month, on the other hand, suggests that assessing 
inflammatory markers at later time points should not be unduly influenced by the tail 
end of the acute inflammatory response. This information is critical for designing the 
necessary randomized controlled trials to prove causality in the association between 
systemic inflammation and periodontitis.
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5.2.1 S u m m a r y
Above-average CRP concentrations are associated with an increased risk of future 
coronary events in prospective studies and it has been suggested that CRP could be used 
to aid risk prediction. A +1444C>T polymorphism in the CRP gene has been associated 
with differences in CRP concentration. We investigated the effect of this polymorphism 
on the CRP response to periodontal therapy, an intermediate inflammatory stimulus. 
Clinical parameters, CRP, and IL-6 concentrations were evaluated in 55 consecutive 
patients suffering from periodontitis at baseline, 1, 7 and 30 days after an intensive 
course of periodontal treatment. In a multivariate analysis individual homozygous for 
the +1444T allele showed higher CRP concentrations (day 1, 21,10±4,81 mg/L and day 
7, 4,89±0,74 mg/L) compared with C-allele carriers (dayl, 12,37±1,61 mg/L and day 7, 
3,08±2,00 mg/L). Homozygosis for the +1444T allele of the CRP gene was associated 
with a greater acute CRP release after a moderate inflammatory stimulus. This effect 
was independent of conventional cardiovascular risk factors and inflammatory factors 
known to affect CRP concentrations. CRP genotype may need to be considered when 
CRP values are used in coronary risk prediction.
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5.2.2 In t r o d u c t io n
Inflammation plays a significant role in the pathogenesis of atherosclerosis.(Libby et al. 
2002) Prospective studies indicate a robust and strong association, in healthy 
individuals and subjects with pre-existing atherosclerosis, between levels of CRP and 
later cardiovascular events (Ridker et al. 1997; Ridker et al. 2000b). The CRP rise seen 
during acute coronary syndromes is also predictive of adverse outcome in the short term 
(Biasucci et al. 1999). Therefore, it has been proposed that measurement of CRP may 
be a useful adjunct to coronary risk assessment (Pearson et al. 2003). The sensitivity of 
CRP to acute intercurrent inflammatory stimuli together with its wide dynamic range 
(0.1-1000 mg/L) render it an excellent clinical marker of infective or inflammatory 
episodes but represent a challenge to its clinical use in coronary risk prediction (Pepys 
& Hirschfield 2003). Understanding the factors that regulate CRP release at baseline 
and during infection or inflammation is therefore critically important in facilitating the 
correct interpretation of elevated CRP concentrations in the context of risk prediction. 
Although CRP might have an important role in the pathogenesis and prediction of 
coronary events, the factors, others than IL-6, influencing the basal and stimulated CRP 
concentrations achieved during acute inflammation in natural occurring human models 
are incompletely understood. Twin and family studies indicate that CRP concentrations 
might be influenced by specific genetics backgrounds (MacGregor et al. 2004; Pankow 
et al. 2001). A polymorphism (+1444C>T) in the 3’ untranslated region of the gene 
encoding CRP has been recently identified. In healthy subjects and CABG patients, 
homozygosity for the T allele of this polymorphism was associated with higher basal 
and stimulated CRP concentrations in male subjects (Brull et al. 2003). However, it is 
likely that other important genetic influences such as, the -174G>C polymorphism of 
the IL-6 gene (Fishman et al. 1998; Vickers et al. 2002) may also determine the basal
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and stimulated concentrations of CRP in natural occurring models of chronic 
inflammation.
In the previous pilot trial we demonstrated how intensive periodontal therapy causes a 
sharp rise in inflammatory markers (CRP, IL-6) sustained up to one week from the 
stimulus. Periodontitis is a natural occurring prototype of chronic low-grade infection 
and inflammation, which has been also associated in prospective studies with an 
increase risk of cardiovascular events (Scannapieco et al. 2003). We therefore evaluated 
the effect of+1444C>T polymorphism on CRP acute release after intensive periodontal 
therapy and its dependence from the IL-6/-174G>C polymorphism and standard CV 
risk factors.
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5.2.3 METHODS
5 .2 .3 .1  St u d y  S u b je c t s
The study was conducted on 55 consecutive healthy individuals referred to the 
Department of Periodontology of the EDI, UCL. Only subjects presenting with severe 
(probing pocket depths greater than 6 mm and marginal alveolar bone loss greater than 
30%), and generalized (at least 50% of teeth affected) periodontitis were invited to 
participate in the study. Exclusion criteria included known systemic diseases 
(hypertension, diabetes, dyslipidaemia and history of myocardial infarction or stroke), 
history and/or presence of other acute or chronic infections, systemic antibiotic 
treatment in the preceding three months, treatment with any medication known to affect 
the serum level of inflammatory markers (e.g. statins, steroids, hormone replacement 
therapy) and or pregnant or lactating females. All patients had given written informed 
consent; the study had been reviewed and approved by the Eastman/UCL Hospitals 
joint ethics committee.
5 .2 .3 .2  S t u d y  D e s ig n  
A baseline visit was 
conducted to collect a 
complete medical history and 
standard clinical periodontal 
parameters (PPD, REC,
CAL). Subjects thereafter, Figure 32 Study Experimental Design 
received an intensive session
of subgingival mechanical instrumentation (including extraction of compromised teeth)
under local anaesthesia (within 6 hrs) as described in section 5.1.3.1 (Figure 32). During
the study period (1 month follow up), patients remained stable and there were no
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changes in lifestyle issues and habits including exercise, diet, smoking or medications 
when patients were asked at following visit.
5 .2 .3 .3  I n f l a m m a t o r y  M a r k e r s  A s s a y s
Serial blood samples at baseline, one, seven and 30 days after periodontal therapy were 
obtained. Serum CRP concentrations were assessed by an automated 
immunoturbidimetric high-sensitivity assay (Cobas Integra, Roche AG Diagnostics, 
Mannheim, Germany) with a detection limit of 0.25 mg/L and inter, and intra-assay 
coefficient of variation of 4% and 5%, respectively. IL-6 was measured with high- 
sensitivity sandwich ELISA kits (Quantikine HS, R&D System, Minneapolis, detection 
limit 0.04 ng/L and inter, and intra-assay coefficient of variation less than 5%. 
Laboratory measurements were carried out in a blind fashion and in single batches to 
limit inter-assays variability.
5 .2 .3 .4  C r p  A n d  I l-6  G e n o t y p in g
DNA was extracted from patients’ leucocytes as mentioned earlier in section 4.2.6. The 
CRP/+1444C>T polymorphism was genotyped by PCR and RFLP analysis using primer 
pairs ( 5’-AGCTCGTTAACTATGCTGGGGCA- 375’-CTTCTCAGCTCTT- 
GCCTTATGAGT-3' ) and the restriction enzymes Sdul which cleaves the 18 lbp PCR 
product into 23bp and 158bp fragments only in the presence of the C allele [Step 1, 
95 °C 4 min., step 2 (95 °C 30 sec), 3 (55 °C 30 sec) and 4 (72°C 1.5 min), termination 
step 72 °C 3min]. The IL-6/174G>C polymorphism was genotyped by PCR and RFLP 
analysis using primer pairs described in general materials and methods section of 
chapter 4.
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5 .2 .3 .5  S t a t is t ic a l  M e t h o d s
Preliminary analysis of normality was performed using the Shapiro-Wilk test. For CRP 
and IL-6, because of the skewed distribution, logarithmic transformations were used and 
data are reported as geometric mean ± SD. Changes in serum concentrations of CRP 
following periodontal therapy were used as the outcome variable in a one-way 
ANCOVA analysis adusting for potential confounders: age, gender, ethnicity, body 
mass index (expressed in kg/m2), smoking, blood pressure, periodontal diagnosis, 
number of teeth extracted and IL- 6. Furthermore a repeated measures ANOVA analysis 
was performed to determine also the effect of the (CRP/+1444C>T and IL-6/-174G>C) 
polymorphisms on time course of inflammatory markers, after adjustment for potential 
confounders. For these analyses recessive (CRP/+1444C>T) and dominant (IL-6/- 
174G>C) genetic models were used as an a priori hypothesis (Brull et al. 2003). Post 
hoc analyses were performed by Bonferroni corrections. A % test was used to compare 
genotype frequencies according to the Hardy-Weinberg equilibrium. Linkage 
disequilibrium between CRP/+1444C>T and IL-6/-174G>C polymorphisms was 
estimated using the method of Chakravarti (Chakravarti et al. 1984). A P-value <0.05 
was considered significant. Data were analyzed with the statistical software package 
SPSS (SPSS version 11, Chicago, IL).
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5.2.4 RESULTS
5 .2 .4 .1  D e s c r ip t io n  o f  t h e  s t u d y  s u b je c t s
Demographic and clinical characteristics of the subjects included according to the 
CRP/+1444C>T polymorphism are reported in table 32. With the exception of the 
smoking status (p=0.02), no significant differences for any other traditional 
cardiovascular risk factors or dental parameters including severity and extent of 
periodontal infections were observed at baseline according the CRP 1444C>T 
polymorphism.
T able 32 Baseline characteristics of the subjects included according to the CRP/+1444C>T genotype.
Va r ia b l e O v er a ll  
(N=55) 
MEANiSD 
(95% Cl)
C-CARRIERS 
(N=45) 
MEANiSD 
(95% Cl)
TT (N=10) 
MEANiSD 
(95% Cl)
P-VALUE f
48±7 48±7 51i7 0.12
Age, years (46.4-50.1) (45.6-49.6) (46.5-56.1)
Gender, Males (%) 29(52.7) 24(53.3) 5(50.0) 0.85*
Ethnicity, Caucasians 40(72.7) 34(75.6) 6(60.0) 0.43*
(%)
BMI, Kg/m2 26±4 26±4 26 il 0.89
(24.7-26.8) (24.5-27.1) (24.6-26.1)
Systolic BP, mm Hg 136±16 134±17 142il4 0.20
(131.2-140.1) (129.2-139.3) (131.7-152.1)
Diastolic BP, mm Hg 87±10 87±11 87 il0 0.84
(79.1-93.9) (84.0-90.4) (79.1-93.9)
Smoking
Never (%) 24(43.6) 16(35.6) 8(80.0) 0.02*
Current & former (%) 31(56.4) 29(64.4) 2(20.0)
FMBS 67±14 65±14 72 il4 0.17
(62.7-70.4) (61.1-69.6) (62.0-82.2)
N° Periodontal lesions 76±26 74±28 83±15 0.30
(68.7-82.7) (65.7-82.3) (72.9-93.9)
IL-6 (ng/L) 1.51±1,88 1.52il.94 1.45il.65 0.83
(1.27-1.79) (1,25-1.86) (1.01-2.08)
Peak (Day 1) 5.44±1.69 5.27±1.70 6.24il.68 0.36
IL-6(ng/L) (4.71-6.27) (4.50-6.18) (4.30-9.06)
CRP (mg/L) 1.93±1.95 1.91il.89 2.00i2.34 0.84
(1.61-2.31) (1.58-2.31) (1.09-3.68)
f; Between C-carriers and TT subjects. For continuous variable, a t-test was performed, and for 
dichotomy variables Chi-Square Test (*) was used. BMI indicates body mass index, BP blood pressure, 
FMBS percentage of tooth sites with bleeding upon probing.
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5.2.4.2 A l l e l e s  a n d  G e n o t y p e  f r e q u e n c i e s
Of the 55 evaluated subjects, 23 were homozygous for the +1444C allele, 22 were 
heterozygous and 10 were homozygous for the +1444T allele. Thirty individuals were 
homozygous for the -174G allele, 10 were heterozygous and 6 were homozygous for the 
-174C allele. The genotype frequencies for the +1444C>T and for the -174G>C 
polymorphisms were as predicted by Hardy-Weinberg equilibrium (p=0.25 and 0.27; 
respectively). The pairwise linkage disequilibrium coefficients (A) revelaed a non­
significant allelic association between these two variants (A=0.04, p=0.76).
5.2.4.3 A c u t e  p h a s e  r e s p o n s e  a n d  e f f e c t  o f  t h e  +1444C>T p o ly m o r p h is m
The inflammatory stimulus (intensive periodontal therapy) resulted in a sharp 
significant increase of CRP at day one (13.64 ± 2.14 mg/L vs 1.93 ± 1.95 mg/L, 
PO.OOOl) and day seven (3.35 ± 1.77 mg/L, PO.OOOl) compared to baseline (Figure 
33). These results remained statistically significant in the multivariate analysis 
(PO.OOOl) after adjusting for age, gender, ethnicity, body mass index, smoking, blood 
pressure, Log[IL-6] and number of teeth extracted during treatment; (corrected model
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Figure 33 Box and whiskers plots showing changes in CRP before and after 
periodontal therapy.
The box refers to the 25th (bottom) and 75th (up) percentiles and the median is the 
horizontal line inside. Open circles represent outliers whereas asterisks stand for extreme 
observations
R2=0.68). The magnitude of the 
acute persistent release of CRP was 
dependent of the +1444C>T 
genotype (Figure 34-A).
Subjects homozygous for T allele 
had a significantly higher 
concentration of CRP at day one 
(21.10 ± 4.81 mg/L vs. 12.37 ± 
1.61 mg/L, P=0.02) and day seven 
(4.89 ± 0.74 mg/L vs. 3.08 ± 2.00 
mg/L, P<0.01) compared to 
carriers of the +1444C-allele. The 
effect persisted (P=0.004) in the 
multivariate repeated measure 
analysis after adding all CV risk 
factors and the baseline and peak 
IL-6 concentrations.
In addition to evaluate the 
likelihood of confounding of the 
CRP-genotype and CRP acute 
release association by the IL-6/- 
174G>C variant, a separate analysis 
was conducted showing no 
significant differences in CRP acute 
release among individuals
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Figure 34 Box and whiskers plots showing changes in CRP 
before and after periodontal therapy according to +1444C>T 
(A) and -174G>C (B) polymorphism’s genotypes.
The box refers to the 25 (bottom) and 75th (up) percentiles 
and the median is the horizontal line inside. Open circles 
represent outliers whereas asterisks stand for extreme 
observations.
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homozygous for the 174G-allele and carriers for the 174C-allele from the IL-6 
polymorphism. (Figure 34-B).
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5.2.5 D isc u ssio n
The main finding of this study is that, in subjects undergoing periodontal treatment 
homozygosis for the +1444T allele of the CRP gene was significantly associated with a 
greater acute CRP release after an inflammatory stimulus. This effect was independent 
of IL-6 concentrations, IL-6/-174G>C variant and also from conventional 
cardiovascular risk factors known to affect the CRP concentrations. In previous studies 
it has been shown that the +1444C>T polymorphism influences basal CRP, as well as 
the magnitude of the CRP response both to a low-grade inflammatory stimulus (48h 
intensive exercise; peak CRP ~ 3mg/L), as well as a more severe inflammatory stimulus 
(coronary artery by-pass surgery; peak CRP ~ 300mg/L)(Brull et al. 2003). Although 
the current study was too small to show the difference in CRP by genotype at baseline, 
it extends the observation that genotype modulates the response to an inflammatory 
stimulus. In the current study, CRP genotype was an independent predictor of the CRP 
response to intensive periodontal instrumentation that elevated CRP to an intermediate 
level (~30mg/L), confirming that over a wide range of concentrations seen in both 
health and disease, CRP is subject to genetic modulation. Much larger studies will now 
be necessary to define the precise magnitude of the genetic and environmental effects 
and the interaction, if any, between the two.
The observation that circulating CRP concentration is subject to genetic regulation has 
important implications for understanding the role of CRP in the pathogenesis of 
coronary artery disease and its potential role in coronary risk prediction. First, since 
CRP concentrations are strongly correlated with smoking status, blood pressure, 
obesity, diabetes, physical activity, social class, low birth weight and other products of 
the inflammatory response, and are also higher in individuals with clinical 
cardiovascular disease, the association of CRP with coronary events in observational
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studies could be subject to residual confounding or, in prevalent case-control studies, to 
reverse causality bias. If CRP actually increases the risk of coronary events, then 
carriage of an allele that exposes individuals to a long-term elevation in CRP should 
confer an increased risk of coronary events proportional to the difference in CRP 
attributable to the allele. Since the inheritance of such a variant should be subject to the 
random assortment of maternal and paternal alleles at the time of gamete formation, 
according to Mendel’s second law, this relationship should be largely unconfounded 
and free of reverse causality bias. If non-genetic observational studies of CRP are 
unbiased, the increase in risk estimated from these studies should be consistent with the 
increase in risk conferred by carriage of the allele. This approach, known as “Mendelian 
randomisation”, has been used recently to clarify the link between homocysteine and 
cardiovascular disease (Smith & Ebrahim 2004; Wald et al. 2002). The identification of 
a common polymorphism in the CRP gene reliably associated with differences in 
circulating CRP concentration will allow large-scale genetic association studies to test 
whether the risk of coronary events in individuals homozygous for this variant is close 
to that predicted from non-genetic studies.
Second, if CRP is a marker for, rather than a mediator of atherosclerosis, then the 
prognostic value of a particular CRP level may differ by genotype. A given level of 
CRP may have a different implication for future risk in individuals of differing CRP 
genotype because it reflects differing degrees of inflammatory disease in the two cases. 
If this is the case, there may eventually be a need to establish genotype-specific risk 
thresholds for coronary risk prediction. Nevertheless, in order to evaluate this negative 
interaction, subjects with high-CRP due to the genotype have a lower risk than those 
with high-CRP without the genotype, adequately powered genetic association studies or 
the pooling of smaller studies are required.
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C o n c l u sio n s
• Periodontal therapy represent a moderate inflammatory stimulus and it is 
accompanied by systemic sequelae resolving within one week from the 
treatment and showing similarities to those of a classical APR.
• CRP and IL-6 represent reliable inflammatory markers to study the individual 
basal and stimulated individual inflammatory burden.
• The acute inflammatory response associated with the delivery of periodontal 
therapy subsides between 1 week and 1 month after treatment. Assessment of 
changes in inflammatory parameters can be done at 1 month after therapy.
• Inter-individual variations exist after similar inflammatory stimuli.
• A novel polymorphism (+1444) was associated with a greater acute release of
CRP independent from traditional cardiovascular risk factors and IL-6 
concentrations and gene polymorphism (-174).
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6.1 Su m m a r y
Severe periodontitis has been associated with increased systemic inflammation in 
otherwise healthy subjects. This study investigated the impact of periodontal therapy on 
serum inflammatory markers and cholesterol levels. 65 healthy subjects with severe 
generalized periodontitis participated in a single-blind, 3 arms randomized controlled 
clinical trial. Medical and periodontal parameters, CRP (primary outcome variable), IL- 
6, total cholesterol and LDL-cholesterol were evaluated prior to and two months after 
treatment. The 3 treatment groups included an untreated control, standard periodontal 
therapy (SPT) and an intensive course of periodontal treatment (IPT). 2 months after 
treatment, both treatment groups resulted in a significant (SPT P=0.030, IPT P=0.001) 
reduction of 0.5±0.2 mg/L and 0.8±0.2 mg/L respectively in serum CRP compared to 
the untreated control. These reductions were independent of age, gender, body mass 
index, ethnicity, whereas a significant interaction effect of cigarette of smoking was 
found. Both reduction in CRP and IL-6 were significant only in non smoker individuals 
(P=0.028 and P=0.003 univariate tests respectively) while in current smokers only IPT 
group showed a significant effect on inflammatory markers. The IPT group further 
showed a decrease in total cholesterol and LDL-cholesterol concentrations after two 
months. These data indicated that periodontitis significantly contributed to the 
inflammatory burden of an otherwise healthy subject.
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6.2 In t r o d u c t io n
Despite the recent advances in the understanding of the atherosclerotic process, its 
primary cause remains unclear in the majority of cases. The presence of well defined 
risk factors (diabetes mellitus, hypertension, hyperlipedaemia, tobacco use and positive 
family history) accounts for only half of the atherosclerotic complications on the 
cardiovascular system (Stamler et al. 1986).
Inflammation plays a significant role in the development and progression of 
atherosclerosis (Libby et al. 2002). Chronic low-grade inflammation, measured as 
elevated CRP serum levels, has been directly associated with the onset and progression 
of CVD (Pearson et al. 2003). CRP hepatic production is usually elicited by an 
inflammatory stimulus and mediated through a complex network of cytokines (mainly 
IL-6); nonetheless several systemic co-factors can influence its concentration (Kluft & 
de Maat 2001). It is still unclear, however, whether its predictive role has etiologic 
implications or whether elevated CRP concentrations are only a marker of 
atherosclerosis and/or vascular damage. Epidemiological evidence that other 
inflammatory markers share the same predictive value of CRP gives strength to the 
significance of systemic inflammation, rather than one specific marker, on the 
atherosclerotic process (Pradhan et al. 2002).
A variety of sources for the atherosclerotic inflammatory process, including infectious 
agents, have been proposed (Danesh 1999; Lowe 2001). Periodontitis is a prototypic 
chronic low-grade infection. It is caused primarily by anaerobic gram negative bacteria 
organized in a protected biofilm in the subgingival portion of the tooth surface. It leads 
to inflammatory destruction of the periodontal tissues and eventually to tooth 
exfoliation (Williams 1990). 10-15% of adults suffer from severe forms of this disease 
(Albandar & Rams 2002).
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Over the last 50 years, the prevailing view among dentists and physicians was that 
periodontal infections were localized only to the marginal periodontium and that, as 
such, they rarely had systemic implications in healthy individuals. More recent 
evidence, however, has indicated that patients with severe generalized periodontitis 
present with increased systemic inflammation as indicated by increased serum levels of 
CRP, fibrinogen, IL-6, moderate leukocytosis function when compared with unaffected 
control populations (Ebersole et al. 1997; Kweider et al. 1993; Loos et al. 2000; Noack 
et al. 2001). Further these individuals have a perturbed metabolic profile (serum 
cholesterol) (Katz et al. 2002) not explained just by their lifestyle but perhaps causally 
related to the chronic episodes of bacteraemia and endotoxin dissemination (Iacopino & 
Cutler 2000).
Our preliminary pilot intervention study (Chapter 4) showed how standard periodontal 
therapy led to a reduction in serum CRP and IL-6. The degree of observed reduction in 
systemic inflammation was associated with the level of dental clinical response as 
determined by periodontal parameters. This suggested a potential dose response 
between the extent of resolution of the local periodontal infection and the level of 
reduction in systemic inflammation. However, the limitations of the design 
(uncontrolled) adopted did not facilitate a proper interpretation of the results which 
might had been confounded by changes in other factors (body weight, smoking, 
medications). Standard periodontal therapy exhibited a delayed systemic anti­
inflammatory effect after six months of its completion. Recent preliminary reports 
suggest that different treatment approaches might exert significant systemic effects 
(Iwamoto et al. 2003).
The specific aim of this 3-arm, single-blind, randomized, controlled intervention trial 
was to test the short term effects of two regimens of periodontal therapy on the 
systemic inflammatory status of medically healthy individuals suffering from severe,
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generalized periodontitis. Changes in serum CRP levels were selected as the primary 
outcome variable, whereas changes in serum IL-6 and cholesterol levels were chosen as 
secondary outcomes.
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6.3 M e t h o d s
6.3 .1  S t u d y  P o p u l a t io n  a n d  D e s ig n
Participants were recruited from subjects referred to the Department of Periodontology 
of the EDI, UCL. Only subjects presenting with severe (probing pocket depths greater 
than 6 mm and marginal alveolar bone loss greater than 30%), generalized (at least 50% 
of teeth affected) periodontitis were invited to participate in the study to increase 
probability of detection of a systemic burden from the local periodontal infection (Slade 
et al. 2000; Slade et al. 2003). Exclusion criteria included: i) known systemic diseases, 
ii) history and/or presence of other infections, iii) systemic antibiotic treatment in the 
preceding three months, iv) treatment with any medication known to affect the serum 
level of inflammatory markers or lipids, v) pregnant or lactating females, vi) allergy to 
tetracyclines. All patients gave written informed consent; the study had been reviewed 
and approved by the Eastman/UCL Hospitals joint ethics committee.
A baseline visit was conducted by a blind calibrated examiner who collected a complete 
medical history, standard clinical periodontal parameters and blood samples. Subjects 
were randomized by the trial coordinator, to one of the three treatments groups using a 
random permuted block approach and stratified based on smoking status (current vs 
non smoker) (Pocock 1977; Pocock 1979). Allocation was concealed using opaque 
envelopes which were opened by the therapist at the treatment visit. All clinical and 
laboratory assessments were performed blind by the investigators. A total of 70 
individuals met the inclusion criteria. 65 subjects were enrolled and randomized to 
treatment, the remaining five subjects did not consent to the proposed plan of therapy 
(which included extraction of compromised teeth)(Figure 35).
187
The 3 groups consisted of 
an untreated control (which 
received the necessary care 
a the end of the trial); a 
community based standard
regimen of periodontal 
therapy (SPT) consisting of 
subgingival mechanical instrumentation; and an intensive course of periodontal 
treatment (IPT) consisting of subgingival mechanical instrumentation with adjunctive 
local delivery of minocycline-HCl (encapsulated in PLGA microspheres for controlled 
delivery, Arestin®, Orapharma, Warminster, Pennsylvania, U.S.A.) into the periodontal 
pockets. Periodontal and inflammatory outcomes were assessed at baseline and at 2 
months following completion of periodontal therapy.
All 65 individuals reached this follow-up visit.
6.3.2 Inflammatory Mark ers  and Blood L ipids M easurements 
Serum samples, collected at baseline and 2 months, were processed and stored at -70°C 
until analysis in a standardized blind fashion. CRP levels were assessed by an 
automated immunoturbidimetric high-sensitivity assay (Cobas Integra, Roche AG 
Diagnostics, Mannheim, Germany detection limit of 0.25 mg/L); IL-6 was measured 
with a high-sensitivity sandwich ELISA (Quantikine HS, R&D System, Minneapolis, 
U.S.A., detection limit 0.04 ng/L). Total and LDL-cholesterol levels were determined 
using standard clinical chemistry procedures on an automated analyzer (Hitachi 917, 
Roche AG Diagnostics, Mannheim, Germany).
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Figure 35 Study Experimental Design
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6 .3 .3  S t a t is t ic a l  M e t h o d s
Based on the variance of CRP differences detected in our previous pilot study, 20 
patients per treatment arm provided 80% power to detect a difference of 0.4 mg/L in 
CRP concentrations, with alpha set at 0.05. The study was not sized to detect changes in 
IL-6 and cholesterol levels. Analysis of normality was performed using the Shapiro- 
Wilk test. Continuous normally distributed variables were reported as mean ± SD and 
95%CI, whereas median and IQR were used to describe not normally distributed data 
(IL-6 only). Significant changes in serum concentrations between baseline and 2 months 
of CRP were used as primary outcomes. One-way analysis of covariance was used to 
compare changes between 0 and 2 months in CRP serum concentrations between the 
three groups. Baseline levels were used as covariate. If the F statistics for the treatment 
effect was significant at the univariate level, multiple comparisons were performed with 
Bonferroni adjustment. A second model was then created including as covariates age, 
gender, ethnicity, body mass index and cigarette smoking.
We also examined whether IL-6, main inducer of CRP hepatic production, was affected 
by periodontal therapy with the same analytical approach. Changes in Total, LDL and 
HDL Cholesterol and Triglycerides were examined as secondary outcomes. Analysis of 
residuals was performed to confirm normality assumptions and validity of each model 
created.
Comparisons of categorical data and proportions were analyzed with the Chi-Square 
test. The alpha value was set at 0.05. SPSS version 11 was used (Chicago, IL, USA).
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6.4 R e su l t s
With the exception of the presence of severe, generalized periodontitis, all subjects 
presented with no reported medical conditions. The baseline demographic and clinical 
characteristics are reported in table 33. There were no significant differences between 
groups for any of the parameters.
Table 33 Clinical and Periodontal Data in the 3 Groups of Patients
V a ria b le  = mean±SD 
(95% Cl)
Control
(N=24)
S ta n d a rd  
Tx 
(N=21) _
Intensive
Tx
(N=20)
Significance
(Anova)
Age, y 48±6(46-51)
48±7
(44-51)
49±7
(45-52) P=0.93
Females, % 37.5 47.6 40 P=0.78a
Caucasians, % 66.7 66.7 85.0 P=0.31a
BMI, Kg/m2b 25.3±3.4(23.8-26.7)
25.7±3.5
(24.1-27.3)
25.6±4.1
(23.7-27.5) P=0.91
Current smokers,% 29.2 28.6 25.0 P=0.95a
Former smokers, % 41.7 52.4 45.0 P=0.77a
CRP, mgL 2.4±1.6 (1.8-3.1)
2.9±2.2 
(2.0-3.9)
2.0±1.1 
(1.6-2.6) P=0.30
Total cholesterol, mmol/L 5.3±0.7 (5.1-5.7)
5.3±0.7
(5.0-5.6)
cri
OO P=0.80
LDL cholesterol, mmol/L 3.2±0.6(3.0-3.5)
3.2±0.6 
(3.1-3.8)
3.4±0.6 
(2.9-3.6) P=0.64
HDL cholesterol, mmol/L 1.3±0.5 (1.1-1.5)
1.3±0.5 
(1.1-1.5)
1.5±0.5 
(1.2-1.7) P=0.59
Triglycerides, mmol/L 1.7±1.2 (1.1-2.2)
1.7±1.1 
(1.2-2.2)
1.4±1.1 
(0.9-1.9) P=0.67
a Chi-Square Test. BMI indicates body mass index. c FMPS is the percentage of tooth sites with dental 
plaque. d FMBS is the percentage of tooth sites with bleeding upon probing. e PPD is the full mouth 
average periodontal pocket depth per patient expressed in mm. f CAL is the full mouth average clinical 
attachment loss per patient expressed in mm.
Subjects were not taking any anti-inflammatory, vasoactive, lipid lowering agents or 
systemic antibiotics. During the study period, patients remained stable and there were 
no changes in lifestyle issues and habits including exercise, diet, smoking and 
medications. Furthermore, no significant changes in body-mass index were observed for 
any group [mean differences ± SD of BMI of 0.1±0.7 (95% Cl -0.1 to 0.4), 0.0±0.8 
(95% Cl -0.4 to 0.4), and 0.3±0.7 kg/m2 (95% Cl 0.0 to 0.6) for control (N=24), SPT
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(N=21) and IPT (N=20), respectively, P>0.56]. In terms of periodontal parameters, 
patients had an average full mouth plaque score of 58 ± 22 % (N=65). They presented 
with high levels of gingival inflammation (full mouth bleeding scores of 68% ± 14%, 
N=65) and severe widespread periodontitis (average o f 81 ± 2 6  periodontal lesions per 
subject with an average clinical attachment level loss of 5.4 ± 1.4 mm, N=65). Both 
SPT and IPT resulted in significant improvements of clinical periodontal parameters 
after two months. A mean reduction of 60±27 (PO.OOOl t-test, N=21) and 60±23 
(PO.OOOl t-test, N=20) periodontal lesions were observed in the SPT and EPT groups 
respectively. No significant changes were observed in the untreated controls (Table 34). 
Table 34 Clinical Periodontal Parameters
V a r ia b l e= B a se lin e  2 M o n th s
MEAN±SD, CTRL SPT IPT CTRL SPT IPT
PPD 4,5±0,8 4,3±0,8 4,5±0,8 4,4±0,7 2,7±0,3 3,0±0,3
REC U ± U 0,8±0,6 0,9±0,9 0,9±1,0 1,4±0,9 1,6±1,1
CAL 5,6±1,5 5,2±1,4 5,4±1,5 5,3±0,8 4,1±1,1 4,6±1,2
FMPS 58,4±19,2 59,7±20,0 52,1±23,2 56±18,3 11,8±7,0 8,2±4,6
FMBS 68,2±15,3 68,2±15,6 66,5±13,1 67,4±16,2 24,2±10,2 22,4±6,1
NPPK 80±26 79±28 80±25 79 27 19±4 20±13
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Table 35 displays the concentrations of primary (CRP), secondary (IL-6) outcomes and 
lipid markers at baseline and at 2 months.
Table 35 Concentrations of serum inflammatory parameters and lipids before and after periodontal 
therapy______________________________________________________________________________
V a r ia b l e ^  C o n t r o l  (N=24) St a n d a r d  Tx(N=21) I n t e n s iv e  Tx (N=20)
M e a n ±SD , -----------------------------------------------------------------------------------------------------------------------
(9 5 % C I) B a s e l in e  2 M o n t h s  B a s e l in e  2 M o n t h s  B a s e l in e  2 M o n t h s
CRP mg/L 2.4±1.6 (1.8-3.1)
2.5±1.7 
(1.8-3.2)
2.9±2.2 
(2.0-4.0)
2.9±2.3 
(1.8-4.0)
2.0±1.1 
(1.5-2.5)
1.6±0.9 
(1.2-2.0)
IL-6 ng/La 1.7 (1.4) (1.5-2.3)
1.7 (0.6) 
(1.5-1.8)
1.7 (1.8) 
(1.5-2.6)
1.8 (1.4) 
(1.5-2.4)
1.3 (0.7) 
(1.0-1.9)
0.9 (0.6) 
(0.8-1.3)
Total
cholesterol
mmol/L
5.4±0.7 
(5.1-5.7)
5.3±0.8 
(4.9-5.7)
5.3±0.7
(5.0-5.6)
5.4±0.9 
(4.9-5.7)
5.5±0.7 
(5.2-5.9)
5.2±0.7
(5.0-5.5)
LDL
cholesterol
mmol/L
3.2±0.6
(3.0-3.5)
3.2±0.7 
(2.9-3.7)
3.2±0.6
(3.0-3.8)
3.4±0.9 
(2.9-3.7)
3.4±0.6 
(2.9-3.6)
3.2±0.6
(3.0-3.5)
HDL
cholesterol
mmol/L
1.3±0.5 
(1.1-1.5)
1.3±0.4 
(1.1-1.5)
1.3±0.5 
(1.1-1.5)
1.4±0.5 
(1.1-1.6)
1.5±0.5 
(1.2-1.7)
1.4±0.4 
(1.2-2.6)
Triglycerides
mmol/L
1.7±1.2 
(1.1-2.2)
1.4±0.9 
(1.0-1.8)
1.7±1.1 
(1.2-2.2)
1.6±1.0 
(1.1-2.0)
1.4±1.1 
(0.9-2.0)
1.3±0.8 
(0.9-1.7)
a Median (IQR).
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The covariance analysis showed a significant univariate effect of the treatment 
(P=0.003, Model R2=0.86). A significant reduction of CRP concentrations was observed 
in both treatment groups when compared to the untreated control. SPT group showed a 
difference in CRP at 2 months of 0.5±0.2 mg/L (95% Cl 0-0.9, P=0.030 Bonferroni 
corrections)(Figure 36) compared to the untreated control group. The respective value 
for EPT group patients was 0.8±0.2 mg/L (95% Cl 0.3-1.2, P=0.001 Bonferroni 
correction). (Figure 36)
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Figure 36 Box and whiskers plots showing differences in CRP, IL-6, total cholesterol and LDL-cholesterol 
between baseline and 2 months post-treatment in the 3 experimental groups.
Boxes refer to the 25th (bottom) and 75th (up) percentiles and the median is the horizontal line inside. Open 
circles represent outliers whereas asterisks stand for extreme observations with the subject number. Positive 
differences indicate a decrease in concentrations at 2 months compared to the pre-treatment baseline. The 
horizontal dashed line indicates the line of no difference between baseline and 2 months.
The analysis was repeated including as covariates in the model age, gender, body mass 
index, ethnicity and cigarette smoking. The results remained unchanged with SPT
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(P=0.048) and IPT (P=0.002) groups clearly showing a significantly reduced CRP 
concentration compared to the untreated control at 2 months (Model R = 0.89). 
Smoking however approached a significant univariate effect (P=0.057) and therefore we 
examined whether there was an interaction between treatment category and smoking 
status. The analysis indicated a significant interaction between the two variables 
(P=0.019) whereby by post-hoc tests, CRP reductions were statistically significant for 
both treatment (SPT and IPT) only in the non smoker group (P=0.048 SPT, P=0.011 
IPT respectively) (Figure 37) compared to the untreated control, whereas in the smoker 
subgroup only IPT patients showed a further decrease (P=0.030) compared to the 
control.
When we examined the differences in IL-6 serum concentrations we found that only the 
IPT group showed a significant decrease in this marker when compared to the untreated 
controls (mean decrease 0.5±0.2 ng/L, 95% Cl 0.2-0.9, P=0.006) and to the SPT group 
(mean decrease 0.6±0.2 ng/L, 95% Cl 0.2-1.0, P=0.002). These finding were confirmed 
after inclusion in the analysis of age, gender, ethnicity, body mass index and cigarette 
smoking which also had a positive interaction with the treatment (P=0.021). Non 
smokers individuals of the IPT group were those showing significant differences in IL-6 
concentrations when compared to the untreated control (P=0.005) and to the SPT group 
(P=0.002). Box and whiskers plots of the differences in CRP, IL-6, total and LDL- 
cholesterol between baseline and 2 months for each treatment group are displayed in 
Figure 36.
Lipid levels did not change significantly among different groups except for total 
cholesterol. We observed a 0.3±0.1 mmol/L (95% Cl 0.01 to 0.6, P=0.05) decrease of 
total cholesterol in the IPT group when compared to the SPT group (Figure 36). A 
within group descriptive analysis showed a reduction in total cholesterol of 0.3 mmol/L
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F ig u re  37 Box and whiskers plots showing differences in CRP according 
to smoking status in the 3 experimental groups.
Boxes refer to the 25th (bottom) and 75th (up) percentiles and the median 
is the horizontal line inside. Open circles represent outliers whereas 
asterisks stand for extreme observations with the subject number. Positive 
differences indicate a decrease in concentrations at 2 months compared to 
the pre-treatment baseline. The horizontal dashed line indicates the line 
of no difference between baseline and 2 months.
(95% Cl 0.1 to 0.5, P=0.004) in the IPT group only and this was accompanied by a
decrease in LDL of the same magnitude (0.3 mmol/L, 95% Cl 0.05 to 0.5, P=0.019).
6.5 D i s c u s s i o n
Periodontal therapy (either standard or intensive) resulted in a significant additional 
reduction in serum CRP of at least 0.5 mg/L compared to the untreated control. The 
magnitude of the observed effect is comparable to that detected in a variety of 
cardiovascular antibiotic intervention trials and prospective statins trials where drug- 
induced reduction of inflammatory parameters was associated also with a reduced 
frequency of primary and secondary cardiovascular events (Anderson et al. 1999; Stone 
et al. 2002). The subjects included in this study had baseline CRP concentrations in the 
upper quartiles of normality (mean of 2.5 ±1 . 7  mg/L) and no differences in possible 
confounders were observed comparing the 3 experimental groups (Table 33). 
Importantly during the study no significant changes in lifestyle, habits, medical health 
or medications were detected. This indicates that severe, generalized periodontitis in 
otherwise healthy individuals contributed to the systemic inflammatory burden in this 
population. Proposed mechanistic explanations include: i) the local, infection-driven 
production of inflammatory mediators, primarily interleukin-1 and 6, in the diseased 
periodontium may be dumped into the systemic circulation (Graves 1999; Offenbacher 
et al. 1981); ii) the ability of periodontal pathogens and/or their toxins to gain access to 
the systemic circulation and thus induce an inflammatory response (Haraszthy et al. 
2000; Herzberg & Weyer 1998); and iii} a combination of the above.
The present results were obtained in a proof of principle randomized controlled clinical 
trial in a population with advanced, widespread periodontitis representing the more 
severely affected, but otherwise systemically healthy, periodontal patients. The interest 
in this group comes from our previous observation (Chapter 4) that these may be the 
subjects presenting with the most significant periodontitis-associated systemic 
inflammatory burden. These results, however, do not allow generalization of the results
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to periodontal patients suffering from less severe and/or more localized forms of 
disease. Data will have to be confirmed and expanded in larger trials to better 
understand what proportion of the 10-15% of subjects suffering from severe 
periodontitis have increased systemic inflammation as a result of this chronic infection. 
Periodontitis is an infection caused by gram negative bacteria that are organized in a 
biofilm in a sub-gingival location between the diseased root surface of the tooth and the 
junctional epithelium of the gingiva. As a chronic biofilm-centred infection, it is 
relatively insensitive to the effect of systemic antibiotics and its treatment requires, in 
the first instance, the removal of the biofilm on the root surface by mechanical 
professional instrumentation. Comparing the results of our pilot intervention cohort 
where we found a dose dependent effect in terms of reduction of systemic inflammation 
based on the degree of local response of periodontal therapy (Chapter 4), the standard 
treatment group in this trial showed a better response after two months of therapy. This 
observation could be explained because in this study we compared CRP changes 
between the standard and the untreated control group whose subjects showed an 
increased concentration of CRP after two months. We observed, therefore a significant 
difference in serum CRP concentrations that would have not been detected within the 
SPT group if we had not enrolled a control population.
In the IPT group, local application in the periodontal pockets of a controlled release 
formulation of minocycline was utilized to supplement the mechanical action of scaling 
and root planing. Such application allowed the achievement and maintenance of high 
local concentrations of antibiotic at the site of infection (the periodontal pockets) 
without reaching detectable levels of minocycline in the serum (Paquette & Santucci 
2000). Previous investigations have indicated that the adjunctive use of controlled 
delivery antibiotic formulations in the periodontal pockets lead to better control of 
periodontal infections and reduction in gingival inflammation (Pavia et al. 2003).
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Interestingly, the adjunctive periodontal effect of the application of minocycline 
microspheres was particularly evident in smokers (Paquette et al. 2004; Paquette et al. 
2003), an observation that agrees well with the current one that IPT but not SPT was 
effective in decreasing systemic inflammation in smokers. Although a possible systemic 
effect of the antibiotic cannot be completely ruled out, the facts that i) the total applied 
dose was 80±25 mg per patient; ii) the antibiotic was delivered from the controlled 
delivery platform over a 21-day period; and iii) minocycline concentrations in serum 
have been shown to remain below detection level (Paquette et al. 2004) after standard 
periodontal treatment, make it unlikely that the observed effect may have been due to a 
systemic effect of minocycline. Within the limitation of this analysis it appears that the 
intensive treatment approach enabled the host to re-establish a better homeostatic status 
compared to the standard therapy. A significant reduction in systemic IL-6 
concentration, which is known to be produced locally in the diseased periodontium and 
is the main inducer of the acute phase response (See Section 1.1.3), was detected only in 
the LPT group.
As indicated, this study was designed to detect changes in CRP concentrations only. A 
serious limitation of theses preliminary results lies in the small number of subjects 
included.
The baseline CRP and IL-6 concentrations although not statistically significantly 
different appeared somehow unbalanced between the three study groups. We cannot 
exclude that such imbalance, other confounding factors and the limited number of 
individuals affected the final outcome of the trial itself. We are confident however of 
the validity of our results since the outcome of a multivariate analysis including the 
main determinants of CRP serum concentrations (age, gender, body mass index) did not 
undermine our conclusions. Further strengths come from the observation that cigarette 
smoking appeared to be the only negative influential factor. There has been a lot of
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debate on the role of smoking as the major confounder in the association between 
periodontitis and systemic health. Our data clearly indicate that smoking affects 
individual responses to periodontal therapy not only resulting in a less good clinical 
outcome as several reports have shown (Tonetti 1998), but also producing a less good 
systemic host response (Fredriksson et al. 2002; Hyman et al. 2002). The fact that 
smokers’ CRP concentrations responded to IPT and not SPT treatment supports the 
notion that periodontitis contributed to the increased inflammatory burden of the 
smokers as well. Further research in this matter is however needed.
Furthermore the exploratory analyses of the effects of periodontal therapy on 
cholesterol levels deserve some discussion. No changes were observed comparing 
baseline and 2 months levels of these parameters in the control and the standard 
treatment groups. The intensive periodontal therapy group, on the other hand, showed a 
significant reduction in total cholesterol compared to the standard therapy group but not 
the untreated control. Descriptive analysis showed that some reductions of total and 
LDL cholesterol were present within the IPT group.(Figure 36).
We cannot exclude that pure chance might stand behind these findings even though a 
biological plausible effect of periodontal infections on the metabolic state of an 
individual has been validated through a series of investigations. A significant 
association between periodontitis and cholesterol has been already reported (Katz et al. 
2002; Wu et al. 2000b). Other chronic infections (C. pneumoniae, H. piilory) have been 
associated with increased concentrations of plasma cholesterol and triglycerides 
(Laurila et al. 1997). Several reports have also indicated that the acute phase response 
induces lipaemia (Khovidhunkit et al. 2000). LDL and total cholesterol are thought to 
be increased in chronic inflammatory conditions due to the recognized scavenging 
effect of lipoproteins on bacterial components (primarily endotoxin) (Harris & Kasravi 
2003). These data support the hypothesis that patients suffering from severe
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periodontitis, subsequent to recurrent phenomena of endotoxaemia and/or bacteraemia, 
experience a similar metabolic change (lipemia). The inflammatory local production of 
cytokines (IL-l,TNF-a) and its effect on other systemic mediators (IL-6) might induce 
alterations of lipid metabolism such as increased LDL and triglycerides due to increased 
hepatic lipogenesis, lipolysis from adipose tissue or reduced blood clearance. (Iacopino 
& Cutler 2000). Bacterial toxins (LPS) can also induce changes in cholesterol 
concentrations (reduced HDL and increased LDL) or target glucose metabolism and 
produce a state of insulin resistance (See section 1.2.1 and 1.2.4). A low-grade state of 
systemic inflammation can also affect directly insulin production and sensitivity. Recent 
experimental evidence support this hypothesis indicating that periodontal infection 
might cause hyper-triglyceridaemia (Uchiumi et al. 2004) and changes in HDL similar 
to that of an acute phase response (Pussinen et al. 2004). Further investigations are 
needed to better explore the relationship between periodontitis, periodontal therapy and 
lipid metabolism.
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C o n c l u sio n s
• Chronic severe periodontitis causes a moderate systemic inflammatory state.
• Standard periodontal therapy contain the systemic host response over a two 
months period whereas an intensive therapy approach, including the use of a 
locally delivered antibiotic, produces a significant reduction in inflammatory 
markers compared to an untreated control.
• Age, obesity and smoking act as confounder in the association between 
periodontal infection and systemic response.
• Intensive periodontal therapy seems to influence lipid profile of an otherwise 
healthy individual.
• This trial reported short term changes in inflammatory markers. Extension of the 
observation period is necessary to assess the persistence of the positive treatment 
effect.
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7.1 S u m m a r y
Infectious diseases such as periodontitis might be linked with increased risk of systemic 
diseases. We investigated whether different periodontal treatment regimens influenced 
overtime inflammatory and lipid markers. Patients with severe chronic generalized 
periodontitis were enrolled into a pilot intervention 6 months trial. They were evaluated 
at baseline, one, two and six months after being randomized to a standard or intensive 
(including local delivery of an antimicrobial) course of periodontal treatment. Individual 
who received the intensive regimen showed significant reductions in inflammatory 
markers at one (p=0.0406) and two (p=0.0060) months together with an improved 
metabolic state (2-6 months reduction in lipid markers p=0.0320 and p=0.0432 
respectively). Our findings indicate that periodontitis causes an increased systemic 
inflammatory burden and an intensive therapy regimen is more effective in re­
establishing a more favourable systemic response.
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7.2 In t r o d u c t io n
Periodontal infections are commonly thought to have limited influence on general 
health and wellbeing. In the beginning of last century however physicians hypothesized 
a possible pathological effect of distant tissue infections (“foci”) on the onset and 
progression of serious systemic diseases (rheumatism, eye problems) (O’Reilly & 
Claffey 2000). An increasing number of new experimental investigations suggests that 
periodontal infections may have systemic implications in otherwise healthy individuals 
(see section 1.3). A plausible biological association between periodontal infections and 
a series of systemic illnesses (pre-eclampsia, coronary atherosclerotic events, 
cerebrovascular ischemia, respiratory infections and metabolic syndrome) has been 
proposed (section 1.3). The chronic infectious-inflammatory burden of periodontitis 
may represent for the individual a possible threat on other systemic inflammatory 
diseases (e.g. metabolic syndrome and atherosclerosis). The issue however remains 
poorly investigated. Oral infections as triggers of a state of chronic systemic 
inflammation represent one mechanistic explanation. However, it is likely that other 
important factors (smoking, gender, body mass index, age, socio-economic status) act as 
confounders on this association. Our previous intervention studies (Chapter 4 and 6) 
resulted in a positive association between periodontal infections and systemic markers 
of low-grade inflammation. Standard periodontal therapy showed a positive effect in 
removing such inflammatory insult only after six months of therapy in a cohort of 94 
individuals (Chapter 4). When we evaluated the short term effects of different 
periodontal therapy regimens comparing the results with an untreated control, data 
showed that an intensive periodontal therapy regimen was in the short term more 
effective in controlling the systemic inflammatory burden compared to the standard 
approach. A secondary analysis of these data indicated a possible effect of the intensive
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therapy on other systemic markers (cholesterol). In this investigation we therefore 
intended to further explore the association between severe periodontal infections and 
systemic health by performing a pilot intervention trial comparing the standard and 
intensive periodontal therapy approach with a longer follow-up (6 months).
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7.3 M e t h o d s  
7.3.1 S t u d y  d e s ig n
40 out of 47 consecutive, eligible otherwise healthy individuals, free from any medical 
treatment, referred to the EDI and in need of treatment for severe generalized 
periodontitis gave written informed consent to participate in this investigation. Possible 
candidates for the investigation were selected and enrolled into the trial according to the 
inclusion and exclusion criteria described in section 3.1.2 with the additional exclusion 
criteria for individuals with allergy to tetracyclines. The study protocol had been 
reviewed and approved by the UCL Hospitals ethics committee.
It was a randomized, single 
blind, controlled clinical 
trial of 6 months duration 
comparing the effects of a 
standard periodontal
treatment regimen
(SPT=mechanical removal 
of subgingival plaque and 
calculus deposits) with an intensive one (IPT= consisting of SPT and adjunctive local 
periodontal delivery of minocycline encapsulated in resorbable microspheres -  Arestin, 
Orapharma, PA, USA) (Figure 38). Primary outcome variables were the differences in 
changes in serum inflammatory and lipid markers between SPT and IPT patients at 1, 2 
and 6 months. We randomized subjects using a permuted block approach, stratifying by 
smoking status. Allocation was concealed to the therapist until completion of the 
common part of therapy for both the test and control groups with opaque envelopes. All 
clinical and laboratory measurements were performed in a blind fashion.
Periodontal
Parameters
Randomization
S c reen in g B ase lin e
STANDARD
Periodontal
Parameters
I  I
INTENSIVE
1 2 6
months
t t I
Biological
Samples
Biological
Samples
Figure 38 Study Experimental Design
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7.3.2 B i o c h e m i c a l  m a r k e r s
We collected serial blood samples (see section 3.4 for detailed procedure) before and 1, 
2 and 6 months after completion of periodontal therapy and processed them in a blind 
fashion for CRP (Immunoturbidimetric assay, Cobas Integra, Roche AG Diagnostics, 
Mannheim, Germany, detection limit 0-25 mg/L, inter- and intra-assay coefficient of 
variation, CV, of 4% and 5%) and IL-6 serum concentrations (ELISA Quantikine HS, 
R&D System, Minneapolis, detection limit 0-04 ng/L and inter- intra- assay CV less 
than 5%). WBC and lipid markers, total (TC) and HDL (HDL-C) cholesterol were also 
quantified using standard clinical chemistry procedures on an automated analyzer.
7.3.3 S t a t i s t i c a l  a n a l y s i s
Data are reported as geometric mean± standard deviation and 95%CI intervals unless 
otherwise specified. Differences between the two treatment groups at baseline were 
assessed by t-test for continuous and Chi-square test among categorical variables. We 
chose a multiple end-point intention to treat statistical approach (O’Brien non 
parametric rank-sum test) anticipating the non normal distribution of most of the data. 
This choice was based upon the study design that assessed multiple parameters for each 
group of factors, e.g. leukocytes, CRP and IL-6 for systemic inflammation. With such 
design, outcomes are examined within the same patient and therefore are correlated. 
This global statistical approach uses the within-patient correlation among different 
outcomes in computing the estimate of the treatment effect and the test statistic (Tilley 
et al. 1999; Tilley et al. 1996).
In the past multiple outcomes have often been assessed by T2 Hotelling test which 
evidenced differences in any direction between treatment groups with respect to 
multiple outcomes (Pocock et al. 1987). Its non specific nature however does not allow 
discriminating between a favourable or an unfavourable effect of the treatments 
compared. Bonferroni multiple comparison is probably the most widely used correction
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for multiple comparisons (O'Brien & Fleming 1979). O’Brien did report that such 
analytical approach for multiple endpoints would produce statistical significance just if 
only one of the endpoints had a significant P statistic (P<0.01) but in the end the 
treatment effect would not be considered significant. Similarly this approach would not 
result in a significant effect if all analysed endpoints improved equally but no single 
outcome was highly significant, we would then speculate that the treatment was not 
effective although each endpoint was positively affected by the treatment. Using a 
global statistical approach there is no need for investigators to indicate primary or 
secondary outcomes and it perhaps may represent a research strategy for summarizing 
and interpreting multiple relevant endpoints in intervention trials. Indeed some 
antibiotic interventional trials have successfully adopted such a strategy (Anderson et al. 
1999; Stone et al. 2002; Wiesli et al. 2002).
In particular we investigated the treatment effect across a global score for inflammatory 
and lipid outcomes (CRP, IL-6, WBC, T-C and HDL-C), an inflammatory score (CRP, 
IL-6, WBC) and a lipid score (T-C and HDL-C). P values less than 0*05 were deemed 
significant. We also conducted a secondary analysis (Mann-Whitney test) to understand 
the relative contribution of each individual variable to the global scores (SAS, version 
8.2, Chicago, USA, statistical software package).
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7.4 R e su l t s
The baseline characteristics of the experimental population are reported in Table 36. At 
baseline, we did not observe significant differences in any characteristics of the subjects 
by treatment group. All subjects had severe generalized periodontitis as indicated by the 
presence of an average of 79±26 periodontal pockets and 67±14% of sites with bleeding 
on probing. Peridontal therapy produced significant improvements in both groups 
(Table 37). No statistically significant differences were found between the two 
treatment regimens.
Table 36 Baseline Patient Characteristics.
V a r ia b l e
O v e r a l l (N = 4 0 )  
M e a n ± S D  
( 9 5 %  C l)
D i f f e r e n c e
BETWEEN TEST 
AND CONTROL 
GROUPS 
P-VALUE f
Age, years
48±7
(460-50-6) 0-8281
Gender, Males (%)
22(55) 0-7512*
Ethnicity, Caucasians (%)
30(75) 0-1981*
BMI, Kg/m2 26±4(24-4-26-8) 0-9675
Systolic BP, mm Hg 134±15(129-1-138-8) 0-4329
Diastolic BP, mm Hg 86±10(82-9-89-4) 0-8533
Never Smokers (%) 
Current & former (%)
30(25)
10(75) 1-0000*
Family history o f  CVD, (%) 26(65) 0-3202*
IL-6, ng/LJ
l-4±0-9 
(1-4-1-9) 0-2333
CRP, mg/LJ 2-0±l-8
(1-9-30) 0-2074
WBC, \0 9t 6-9±l-9(6-6-7-8) 0-2065
Cholesterol, mmol/LJ 5-4±0-7 
(5-2-5-7) 0-7252
HDL-C, mmol/LJ l-3±0-4 (1-3-1-5) 0-6108
t  Independent t-test (or Chi-Square Test for dichotomous- 
variables *) comparing SPT(standard periodontal treatment) with 
IPT(intensive periodontal treatment) subjects J Geometric mean 
values are reported
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Table 37 Clinical periodontal parameters before and after treatment.
VARIABLE^ BASELINE
Mean±SD, SPT IPT
2 M o n th s 6 MONTHS
SPT IPT SPT IPT
PPD 4,3±0,8 4,5±0,8 2,9±0,3 3,0±0,3 3,0±0,4 2,9±0,3
REC 1,0±1,1 1,0±0,9 1,6±1,2 1,8±1,1 1,4±1,2 1,7±1,2
CAL 5,4±1,5 5,5±1,5 4,5±1,3 4,8±1,3 4,5±1,3 4,5±1,4
FMPS 59,5±20,5 52,2±23,2 13,9±14,8 15,7±13,8 15,5±11,7 14,5±10,7
FMBS 68,4±15,9 66,4±13,0 25,1±8,9 19,9±7,9 31,7±11,5 25,5±11,3
NPPK 79±29 80±25 19±12 20±11 22±12 16±9
When we examined the global scores, combining inflammation and lipid results, the 
intensive treatment regimen produced a significantly better effect on systemic 
parameters than the standard treatment at each time point examined (one, two and six 
months after therapy) (Figure 39).
GLOBAL SCORE
SPT IPT SPT IPT
INFLAMMATORY MARKERS SCORE
l— P "0-0408
I
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|
cO,
I
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N :4o 40
<0
I
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Figure 39 Rank-sum Score Differences (O’Brien non-parametric test) for global, inflammatory and lipid 
markers by treatment groups.
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We found that patients in the intensive group 
had significant changes in inflammatory 
markers at one (weak) and two (strong) 
months (inflammatory score). The same group 
also showed a significant change in lipid 
markers sustained from two to six months 
after treatment (lipid marker score). Subjects 
did not show significant changes in body mass 
index over time (0-13±0-74 difference at two 
and six months, p=ns) nor reported any 
change in diet, habits or medical treatments.
The IPT regimen resulted in significantly 
better changes in IL-6 concentrations than 
SPT at one and two months (0-43±0-23 ng/L 
difference Baseline-1 Month, 95%CI 003- 
0-88 p=0-0284, 0-34±0-20 ng/L Baseline-2 
Months, 95%CI 0-07-0-76 p=0-0284
respectively)(Figure 40-A). Similar results 
were observed for CRP (0-41 ±0-20 mg/L 
difference Baseline-2 Months, 95%CI 0-01- 
0-82 p=0-0438)(Figure 40-B) and total
cholesterol (0-32±0-14 mmol/L difference 
Baseline-2 Months, 95%CI 0-04-0-60 p=0-0254) 
at two months only (Figure 40-C).
ac
in
(Do>c
CD
A Delta BL-1M Delta BL-6M
— lO)
E
□:DCo
in<u
cn
c
CO
B Delta BL-1M Delta BL-2M Delta BL-6M
2,0
1,0
o
E
E
_ iOxo
in
CDO)
c=
COxzo
- 1,0
-2,0
Delta BL-1M Delta BL-2M Delta BL-6M
Figure 40 Box and whiskers plots showing 
changes in IL-6 (A), CRP (B) and
Cholesterol (C) between standard (SPT) 
and intensive (IPT) periodontal therapy 
The box refers to the 25th (bottom) and 75 (up) 
percentiles and the median is the horizontal line 
inside. Open circles represent outliers whereas 
asterisks stand for extreme observations. The 
horizontal dashed line indicates the line of no 
difference.
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7.5 D isc u ssio n
Our results indicate that severe generalized periodontitis causes a chronic systemic 
inflammatory response and possibly changes in serum cholesterol. However due to the 
small number of patients examined and the severe, generalized nature of the 
periodontitis we would urge caution in generalizing these data to all patients affected by 
periodontitis. Previous association studies have established a dose dependent effect 
between the extent and severity of periodontitis and cardiovascular events (Slade et al. 
2000; Slade et al. 2003). This study does not establish the level of local periodontal 
infection that is capable of having a systemic effect. Larger studies including a wider 
spectrum of disease presentation will be necessary to better define the periodontitis 
subjects in whom the local infection causes significant systemic inflammation.
With regards to the magnitude of the systemic inflammatory response that is attributable 
to periodontitis in this population, the present design utilized a control group that 
represents the current standard periodontal therapy. The test group received an intensive 
periodontal therapy regimen that consisted of SPT with an adjunctive local delivery of 
minocycline microspheres in all periodontal pockets of the affected subjects. The choice 
of this design was largely due to ethical considerations: the severity of disease in the 
population required delivery of standard care to assess the primary outcomes over a 6 
month period. Differences between the two groups in this study, therefore, represent the 
added benefit of the adjunctive antibiotic and are likely to be an underestimation of the 
probable effect of periodontal therapy. In previous studies we have observed a treatment 
associated decrease in CRP ranging between 0.4 to 0.7 mg/L. Such magnitude of 
change was essentially identical in a cohort design comparing 6 month follow up with 
baseline values (chapter 4) and in the short term randomised controlled clinical trial 
described in chapter 6 comparing changes observed in the untreated control and IPT.
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In the context of the two previous intervention studies by our group, these data also 
provide considerable insight into the kinetics of change observed following different 
regimens of periodontal therapy. Periodontal therapy successfully reduces the individual 
systemic inflammatory burden already after 2 months from therapy. The use of locally 
delivered antimicrobials may accelerate the resolution of the infectious and 
inflammatory burden in the diseased periodontium (see the presence of significant 
differences already at 1 and 2 months with IPT compared to the improvements in SPT 
observed by 6 months). At 6 months, however, even a standard treatment approach 
would significantly re-establish a systemic homeostatic state.
In this investigation we aimed at exploring the effect of periodontitis on a cluster of 
systemic inflammatory markers including WBC and lipid levels. We chose a global 
statistical approach to ascertain whether the treatment used had any impact on these 
markers. CRP and IL-6 serum concentrations are very sensitive and reliable markers 
used to assess the individual systemic inflammatory burden (See section 1.1). Both 
markers have also been independently defined as good predictors of future 
developments of serious systemic condition (coronary artery events, insulin resistance 
and type-2 diabetes, hypertension). WBC is known as a crude marker of systemic 
inflammation and it correlates well with the host response to a variety of stimuli (Da 
Silva et al. 1995) . This marker has also been associated with a significant prediction of 
future cardiovascular events and glucose intolerance in different populations (Brown et 
al. 2004; Haim et al. 2004; Ohshita et al. 2004). Independent of which therapy was 
performed, individuals in our study showed a significant reduction of WBC already 
after 1 month and such effect remained constant up to six months after therapy. No 
differences however were noted between treatment regimens.
Lipid markers such as total cholesterol, HDL have assumed crucial importance when it 
comes to predict individual future risk for cardiovascular events (Stamler et al. 1986).
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Changes in concentrations of these markers however have also been associated with 
acute and chronic infections (Leinonen & Saikku 2002). Our data suggest that severe 
periodontitis may represent one triggering factor of lipid levels alterations. Whether this 
finding is true or confounded by other important factors (diet, smoking, age) can only 
be ascertained by re-addressing the question in further clinical intervention trials.
The observation that circulating levels of inflammatory markers (CRP, IL-6, WBC) as 
well as cholesterol might be influenced by a chronic oral infection may have important 
clinical consequences. First, since inflammation plays an important role in the 
pathophysiology of various conditions (metabolic syndrome, blood pressure, vascular 
health) the association of mild chronic inflammation with future serious events 
(cardiovascular, ischemic) in observational studies could be influenced by an underlying 
severe periodontal infection.
Second, if the inflammatory processes associated with these serious events are caused 
by yet unknown noxious stimuli, severe periodontal infections might contribute to 
exacerbate the inflammatory burden of the affected individual and thus participate in the 
pathophysiology of chronic inflammatory disease such as atherosclerosis or metabolic 
syndrome.
Third, if periodontitis were the major inflammatory stimulus in at least some 
periodontitis patients, severe periodontal infections may represent a major etiologic 
factor for atherosclerosis, metabolic syndrome and their sequelae.
The significance of periodontitis as a cause of systemic inflammation and potentially 
disease has to be discussed in the context of the high prevalence of chronic periodontitis 
which affects in mild forms up to 40% and in more severe forms a good 10% of the 
adult population (Albandar & Rams 2002; Papapanou 1996; Papapanou 1999). The 
significance of recognizing this source of chronic inflammation comes also from the 
nature of the infection: periodontitis is unique since it is a biofilm centred infection that,
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as such, is not responsive to systemic antibiotics treatment in the absence of specific 
local measures to disperse the biofilm. In this respect the presence of periodontitis can 
also represent a confounder for the assessment of the health benefits of the ongoing 
intervention trials based on the administration of systemic antibiotics to eliminate 
undetected chronic infections.
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C o n c l u s i o n s
• Intensive periodontal therapy produces a significant effect on a cluster of 
inflammatory and lipid markers compared to a standard treatment approach.
• A significant anti-inflammatory effect (reduction in IL-6 and CRP) is exerted as 
early as 1 and 2 months after therapy.
• These improvements in inflammatory parameters are sustained for at least 6 
months after periodontal therapy.
• A concomitant reduction in total cholesterol is observed after 2 and six months.
• The results of this trial extend and are consistent with those reported in Chapter 
6 .
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C h a p t e r  8.
G e n e r a l  D is c u s s io n  a n d  C o n c l u sio n s
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The results of the 3 reported intervention trials demonstrated that periodontitis causes 
systemic inflammation. Periodontal therapy resulted in significant improvements of the 
local periodontal condition: decreases in infection with marker periodontal pathogens 
and in local inflammation were observed.
The novelty and importance of such findings lie in the biologically plausible hypothesis 
that sustained periodontal infections triggering a systemic low-grade inflammation may 
produce systemic complications (atherosclerosis, type-2diabetes, pre-eclampsia, PBLW 
delivery).
APR is a rapid and effective host defensive mechanism mounted to clear a variety of 
tissues’ insults. In most of the cases this defence is successfully accomplished without 
complications. However in case the insult persists, repetitive stimulation of this host 
innate response may be harmful to the host. An exhaustive body of literature support the 
pathogenetic role of chronic inflammation, assessed by small but significant increases 
of specific markers (CRP, IL-6), on the onset of serious systemic illnesses 
(hypertension, insulin resistance, type-2 diabetes, metabolic syndrome and 
atherosclerosis)(See chapter 1 for more details).
As a result of periodontal treatment patients with severe generalized periodontitis 
displayed a clinically relevant decrease in serum inflammation (and CRP in particular). 
The magnitude of the observed improvement was in the range of 0.5 mg/L (cohort 
design) to 0.8 mg/L (intensive periodontal therapy compared to the untreated control). 
The observed size of the effect and the consistency across the trials add validity to the 
results. A “real” effect of this scale is consistent with a change in CRP associated 
cardiovascular risk class, an excellent long term predictor of cardiovascular events and 
diabetes onset (Ridker et al. 1998; Ridker et al. 1999; Pearson et al. 2003; Yudkin et al. 
2004).
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Moreover the observed improvements could be maintained for up to 12 months without 
additional periodontal therapy indicating that, in the presence of supportive periodontal 
care at 3 month intervals as delivered in standard practice, the benefits could be 
sustained for a sufficient period to observe potential general health benefits.
Taken together, the data reported in these trials indicate that to achieve a significant 
serum outcome, a clinical significant response in terms of resolution of the local 
infectious and inflammatory parameters was necessary. This may explain the 
controversial results reported in previous intervention trials where the clinical outcomes 
of periodontal therapy did not achieve the expected improvements.
In our first pilot trial we were able to observe a statistically significant reduction in 
serum inflammatory markers after standard periodontal therapy only six months after 
completion of therapy. Significant added benefit in serum response was observed with 
the adjunctive application of minocycline microspheres. Its adjunctive effect could not 
be fully accounted for by the differences in clinical periodontal outcomes; this supports 
the hypothesis that periodontal therapy needs to be optimised to achieve systemic 
benefits. Our data indicate that an intensive regimen including adjunctive local delivery 
of minocycline may be more suited than classical mechanical instrumentation alone: 
bigger decreases at earlier time points were observed following delivery of this form of 
treatment. This notion is consistent with the recognised adjunctive benefit of local 
controlled delivery of antibiotics in terms of better suppression of the periodontal 
infection and inflammation. The data indicating that IPT provided benefits to both 
smokers and non-smokers, while SPT did not provide significant changes in the 
smoking population merits attention: IPT has been known to achieve better control of 
periodontitis in smokers. Further research however is needed in order to explore the 
potential additional effect of locally delivered or systemic antibacterial and/or anti­
inflammatory medications in different populations presenting with a wider spectrum of
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severity of periodontal infection. Moreover these data indicated the need o f novel intra­
oral clinical or biochemical parameters which better define the potential systemic 
inflammatory burden of periodontal infections.
The changes in cholesterol levels preliminarily detected in the two randomised 
controlled trials are noteworthy. Even though these trials were not designed to 
specifically address this question, since we observed an improvement in the lipid 
markers in both trials we would raise the hypothesis that periodontal infections may 
lead to complex metabolic changes (metabolic syndrome) possibly through the 
increased systemic inflammation. This hypothesis is consistent with previous data 
indicating that chronic infections may lead to changes in metabolism (Fernandez-Real 
& Ricart 2003). Changes in cholesterol mediated by the inflammatory response may 
represent an additional mechanism that would explain the observed increase in carotid 
intima thickness in periodontitis patients as well as the complex interaction between 
infection, diet and atherogenesis seen in experimental animal models (Jain et al. 2003; 
Li et al. 2002; Lalla et al. 2003).
Having established a causal link between periodontitis and systemic inflammation with 
a possible effect on lipid metabolism, the next logical step would be to perform large 
intervention trials for primary prevention of inflammatory-driven systemic illnesses. 
However it would be advisable to first look at the potential beneficial effect of 
periodontal therapy on other surrogate parameters (carotid intima thickness, 
endothelium dependent vaso-dilatation, blood pressure, insulin resistance) and 
eventually on true cardiovascular and metabolic diseases end-points (fatal and non fatal 
MI, non-haemorrhagic stroke, glucose intolerance, type-2 diabetes).
Data on the differential performance of the tested periodontal treatment regimens are 
relevant for the design of intervention trials wishing to establish the nature of the 
association between periodontitis and systemic diseases. Of interest to this discussion
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was also our description of the APR associated with the first week following delivery of 
periodontal therapy: these acute changes require further investigations in particular in 
the context of utilising these treatment approaches in subjects with significant systemic 
pathology such as advanced atherosclerosis, metabolic syndrome or history of 
cardiovascular events.
Another important aspect emerging from our results is the fact that the risk of having 
systemic inflammatory sequelae does not seem to be equally shared by the population of 
patients with severe generalized periodontitis. Specific polymorphisms in the IL-1A, 
TNF-A and IL-6 genes have been associated with higher concentrations of serum 
inflammatory mediators after correcting for disease severity and known risk factors. 
Identification of high risk groups for systemic inflammatory sequelae of periodontitis is 
an important development. If periodontitis associated inflammation will contribute to 
causality of major chronic inflammatory disease, these findings on the genetic 
influences may allow better identification of those periodontitis patients requiring more 
stringent control of the local infection. Interestingly, these gene polymorphisms have 
been associated with greater severity of periodontal disease and hence could both 
contribute to more aggressive disease and more significant systemic sequelae. 
Furthermore the significance of these polymorphisms is not expected to be limited to 
the systemic inflammatory response of subjects with periodontitis but should be 
extended to those observed following the other chronic infections that have been 
implied in chronic inflammatory diseases.
The extent and severity profile of patients recruited in terms of periodontitis was chosen 
in order to identify a population with high levels of exposure to periodontal infections. 
The external applicability of our results to the population of subjects affected with 
periodontitis requires further studies. A dose dependent effect of periodontitis exposure 
in terms of both cardiovascular events and systemic inflammatory markers has been
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reported. The size of the effect is thought to decrease with a decrease in periodontitis 
extent and severity; available data however do not allow the establishment of critical 
levels of disease beyond which systemic implications become more significant. Our 
data on the relevance of cytokine polymorphisms, furthermore, suggest that such cut-off 
points may indeed be dependent on the genotype and the environmental exposure 
profile of the subject.
Individuals are continuously challenged by a vast number of micro-organisms present 
on the external and internal surfaces of their bodies. The ability to mount a prompt 
inflammatory response to bacterial pathogens represents an advantage for the innate 
immune system. Genetic factors play an important role in modulating the individual 
host response and a series of metabolic pathways have changed during evolution in 
order to maximise this response to a variety of insults (Fernandez-Real & Ricart 2003). 
The association between acute phase reactants, insulin resistance and atherosclerotic 
heart diseases could be considered as the response of the organism to a chronic 
infectious disease such as periodontitis. Continuous bacterial challenges in addition to a 
systemic low-grade inflammatory response produce fertile ground for endothelial 
damage/dysfunction and insulin resistance. Further properly sized and designed clinical 
trials assessing the relationship between periodontal, cardiovascular and metabolic 
diseases will answer many of the questions that our results have raised in these areas. 
Lastly it seems important to observe that periodontitis is only one of the possible low 
grade chronic infections that may contribute to this process. The concept of total 
bacterial and inflammatory burden seems critical to put the role of periodontitis in 
perspective. After completion of our studies it is possible to state that periodontitis is a 
cause of systemic inflammation in the studied subjects. At the population level, 
however, it is perhaps more appropriate to hypothesise that periodontitis contributes to 
the overall inflammatory burden of the individual. As such, given its high prevalence
222
and lack of response to systemic administration of antimicrobials, it merits further 
attention as a possible cause of chronic inflammatory diseases.
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Subject Information Sheet
A pilot study on the effects of non-surgical periodontal therapy 
on acu te  phase  serum  m arkers
Please read this sheet carefully. Please ask if you do not understand or would like more 
information
You are being asked to participate in a research project being conducted with the approval of the 
Eastman Dental Institute and Hospital Joint Research and Ethics Committee. You have been 
selected as a potential subject because you have the appropriate oral condition that we are 
studying. The following information is provided so that you can make an informed decision 
regarding your willingness to participate.
1 Background and purpose
This 1-month clinical study aims to understand better the impact if any, of periodontal disease 
(gum disease) on general health. In the last ten years considerable evidence has associated 
chronic, low-grade infections with an increased risk of heart disease. Severe periodontitis is one 
such infection that has been associated with the risk of heart disease. The nature of this 
association, however, has not yet been established. Specific protein substances (acute phase 
proteins) in the bloodstream are known to be risk indicators of heart disease. Infections like 
periodontal disease may also cause an increase in the blood levels of these proteins. By treating 
gum disease and maintaining oral health it may be possible to decrease the level of these 
proteins and thus reduce the risk of heart disease. In this study we wish to monitor changes in 
these proteins, resulting from initial periodontal therapy, comprised of instruction in oral hygiene 
techniques followed by thorough scaling and polishing of your teeth in two consecutive 
appointments.
2. Procedures
Approximately 10 patients with periodontitis will participate in this study. You will be asked to 
make a total of 8 attendances at the Eastman Dental Institute over a period of 2 months.
At the first study visit, a full medical and dental history will be taken. You will be asked to fill in a 
short questionnaire. Medical signs (weight, height, blood pressure) will be recorded and a 
periodontal evaluation will be performed. A plaque sample will be collected and a blood sample 
will also be taken from your arm.
Subsequently, your gum disease will be treated by removal of the tartar, plaque, and bacteria 
responsible for the disease in two consecutive appointments of about 2 hours each (study visit 2 
and 3). At the fourth, fifth, sixth and seventh visit (one, three, five and seven days respectively 
after the completion of treatment), your oral hygiene will be controlled, you will receive a 
professional tooth cleaning and a blood sample will be collected and any side effects you may 
have experienced since last visit will be noted.
At 1 month (eighth visit) after the treatment a periodontal evaluation will be performed and a 
blood sample taken. Any changes in medications or any side effects you may have experienced 
since last visit will be noted. This will be carried so we can measure the changes in your 
periodontal health and in the blood levels of the proteins mentioned above.
3. Risks and discomforts
Periodontal probing, scaling and root planing and dental anesthesia injections may involve some 
discomfort. Blood collection will also cause you some discomfort.
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4. Alternatives
You do not have to be in this study to be treated for periodontitis (gum disease).
5. Exclusions
A history of certain d iseases and conditions, or use of certain medications are not allowed in this 
study. Your study doctor will discuss with you what may exclude you from participating in this 
study.
6. Possible Benefits to Participants
As a result of your improved oral hygiene and the periodontal treatment you will receive during 
the study, you will have an improvement in your periodontal health. We will compare the 
improvement of your periodontal condition with the level of the blood proteins analysed, in order 
to evaluate if reducing the extent and severity of periodontal d isease also results in reduction of 
the blood level of proteins which act as indicators for heart disease.
7. R esearch Related Injury
In the event of personal injury resulting directly from the research procedures, financial 
compensation cannot be provided. However, every effort will be made to make available to you 
the facilities and professional skills at the Eastman Dental Institute and Hospital. If complications 
related to study participation arise, the researchers will assist you in obtaining appropriate 
medical treatment.
8. Confidentiality
The Investigator (study doctor) will make every possible effort to keep your personal information 
confidential. The results of this research project may be presented at meetings or in publications; 
however, any research data released or published will not identify volunteers by name.
9. Whom to Ask Q uestions Regarding this S tudy
You have the right to ask questions concerning this study at any time, and you are urged to do 
so. You will be informed of any significant new information pertaining to your safety. If you have 
any questions concerning this study, please contact Jean ie  Suvan at 020 7915 2335. If you 
have questions about or would like to report any research related injuries, please contact Prof. 
Tonetti at +44 (0)20 7915 1075.
10. Voluntary Participation and  Right to R efuse or W ithdraw
Your participation in this study is voluntary. You may refuse to participate or may discontinue 
participation at any time during the study without penalty or loss of benefits to which you are 
otherwise entitled.
11. Termination of Your Participation
Your participation may be ended by the study doctor, without regard to your consent, if you 
become ineligible to continue in the study, if you fail to follow the study instructions given to you, if 
you experience a study-related injury, or for any other reason.
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University College London Hospitals
NHS T ru s t
Version 1.1 10-January-2003 
Centre Number:
Study Number:
Patient Identification Number for this trial:
CONSENT FORM
Title of project:
A  p ilo t study on the effects of non-surgical periodontal therapy on acute phase serum markers
Name of Principal Investigator: Professor Maurizio Tonetti, DMD, PhD, MMSc, FDS RCPS
I P lease initial box
1. I confirm that I have read and understood the information sheet dated 
10.01.2003 (version 1.2) for the above study and have had the opportunity 
to ask questions.
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal 
rights being affected.
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my 
taking part in research. I give permission for these individuals to have 
access to my records. I understand that the samples taken from me may be 
stored and used for the purpose of research. I understand that these results 
will also remain anonymous.
4. I agree to take part in the above study
Name of patient Date Signature
Name of Person taking consent Date Signature 
(if different from researcher)
Researcher Date Signature
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett Anderson and 
•gsogx, Obstetric Hospital, Hospital for Tropical Diseases, The Middlesex Hospital, National Hospital for Neurology & 
h o spit a l s  Neurosurgery and University College Hospital.
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Stockl
Dibasic potassium phosphate 0.6 g
Distilled water 100 ml
Magnesium Sulphate Stock Solution
Magnesium sulphate 2.5 g
Distilled water 100 ml
Stock Solution 2
Potassium Chloride 1.2 g
Ammonium Sulphate 1.2 g
Monobasic potassium sulphate 0.6 g
Magnesium sulphate stock 1 ml
Distilled water 99 ml
Sodium Carbonate Solution
Sodium Carbonate 0.8 g
Distilled water 10 ml
100 ml of RTF
Stock 1 7.5 ml
Stock 2 7.5 ml
Sodium Carbonate 0.5 ml
Distilled water 80 ml
Solutions are autoclaved at 121 °C for 15 minutes and allowed to cool. A filter-sterilized 
solution of dithiothreitol (Sigma, 0,02 g in 5m of distilled water) is added.
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